<SEC-DOCUMENT>0001193125-18-099579.txt : 20180328
<SEC-HEADER>0001193125-18-099579.hdr.sgml : 20180328
<ACCEPTANCE-DATETIME>20180328163336
ACCESSION NUMBER:		0001193125-18-099579
CONFORMED SUBMISSION TYPE:	S-3/A
PUBLIC DOCUMENT COUNT:		8
FILED AS OF DATE:		20180328
DATE AS OF CHANGE:		20180328

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TEVA PHARMACEUTICAL INDUSTRIES LTD
		CENTRAL INDEX KEY:			0000818686
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-222767
		FILM NUMBER:		18719235

	BUSINESS ADDRESS:	
		STREET 1:		5 BAZEL ST
		STREET 2:		P O B 3190
		CITY:			PETACH TIKVA
		STATE:			L3
		ZIP:			49131
		BUSINESS PHONE:		9729267267

	MAIL ADDRESS:	
		STREET 1:		TEVA PHARMACEUTICAL INDUSTRIES LIMITED
		STREET 2:		5 BAZEL ST PO B 3190
		CITY:			PETACH TIKVA
		STATE:			L3
		ZIP:			49131

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Teva Pharmaceutical Finance Netherlands III B.V.
		CENTRAL INDEX KEY:			0001679183
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		S-3/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-222767-07
		FILM NUMBER:		18719237

	BUSINESS ADDRESS:	
		STREET 1:		PIET HEINKADE 107
		CITY:			AMSTERDAM
		STATE:			P7
		ZIP:			1019 GM
		BUSINESS PHONE:		31 (0)20-2193000

	MAIL ADDRESS:	
		STREET 1:		PIET HEINKADE 107
		CITY:			AMSTERDAM
		STATE:			P7
		ZIP:			1019 GM

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Teva Pharmaceutical Finance Netherlands IV B.V.
		CENTRAL INDEX KEY:			0001679174
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		S-3/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-222767-06
		FILM NUMBER:		18719236

	BUSINESS ADDRESS:	
		STREET 1:		PIET HEINKADE 107
		CITY:			AMSTERDAM
		STATE:			P7
		ZIP:			1019 GM
		BUSINESS PHONE:		31 (0)20-2193000

	MAIL ADDRESS:	
		STREET 1:		PIET HEINKADE 107
		CITY:			AMSTERDAM
		STATE:			P7
		ZIP:			1019 GM

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TEVA PHARMACEUTICAL FINANCE NV
		CENTRAL INDEX KEY:			0001161052
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		S-3/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-222767-03
		FILM NUMBER:		18719239

	BUSINESS ADDRESS:	
		STREET 1:		C/O MEESPIERSON TRUST CURACAO NV
		STREET 2:		JB GORSIAWEG 14
		CITY:			CURACAO NETHERLANDS ANTILLES
		STATE:			P8
		ZIP:			00000

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Teva Pharmaceutical Finance IV, LLC
		CENTRAL INDEX KEY:			0001451275
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		S-3/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-222767-10
		FILM NUMBER:		18719244

	BUSINESS ADDRESS:	
		STREET 1:		1090 HORSHAM ROAD
		CITY:			NORTH WALES
		STATE:			PA
		ZIP:			19454
		BUSINESS PHONE:		215-591-3000

	MAIL ADDRESS:	
		STREET 1:		1090 HORSHAM ROAD
		CITY:			NORTH WALES
		STATE:			PA
		ZIP:			19454

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TEVA PHARMACEUTICAL FINANCE VI, LLC
		CENTRAL INDEX KEY:			0001536702
		IRS NUMBER:				221734359
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-222767-08
		FILM NUMBER:		18719242

	BUSINESS ADDRESS:	
		STREET 1:		1090 HORSHAM ROAD
		CITY:			NORTH WALES
		STATE:			PA
		ZIP:			19454
		BUSINESS PHONE:		212-591-3000

	MAIL ADDRESS:	
		STREET 1:		1090 HORSHAM ROAD
		CITY:			NORTH WALES
		STATE:			PA
		ZIP:			19454

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TEVA PHARMACEUTICAL FINANCE V, LLC
		CENTRAL INDEX KEY:			0001536701
		IRS NUMBER:				221734359
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-222767-09
		FILM NUMBER:		18719243

	BUSINESS ADDRESS:	
		STREET 1:		1090 HORSHAM RD
		CITY:			NORTH WALES
		STATE:			PA
		ZIP:			19454
		BUSINESS PHONE:		215-591-3000

	MAIL ADDRESS:	
		STREET 1:		1090 HORSHAM RD
		CITY:			NORTH WALES
		STATE:			PA
		ZIP:			19454

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Teva Pharmaceutical Finance Netherlands II B.V.
		CENTRAL INDEX KEY:			0001628587
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-222767-01
		FILM NUMBER:		18719238

	BUSINESS ADDRESS:	
		STREET 1:		PIET HEINKADE 107
		CITY:			AMSTERDAM
		STATE:			P7
		ZIP:			1019 GM
		BUSINESS PHONE:		31(0) 20-2193000

	MAIL ADDRESS:	
		STREET 1:		PIET HEINKADE 107
		CITY:			AMSTERDAM
		STATE:			P7
		ZIP:			1019 GM

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TEVA PHARMACEUTICAL FINANCE V B.V.
		CENTRAL INDEX KEY:			0001527030
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-222767-02
		FILM NUMBER:		18719234

	BUSINESS ADDRESS:	
		STREET 1:		SCHOTTEGATWEG OOST 29D
		CITY:			CURACAO
		STATE:			P8
		ZIP:			00000
		BUSINESS PHONE:		5999-736-6066

	MAIL ADDRESS:	
		STREET 1:		SCHOTTEGATWEG OOST 29D
		CITY:			CURACAO
		STATE:			P8
		ZIP:			00000

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TEVA PHARMACEUTICAL FINANCE IV B.V.
		CENTRAL INDEX KEY:			0001527029
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-222767-04
		FILM NUMBER:		18719240

	BUSINESS ADDRESS:	
		STREET 1:		SCHOTTEGATWEG OOST 29D
		CITY:			CURACAO
		STATE:			P8
		ZIP:			00000
		BUSINESS PHONE:		5999-736-6066

	MAIL ADDRESS:	
		STREET 1:		SCHOTTEGATWEG OOST 29D
		CITY:			CURACAO
		STATE:			P8
		ZIP:			00000

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TEVA PHARMACEUTICAL FINANCE CO B.V.
		CENTRAL INDEX KEY:			0001347410
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-222767-05
		FILM NUMBER:		18719241

	BUSINESS ADDRESS:	
		STREET 1:		SCHOTTEGATWEG OOST 29-D
		CITY:			CURACAO
		STATE:			P8
		ZIP:			599-9-463
		BUSINESS PHONE:		5999-7366066

	MAIL ADDRESS:	
		STREET 1:		SCHOTTEGATWEG OOST 29-D
		CITY:			CURACAO
		STATE:			P8
		ZIP:			599-9-463
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3/A
<SEQUENCE>1
<FILENAME>d552144ds3a.htm
<DESCRIPTION>FORM S-3 AMENDMENT NO. 2
<TEXT>
<HTML><HEAD>
<TITLE>Form S-3 Amendment No. 2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>As filed with the Securities and Exchange Commission on March 28, 2018 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Registration No.&nbsp;333-222767 </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">S-3</FONT> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Amendment
No.&nbsp;2 to </B></P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B>TEVA&nbsp;PHARMACEUTICAL&nbsp;INDUSTRIES&nbsp;LIMITED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter and translation of registrant&#146;s name into English) </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Israel</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>N/A</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>5 Basel Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>P.O. Box 3190 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Petach
Tikva, 4951033 Israel </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+972-3-926-7267</FONT></FONT></FONT>
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address and telephone number of registrant&#146;s principal executive offices) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>TEVA PHARMACEUTICAL FINANCE IV, LLC</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>TEVA PHARMACEUTICAL FINANCE V, LLC</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>(Exact name of registrant as specified in its charter)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>(Exact name of registrant as specified in its charter)</B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">22-1734359</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">22-1734359</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(State&nbsp;or&nbsp;other&nbsp;jurisdiction&nbsp;of incorporation&nbsp;or&nbsp;organization)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation or</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TEVA PHARMACEUTICAL FINANCE VI, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">22-1734359</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>1090 Horsham Road </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>North Wales, Pennsylvania 19454 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Attention: Deborah Griffin </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(215) <FONT STYLE="white-space:nowrap">591-3000</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address and telephone number of registrant&#146;s principal executive offices) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>TEVA PHARMACEUTICAL FINANCE COMPANY B.V.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>TEVA PHARMACEUTICAL FINANCE IV B.V.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>(Exact name of registrant as specified in its charter)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>(Exact name of registrant as specified in its charter)</B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Cura&ccedil;ao</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>N/A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Cura&ccedil;ao</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>N/A</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S.&nbsp;Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification&nbsp;No.)</B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>TEVA PHARMACEUTICAL FINANCE V B.V.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>TEVA PHARMACEUTICAL FINANCE N.V.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>(Exact name of registrant as specified in its charter)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>(Exact name of registrant as specified in its charter)</B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Cura&ccedil;ao</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>N/A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Cura&ccedil;ao</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>N/A</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(State or other jurisdiction of incorporation or organization)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schout Bij Nacht Doormanweg 40 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Cura&ccedil;ao </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Attention: Iseline Gouverneur </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Tel. +5999 7366066 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Fax.
+5999 7367066 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address and telephone number of registrant&#146;s principal executive offices) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TEVA PHARMACEUTICAL FINANCE NETHERLANDS II B.V. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Netherlands</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>N/A</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TEVA PHARMACEUTICAL FINANCE NETHERLANDS III B.V. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Netherlands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>N/A</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TEVA PHARMACEUTICAL FINANCE NETHERLANDS IV B.V. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Netherlands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>N/A</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Piet Heinkade 107 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>1019 GM Amsterdam, Netherlands </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Attention: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Bibianne Bon
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>+31 <FONT STYLE="white-space:nowrap">(0)20-2193000</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address and telephone number of registrant&#146;s principal executive offices) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Teva Pharmaceuticals USA, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>1090 Horsham Road </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>North
Wales, Pennsylvania 19454 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Attention: Deborah Griffin </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(215) <FONT STYLE="white-space:nowrap">591-3000</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address and telephone number of agent for service) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>with copies to: </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Joshua N. Korff, P.C. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Ross M. Leff </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Kirkland&nbsp;&amp; Ellis LLP </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>601 Lexington Avenue </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>New
York, New York 10022 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(212) <FONT STYLE="white-space:nowrap">446-4800</FONT> </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approximate date of commencement of proposed sale to the public: From time to time on or after the effective date of this Registration
Statement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans,
please check the following box.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of the securities being registered on this Form are to be offered on a delayed
or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box.&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If
this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following
box.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D.
filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
<FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, a smaller reporting company, or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting
company&#148; and &#147;emerging growth company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Non-accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;&nbsp;&nbsp;(Do not check if a smaller reporting company)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging&nbsp;growth&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities
Act.&nbsp;&nbsp;<FONT STYLE="font-family:pmingliu"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CALCULATION OF REGISTRATION FEE </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of each class of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>securities&nbsp;to be registered</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Amount</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>to be</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>registered
(1)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Proposed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>maximum</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>offering
price</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>per unit (2)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Proposed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>maximum</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>aggregate</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>offering price (2)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Amount of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>registration&nbsp;fee (3)</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Teva Pharmaceutical Industries Limited Ordinary Shares
(4)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Teva Pharmaceutical Industries Limited Purchase<BR>Contracts
(5)(6)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Teva Pharmaceutical Industries Limited
Units&nbsp;(5)(7)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Teva Pharmaceutical Industries Limited Senior Debt
Securities&nbsp;(5)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Teva Pharmaceutical Industries Limited Subordinated Debt
Securities&nbsp;(5)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Teva Pharmaceutical Finance IV, LLC Senior Debt
Securities&nbsp;(5)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Teva Pharmaceutical Finance IV, LLC Subordinated Debt
Securities&nbsp;(5)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Teva Pharmaceutical Finance V, LLC Senior Debt
Securities&nbsp;(5)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Teva Pharmaceutical Finance V, LLC Subordinated Debt
Securities&nbsp;(5)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Teva Pharmaceutical Finance VI, LLC Senior Debt
Securities&nbsp;(5)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Teva Pharmaceutical Finance VI, LLC Subordinated Debt
Securities&nbsp;(5)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Teva Pharmaceutical Finance Company B.V. Senior Debt
Securities&nbsp;(5)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Teva Pharmaceutical Finance Company B.V. Subordinated Debt
Securities&nbsp;(5)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Teva Pharmaceutical Finance IV B.V. Senior Debt
Securities&nbsp;(5)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Teva Pharmaceutical Finance IV B.V. Subordinated Debt
Securities&nbsp;(5)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Teva Pharmaceutical Finance V B.V. Senior Debt
Securities&nbsp;(5)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Teva Pharmaceutical Finance V B.V. Subordinated Debt
Securities&nbsp;(5)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Teva Pharmaceutical Finance N.V. Senior Debt
Securities&nbsp;(5)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Teva Pharmaceutical Finance N.V. Subordinated Debt
Securities&nbsp;(5)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Teva Pharmaceutical Finance Netherlands II B.V. Senior Debt
Securities&nbsp;(5)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Teva Pharmaceutical Finance Netherlands II B.V. Subordinated
Debt Securities&nbsp;(5)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Teva Pharmaceutical Finance Netherlands III B.V. Senior Debt
Securities&nbsp;(5)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Teva Pharmaceutical Finance Netherlands III B.V. Subordinated
Debt Securities&nbsp;(5)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Teva Pharmaceutical Finance Netherlands IV B.V. Senior Debt
Securities&nbsp;(5)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Teva Pharmaceutical Finance Netherlands IV B.V. Subordinated
Debt Securities&nbsp;(5)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Guarantees by Teva Pharmaceutical Industries Limited of Debt
Securities of each finance subsidiary listed above&nbsp;(8)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$5,000,000,000</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$622,500&nbsp;(9)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt">Not specified pursuant to General Instruction II.D of Form <FONT STYLE="white-space:nowrap">S-3,</FONT> not
specified as to each class of securities to be registered. These offered securities may be sold separately, together or as units with other offered securities. An indeterminate aggregate initial offering price or number of securities of each
identified class is being registered as may </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
from time to time be issued at indeterminate prices. Separate consideration may or may not be received for securities that are issuable on exercise, conversion or exchange of other securities or
that are issued in units or represented by depositary shares. Securities registered hereunder may be offered in U.S. dollars or the equivalent thereof in foreign currencies. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Estimated solely for the purpose of computing the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;) and exclusive of accrued interest, distributions
and dividends, if any. The proposed maximum offering price will be determined from time to time in connection with the issuance of the securities registered hereunder. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">The registration fee has been calculated in accordance with Rule 457(o) under the Securities Act. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Such ordinary shares may be represented by American Depositary Shares. Such American Depositary Shares are or will be registered on a separately filed registration statement on Form F-6. Each American Depositary Share
represents one ordinary share. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Also includes such currently indeterminate number of ordinary shares of Teva Pharmaceutical Industries Limited as may be issued upon conversion of or exchange for any securities that provide for conversion or exchange
into such ordinary shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">There are being registered hereby such indeterminate number of Purchase Contracts as may be issued at indeterminate prices. Such Purchase Contracts may be issued together with any of the other securities being
registered hereby. Purchase Contracts may require the holder thereof to purchase or sell any of the other securities registered hereby or to purchase or sell a basket of such securities, an index or indices of such securities or any combination of
the above. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top">There are being registered hereby such indeterminate number of Units as may be issued at indeterminate prices. Units may consist of any combination of the securities being registered hereby or an indeterminate number of
ordinary shares of Teva Pharmaceutical Industries Limited. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top">The guarantees will be issued by Teva Pharmaceutical Industries Limited. No separate consideration will be received for any of these guarantees. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top">Previously paid. </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The registrants hereby amend
this Registration Statement on such date or dates as may be necessary to delay its effective date until the registrants shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in
accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until this Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may
determine. </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXPLANATORY NOTE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Teva Pharmaceutical Industries Limited (the &#147;Registrant&#148;) is filing this Registration Statement on Form S-3, as amended by this pre-effective
Amendment No. 2, to replace its prior shelf registration statements on Form F-3 (File No. 333-208238 and File No. 333-201984) since the Registrant is no longer deemed to be a foreign private issuer as defined in Rule 405 of the Securities Act of
1933, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Amendment No.&nbsp;2 (this &#147;Second Amendment&#148;) to the Registration Statement on Form S-3 originally filed by the
Registrant and its finance subsidiaries on January&nbsp;29, 2018, as amended by Amendment No. 1 filed on February 16, 2018 (the &#147;Original Registration Statement&#148;), is being filed solely to (i)&nbsp;revise the &#147;Calculation of
Registration Fee table,&#148; (ii)&nbsp;amend the Original Registration Statement to include the offering of American Depositary Shares, each representing one Ordinary Share, and (iii)&nbsp;include updated Exhibits 5.1, 5.2 and 23.1. This Second
Amendment does not modify any provision of the Original Registration Statement except as specifically noted herein. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#ff4338"><B>The information in this prospectus is not complete and may be changed. We may not sell
or offer these securities until the Registration Statement filed with the Securities and Exchange Commission is declared effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in
any jurisdiction where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ff4338"><B>Subject to completion, dated March 28, 2018 </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PRELIMINARY PROSPECTUS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:19pt; font-family:Times New Roman" ALIGN="center"><B>TEVA
PHARMACEUTICAL INDUSTRIES LIMITED </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>$5,000,000,000 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>American Depositary Shares, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>each representing one Ordinary Share, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Debt Securities, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Purchase Contracts and Units </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>TEVA PHARMACEUTICAL FINANCE IV, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>TEVA PHARMACEUTICAL FINANCE V, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>TEVA PHARMACEUTICAL FINANCE VI, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>TEVA PHARMACEUTICAL FINANCE COMPANY B.V. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>TEVA PHARMACEUTICAL FINANCE IV B.V. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>TEVA PHARMACEUTICAL FINANCE V B.V. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>TEVA PHARMACEUTICAL FINANCE N.V. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>TEVA PHARMACEUTICAL FINANCE NETHERLANDS II B.V. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>TEVA PHARMACEUTICAL FINANCE NETHERLANDS III B.V. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>TEVA PHARMACEUTICAL FINANCE NETHERLANDS IV B.V. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B><I>Debt Securities, fully and unconditionally guaranteed by </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>TEVA PHARMACEUTICAL INDUSTRIES LIMITED </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman">Teva
Pharmaceutical Industries Limited and its finance subsidiaries (&#147;Teva,&#148; the &#147;Company,&#148; &#147;we,&#148; &#147;us&#148; or &#147;our&#148;) may offer and sell from time to time: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">American Depositary Shares (&#147;ADSs&#148;), each representing one ordinary share; </TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">senior or subordinated debt securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">purchase contracts; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">units. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman">This prospectus describes some of the general terms that may apply to the securities.
Teva will provide the specific terms and public offering prices of these securities in supplements to this prospectus. Before investing, you should carefully read this prospectus and any related prospectus supplement, including any document
incorporated or deemed incorporated by reference into this prospectus or any prospectus supplement. The prospectus supplements may also add, update or change information contained in this prospectus. Our registration of securities covered by this
prospectus does not mean that we will offer or sell any securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman">We may sell these securities to or through one or more underwriters,
dealers or agents, or directly to purchasers, on a continuous or delayed basis. The names of any underwriters, dealers or agents will be stated in a supplement to this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman">Our ADSs are quoted on the New York Stock Exchange (the &#147;NYSE&#148;) under the symbol &#147;TEVA.&#148; On March 27, 2018, the last
reported sale price for the ADSs on the NYSE was $16.68. If we decide to list any of these securities on a national securities exchange upon issuance, the applicable prospectus supplement to this prospectus will identify the exchange and the date
when we expect trading to begin. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman">Our principal executive offices are located at 5 Basel Street, P.O. Box 3190, Petach Tikva 4951033,
Israel, and our telephone number is <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+972-3-926-7267.</FONT></FONT></FONT> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman"><B>Investing in our securities involves risks. You should consider the risk factors described in any accompanying prospectus supplement and the
documents we incorporate by reference. See <U>&#147;<A HREF="#toc552144_4">Risk Factors</A>&#148;</U> on page 5 of this prospectus. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed
upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>The date of this
prospectus is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018. </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="96%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc552144_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc552144_2">TEVA PHARMACEUTICAL INDUSTRIES LIMITED</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc552144_3">FINANCE SUBSIDIARIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc552144_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc552144_5">FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc552144_6">RATIO OF EARNINGS TO FIXED CHARGES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc552144_7">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc552144_7a">DESCRIPTION OF ORDINARY SHARES </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc552144_7b">DESCRIPTION OF AMERICAN DEPOSITARY SHARES </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc552144_8">DESCRIPTION OF DEBT SECURITIES AND GUARANTEES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc552144_9">DESCRIPTION OF PURCHASE CONTRACTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc552144_10">DESCRIPTION OF UNITS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc552144_11">TAXATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc552144_12">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc552144_13">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc552144_14">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc552144_15">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc552144_16">ENFORCEMENT OF CIVIL LIABILITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc552144_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a Registration Statement that Teva and the other registrants filed with the United States Securities and Exchange
Commission (the &#147;SEC&#148;) utilizing a &#147;shelf&#148; registration process. Under this shelf process, any of the registrants may, from time to time, sell the securities described in this prospectus in one or more offerings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus provides you with a general description of the securities which we may offer and the related guarantees, if any, of those
securities. Each time we sell securities we will provide a prospectus supplement that will contain specific information about the terms of the offering. The prospectus supplement may also add, update or change information contained in this
prospectus. You should read both this prospectus and any prospectus supplement together with additional information described below under the heading &#147;Where You Can Find More Information&#148; before purchasing any of our securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not authorized anyone to provide any information or to make any representation other than those contained or incorporated by reference
in this prospectus. &#147;Incorporated by reference&#148; means that we can disclose important information to you by referring you to another document filed separately with the SEC. We have not authorized any other person to provide you with
different information. If anyone provides you with different or inconsistent information, you should not rely on it. We are not making, and we will not make, an offer to sell securities in any jurisdiction where the offer or sale is not permitted.
You should assume that the information appearing in this prospectus and any supplement to this prospectus is current only as of the dates on their respective covers. Our business, financial condition, results of operations and prospects may have
changed since that date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context otherwise requires, references in this prospectus and any supplement to this prospectus to
&#147;Teva,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to Teva Pharmaceutical Industries Limited and its subsidiaries, collectively. References to &#147;Teva Finance IV LLC&#148; refer to Teva Pharmaceutical Finance IV, LLC.
References to &#147;Teva Finance V LLC&#148; refer to Teva Pharmaceutical Finance V, LLC. References to &#147;Teva Finance VI LLC&#148; refer to Teva Pharmaceutical Finance VI, LLC. References to the &#147;LLCs&#148; refer to Teva Finance IV LLC,
Teva Finance V LLC and Teva Finance VI LLC. References to &#147;Teva Finance Company BV&#148; refer to Teva Pharmaceutical Finance Company B.V. References to &#147;Teva Finance IV BV&#148; refer to Teva Pharmaceutical Finance IV B.V. References to
&#147;Teva Finance V BV&#148; refer to Teva Pharmaceutical Finance V B.V. References to &#147;Teva Finance NV&#148; refer to Teva Pharmaceutical Finance N.V. References to the &#147;BVs&#148; refer to Teva Finance Company BV, Teva Finance IV BV,
Teva Finance V BV and Teva Finance NV. References to &#147;Teva Finance Netherlands II&#148; refer to Teva Pharmaceutical Finance Netherlands II B.V. References to &#147;Teva Finance Netherlands III&#148; refer to Teva Pharmaceutical Finance
Netherlands III B.V. References to &#147;Teva Finance Netherlands IV&#148; refer to Teva Pharmaceutical Finance Netherlands IV B.V. References to the &#147;Netherlands BVs&#148; refer to Teva Finance Netherlands II, Teva Finance Netherlands III and
Teva Finance Netherlands IV. References to the &#147;finance subsidiaries&#148; refer to the LLCs, the BVs and the Netherlands BVs, collectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc552144_2"></A>TEVA PHARMACEUTICAL INDUSTRIES LIMITED </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a global pharmaceutical company, committed to increasing access to high-quality healthcare to patients around the world. We operate
worldwide, with a significant presence in the United States, Europe and many other markets around the world. Our key strengths include our world-leading generics expertise and portfolio, focused specialty portfolio and global infrastructure and
scale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2017, we announced a new organizational structure and leadership changes to enable strategic alignment across our
portfolio, regions and functions. Under this new structure, our business will be integrated into one commercial organization, operating through three regions &#150; North America, Europe and Growth Markets. Each region will manage the entire
portfolio of our medicines, including generics, specialty and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> (&#147;OTC&#148;). The new structure will enable stronger alignment and integration
between R&amp;D, operations and commercial regions, allowing us to become a more agile, lean and profitable company. Prior to the implementation of our new organizational structure, we operated our business in two segments: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Generic Medicines</B>, which includes chemical and therapeutic equivalents of originator medicines in a variety of dosage forms, such as tablets, capsules, injectables, inhalants, liquids, ointments and creams. This
segment includes our OTC business, a significant part of which is conducted through PGT Healthcare LLP, our consumer healthcare joint venture with The Procter&nbsp;&amp; Gamble Company, as well as our world-leading active pharmaceutical ingredient
manufacturing business. We are the leading generic drug company in the United States and Europe, and we have a significant presence in certain &#147;rest of the world&#148; markets. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Specialty Medicines</B>, which includes our core therapeutic areas of central nervous system medicines such as COPAXONE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and AUSTEDO<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and respiratory medicines such as ProAir<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and QVAR<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. Our specialty medicines
segment also includes other products, such as BENDEKA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and GRANIX<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> in oncology. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to these two segments, we have other activities, primarily sales of third-party products for which we act as distributor in the
United States and in other countries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva was incorporated in Israel on February&nbsp;13, 1944, and is the successor to a number of
Israeli corporations, the oldest of which was established in 1901. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc552144_3"></A>FINANCE SUBSIDIARIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva has organized various finance subsidiaries for the purpose of issuing debt securities. There are no separate financial statements of the
finance subsidiaries in this prospectus because these entities are, or will be treated as, subsidiaries of Teva for financial reporting purposes. We do not believe the financial statements would be helpful to the holders of the securities of these
entities because: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Teva is a reporting company under the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;) and owns, directly or indirectly, all of the voting interests of these entities; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">these entities do not have any independent operations and do not propose to engage in any activities other than issuing securities and investing the proceeds in Teva or its affiliates; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">these entities&#146; obligations under the securities will be fully and unconditionally guaranteed by Teva. These entities are exempt from the information reporting requirements of the Exchange Act. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Teva Finance IV LLC </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva Finance
IV LLC is a limited liability company that was formed on December&nbsp;1, 2008 under the Delaware Limited Liability Company Act, as amended. Its address is 1090 Horsham Road, North Wales, Pennsylvania 19454, telephone number (215) <FONT
STYLE="white-space:nowrap">591-3000.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Teva Finance V LLC </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva Finance V LLC is a limited liability company that was formed on December&nbsp;1, 2011 under the Delaware Limited Liability Company Act, as
amended. Its address is 1090 Horsham Road, North Wales, Pennsylvania 19454, telephone number (215) <FONT STYLE="white-space:nowrap">591-3000.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Teva Finance VI LLC </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva Finance
VI LLC is a limited liability company that was formed on December&nbsp;1, 2011 under the Delaware Limited Liability Company Act, as amended. Its address is 1090 Horsham Road, North Wales, Pennsylvania 19454, telephone number (215) <FONT
STYLE="white-space:nowrap">591-3000.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Teva Finance Company BV </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva Finance BV is a Cura&ccedil;ao private limited liability company that was formed on November&nbsp;23, 2005. Its address is Schout Bij
Nacht Doormanweg 40, Cura&ccedil;ao, telephone number +5999 7366066. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Teva Finance IV BV </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva Finance IV BV is a Cura&ccedil;ao private limited liability company that was formed on June&nbsp;28, 2011. Its address is Schout Bij Nacht
Doormanweg 40, Cura&ccedil;ao, telephone number +5999 7366066. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Teva Finance V BV </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva Finance V BV is a Cura&ccedil;ao private limited liability company that was formed on June&nbsp;28, 2011. Its address is Schout Bij Nacht
Doormanweg 40, Cura&ccedil;ao, telephone number +5999 7366066. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Teva Finance NV </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva Finance NV is a Cura&ccedil;ao limited liability company that was formed on December&nbsp;29, 2000. Its address is Schout Bij Nacht
Doormanweg 40, Cura&ccedil;ao, telephone number +5999 7366066. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Teva Finance Netherlands II </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva Finance Netherlands II is a Dutch private limited liability company that was formed on October&nbsp;16, 2013. Its address is Piet Heinkade
107, 1019 GM Amsterdam, Netherlands, telephone number <FONT STYLE="white-space:nowrap">+31&nbsp;(0)20-2193000.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Teva Finance Netherlands III
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva Finance Netherlands III is a Dutch private limited liability company that was formed on September&nbsp;21, 2015. Its address
is Piet Heinkade 107, 1019 GM Amsterdam, Netherlands, telephone number <FONT STYLE="white-space:nowrap">+31&nbsp;(0)20-2193000.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Teva Finance
Netherlands IV </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva Finance Netherlands IV is a Dutch private limited liability company that was formed on April&nbsp;22, 2016.
Its address is Piet Heinkade 107, 1019 GM Amsterdam, Netherlands, telephone number <FONT STYLE="white-space:nowrap">+31&nbsp;(0)20-2193000.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc552144_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investing in our securities involves risk. Please see the risks incorporated by reference from our most recent Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K,</FONT> the risk factors described under the caption &#147;Risk Factors&#148; in any applicable prospectus supplement and any risk factors set forth in our other filings with the SEC. See &#147;Where You Can Find More
Information&#151;Incorporation by Reference.&#148; Our business, financial condition, liquidity or results of operations could be materially adversely affected by any of these risks. Before making an investment decision, you should carefully
consider these risks as well as other information we include or incorporate by reference in this prospectus and any accompanying prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc552144_5"></A>FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The disclosure and analysis in this prospectus, including statements that are predictive in nature, or that depend upon or refer to future
events or conditions, contain or incorporate by reference some forward-looking statements within the meaning of Section&nbsp;21E of the Exchange Act and Section&nbsp;27A of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;).
Forward-looking statements describe our current expectations or forecasts of future events. You can identify these forward-looking statements by the use of words such as &#147;should,&#148; &#147;expect,&#148; &#147;anticipate,&#148;
&#147;estimate,&#148; &#147;target,&#148; &#147;may,&#148; &#147;project,&#148; &#147;guidance,&#148; &#147;intend,&#148; &#147;plan,&#148; &#147;believe&#148; and other words and terms of similar meaning and expression in connection with any
discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our generics medicines business, including: that we are substantially more dependent on this business, with its significant attendant risks, following our acquisition of Allergan plc&#146;s worldwide generic
pharmaceuticals business; consolidation of our customer base and commercial alliances among our customers; the increase in the number of competitors targeting generic opportunities and seeking U.S. market exclusivity for generic versions of
significant products; price erosion relating to our generic products, both from competing products and increased regulation; delays in launches of new generic products; our ability to take advantage of high-value biosimilar opportunities; efforts of
pharmaceutical companies to limit the use of generics including through legislation and regulations; the difficulty and expense of obtaining licenses to proprietary technologies; returns, allowances and chargebacks; and investigations of the
calculation of wholesale prices; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our specialty medicines business, including: competition for our specialty products, especially COPAXONE<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, our leading medicine, which faces competition from
existing and potential additional generic versions and orally-administered alternatives; our ability to achieve expected results from investments in our product pipeline; competition from companies with greater resources and capabilities; and the
effectiveness of our patents and other measures to protect our intellectual property rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our substantially increased indebtedness and significantly decreased cash on hand, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments, and may result
in a further downgrade of our credit ratings; and our inability to raise debt or borrow funds in amounts or on terms that are favorable to us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our business and operations in general, including: failure to effectively execute the recently announced restructuring plan; uncertainties related to, and failure to achieve, the potential benefits and success of our
new senior management team and organizational structure; harm to our pipeline of future products due to the expected review of our Research &amp; Development programs; our ability to develop and commercialize additional pharmaceutical products;
potential additional adverse consequences following our resolution with the U.S. government of our Foreign Corrupt Practice Act investigation; compliance with sanctions and other trade control laws; manufacturing or quality control problems, which
may damage our reputation for quality production and require costly remediation; interruptions in our supply chain; disruptions of our or third party information technology systems or breaches of our data security; the failure to recruit or retain
key personnel; variations in intellectual property laws that may adversely affect our ability to manufacture our products; challenges associated with conducting business globally, including adverse effects of political or economic instability, major
hostilities or terrorism; significant sales to a limited number of customers in our U.S. market; our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions; and our
prospects and opportunities for growth if we sell assets; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">compliance, regulatory and litigation matters, including: costs and delays resulting from the extensive governmental regulation to which we are subject; the effects of reforms in healthcare regulation and reductions in
pharmaceutical pricing, reimbursement and coverage; governmental investigations into sales and marketing practices; potential liability for patent infringement; product liability claims; increased government scrutiny of our patent settlement
agreements; failure to comply with complex Medicare and Medicaid reporting and payment obligations; and environmental risks; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">other financial and economic risks, including: our exposure to currency fluctuations and restrictions as well as credit risks; potential impairments of our intangible assets; potential significant increases in tax
liabilities; and the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The forward-looking statements contained or incorporated by reference herein involve a number of known and unknown risks and uncertainties
that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. You should understand that many important factors, in
addition to those discussed or incorporated by reference in this prospectus, could cause our results to differ materially from those expressed in the forward-looking statements. Potential factors that could affect our results, include, in addition
to others not described in this prospectus, those referenced under &#147;Risk Factors.&#148; These are factors that we think could cause our actual results to differ materially from our expected results. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Forward-looking statements speak only as of the date on which they are made, and we undertake no obligation to update any forward-looking
statements or other information contained in this prospectus, whether as a result of new information, future events or otherwise, except as may be required by law. You are advised, however, to consult any additional disclosures we make in our Annual
Reports on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> that are filed with the SEC. See &#147;Risk Factors.&#148; Other factors besides those listed here could also
adversely affect us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc552144_6"></A>RATIO OF EARNINGS TO FIXED CHARGES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ratio of earnings to fixed charges in accordance with U.S. GAAP for each of the periods presented below was as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ratio of earnings to fixed charges</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18.7<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom">)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The ratio of earnings to fixed charges was less than 1:1 for the fiscal year ended December 31, 2017. In order to achieve a ratio of earnings to fixed charges of 1:1, we would have had to generate an additional $18,380
million in pre-tax earnings in the fiscal year ended December 31, 2017. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The finance subsidiaries did not have any
independent operations for the relevant periods. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc552144_7"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the applicable prospectus supplement states otherwise, the net proceeds from the sale of securities offered by Teva or the finance
subsidiaries will be used for general corporate purposes, which may include additions to working capital, investments in or extensions of credit to our subsidiaries and the repayment of indebtedness. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc552144_7a"></A>DESCRIPTION OF ORDINARY SHARES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following is a summary of the terms of Teva ordinary shares, including certain provisions contained in Teva&#146;s memorandum of
association (the &#147;Memorandum&#148;), Teva&#146;s articles of association (the &#147;Articles&#148;) and applicable Israeli laws in effect on the date of this Registration Statement. This summary is qualified by reference to the full text of the
Memorandum and the Articles, which are incorporated by reference as exhibits hereto. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Description of Ordinary Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The par value of Teva&#146;s ordinary shares is NIS 0.10&nbsp;per share, and all issued and outstanding ordinary shares are fully paid and
non-assessable. Holders of ordinary shares are entitled to participate equally in the receipt of dividends and other distributions and, in the event of liquidation, in all distributions after the discharge of liabilities to creditors and subject to
the preferences and priorities of the mandatory convertible preferred shares. Teva&#146;s mandatory convertible preferred shares rank senior to our ordinary shares with respect to dividend rights and distribution rights upon our liquidation,
winding-up or dissolution. Accordingly, in the event of our voluntary or involuntary liquidation, holders of mandatory convertible preferred shares will be entitled to receive, from assets lawfully available for distribution to shareholders, a
liquidation preference of $1,000.00 per share plus any accumulated and unpaid dividends thereon before any payment is made to holders of our ordinary shares and ADSs. All ordinary shares represented by the ADSs will be issued in registered form
only. The Israeli Companies Law, 5759-1999 (the &#147;Companies Law&#148;) and the Articles do not provide for preemptive rights to the holders of Teva&#146;s shares. Each Teva ordinary share entitles the holder thereof to one vote. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither the Memorandum nor the Articles or the laws of the State of Israel restrict the ownership or voting of Teva&#146;s ordinary shares or
ADSs by non-residents or persons who are not citizens of Israel, except with respect to citizens or residents of countries that are in a state of war with Israel. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General Shareholder Meetings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the
Companies Law and the Articles, Teva is required to hold an annual general meeting every calendar year, no later than 15 months after the previous annual general meeting. In addition, Teva is required to convene a special meeting of shareholders:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">upon the demand of two directors or one-quarter of the serving directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">upon the demand of one or more shareholders holding at least 5% of our issued share capital and 1% or more of our voting rights; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">upon the demand of one or more shareholders holding at least 5% of our voting rights; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided that a demand
by a shareholder to convene a special shareholders meeting must set forth the matters to be considered at the meeting and otherwise comply with all other requirements of applicable law and the Articles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the board of directors receives a demand to convene a special meeting satisfying the above conditions, it must announce the scheduling of
the meeting within 21 days after the demand was delivered, subject to the relevant requirements of the Companies Law and the regulations thereunder. If the board of directors fails to do so, the party who demanded to convene the special meeting may
convene the meeting itself, subject to the provisions of the Companies Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The agenda of a general meeting is determined by the board of
directors. The agenda must also include matters for which the convening of a special meeting was demanded, as well as any matter requested by one or more shareholders who hold at least 1% of Teva&#146;s voting rights, subject to complying with
certain requirements. Pursuant to Israeli law, a Teva shareholder who wishes to include a matter on the agenda of a general meeting </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
must submit the request within seven days of publication of the notice with respect to the general meeting or within 14 days of a preliminary notice of the intention to convene the general
meeting, if such was filed, in order for it to be eligible to be considered at the general meeting. Under the Articles, a request by a shareholder who holds at least 1% of Teva&#146;s voting rights to include a matter on the agenda of a general
meeting must be submitted in writing to Teva no later than 14 days after the first publication of Teva&#146;s annual consolidated financial statements preceding the annual general meeting at which the consolidated financial statements for such year
are to be presented. Any such demands or requests must comply with the requirements of applicable law, applicable stock exchange rules and the Articles. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notices </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Companies Law,
the regulations thereunder and the Articles, Teva is generally required to announce the convening of general meetings at least 35 days in advance, but is not required to deliver personal notices of a general meeting or of any adjournment thereof to
shareholders. Teva may reasonably determine the method of publicizing the convening of general meetings, including by publishing a notice in one or more daily newspapers in Israel or in one or more international wire services, and any such
publication will be deemed to have been duly given and delivered on the date of such publication. Shareholders as of the record date determined in respect of the general meeting are entitled to participate in and vote at the meeting. The Articles
require that shareholder meetings take place in Israel, unless Teva&#146;s center of management has been transferred to another country in accordance with the Articles. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting and Quorum Requirements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
quorum required for a general meeting of shareholders is at least two shareholders present in person or by proxy or represented by an authorized representative, who jointly hold at least 25% of our paid-up share capital. If a meeting is adjourned
for lack of a quorum, it will generally be adjourned to the same time and place on the same day of the following week unless the board of directors sets another date, time and place in a notice to all persons who are entitled to receive notice of
general meetings. Should no legal quorum be present at such reconvened meeting a half hour following the time set for such meeting, the necessary quorum consists of any two shareholders present, in person or by proxy, who jointly hold at least 20%
of Teva&#146;s paid-up share capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the terms of the mandatory convertible preferred shares, certain matters,
including certain amendments to the Articles, also require the approval of the holders of the mandatory convertible preferred shares. Holders of mandatory convertible preferred shares generally have no voting rights or any other right with respect
to our annual meetings and special meetings, except with respect to amendments to our Memorandum or Articles that adversely affect the rights, preferences, privileges or voting powers of the mandatory convertible preferred shares, including the
creation or increase of the authorized amount of, a class of senior shares, the consummation of certain mergers, consolidations with another entity, share exchanges or reclassifications involving the mandatory convertible preferred shares or as
specifically required by Israeli law. Any such amendments or actions generally must be approved by holders of at least three-quarters of the mandatory convertible preferred shares present at a meeting of holders of mandatory convertible preferred
shares where a quorum of two-thirds of the then outstanding mandatory convertible preferred shares is present in person or by proxy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A
shareholder who intends to vote at a meeting must demonstrate ownership of shares in accordance with the Companies Law and the regulations promulgated thereunder. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Shareholder Resolutions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Companies
Law provides that resolutions on certain matters, such as amending a company&#146;s articles of association, exercising the authority of the board of directors in certain circumstances, appointing auditors,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approving certain transactions, increasing or decreasing the registered share capital and approving certain mergers, must be approved by the shareholders at a general meeting. A company may
determine in its articles of association certain additional matters with respect to which decisions will be made by the shareholders at a general meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, under the Articles, shareholder resolutions are deemed adopted if approved by the holders of a simple majority of the voting rights
represented at a general meeting in person or by proxy and voting, unless a different majority is required by law or the Articles. Pursuant to the Companies Law and the Articles, certain shareholder resolutions (for example, resolutions amending
many of the provisions of the Articles) require the affirmative vote of at least 75% of the voting rights represented at a general meeting and voting in person or by proxy, and certain other amendments to the Articles require the affirmative vote of
at least 85% of the voting rights represented in a general meeting voting in person or by proxy, unless the board of directors sets a lower percentage, by a supermajority of three-quarters of the voting directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Change of Control </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to certain
exceptions, the Companies Law requires that a merger (which, for these purposes, is defined as involving two Israeli companies) be approved by both the board of directors and by the shareholders of each of the merging companies and, with respect to
the target company, if its share capital is divided into more than one class, the approval of each class of shares is required (in accordance with the majority and legal quorum requirements set forth in the Companies Law and the Articles). However,
a merger may not be approved if it is objected to by shareholders holding a majority of the voting rights participating and voting at the meeting (disregarding any abstentions), after excluding the shares held by the other party to the merger, by
any person who holds 25% or more of the other party to the merger or by anyone on their behalf, including the relatives of or corporations controlled by these persons, unless an Israeli court determines otherwise at the request of shareholders
holding at least 25% of the voting rights of the company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In approving a merger, the board of directors of both merging companies must
determine that there is no reasonable concern that, as a result of the merger, the surviving company will not be able to satisfy its obligations to its creditors. Similarly, upon the request of a creditor of either party to the proposed merger, an
Israeli court may prevent or delay the merger if it concludes that there exists a reasonable concern that, as a result of the merger, the surviving company will not be able to satisfy the obligations of the merging parties. A court may also issue
other instructions for the protection of creditors&#146; rights in connection with a merger. Further, a merger may not be completed unless at least (i)&nbsp;50 days have passed from the time that the requisite proposals for the approval of the
merger were filed with the Israeli Registrar of Companies; and (ii)&nbsp;30 days have passed since the merger was approved by the shareholders of each party to the merger. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Companies Law, subject to certain exceptions, an acquisition of shares in a public company must be made by means of a tender offer
if, as a result of the acquisition, the purchaser would hold (i)&nbsp;25% or more of the voting rights of the company if there is no other holder of 25% or more of the company&#146;s voting rights; or (ii)&nbsp;more than 45% of the voting rights of
the company if there is no other holder of more than 45% of the company&#146;s voting rights. This requirement does not apply to certain events set forth in the Companies Law, including a purchase of shares by an offeree in a &#147;private
placement&#148; that receives specific shareholder approval. The board of directors must either give the shareholders its opinion as to the advisability of the tender offer or explain why it is unable to do so. The board of directors must also
disclose any personal interest of any of its members in the proposed acquisition. The tender offer may be consummated only if (i)&nbsp;at least 5% of the company&#146;s voting rights will be acquired; and (ii)&nbsp;the majority of the offerees who
responded to the offer accepted the offer, excluding offerees who are controlling shareholders of the offeror, offerees who hold 25% or more of the voting rights in the company or who have a personal interest in accepting the tender offer, or anyone
on their behalf or on behalf of the offeror including the relatives of or corporations controlled by these persons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Companies
Law, a person may not acquire shares in a public company if, after the acquisition, he will hold more than 90% of the shares or more than 90% of any class of shares of that company, unless a tender </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
offer is made to purchase all of the shares or all of the shares of the particular class, which we refer to as a full tender offer. The Companies Law also generally provides that as long as a
shareholder in a public company holds more than 90% of the company&#146;s shares or of a class of shares, that shareholder shall be precluded from purchasing any additional shares. In order that all of the shares that the purchaser offered to
purchase be transferred to the purchaser by operation of law, one of the following must have occurred: (i)&nbsp;the shareholders who declined or who did not respond to the full tender offer hold less than 5% of the company&#146;s outstanding share
capital or of the relevant class of shares and the majority of offerees who do not have a personal interest in accepting the full tender offer accepted the offer, or (ii)&nbsp;the shareholders who declined or who did not respond to the full tender
offer hold less than 2% of the company&#146;s outstanding share capital or of the relevant class of shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the conditions set forth
above are not met, the purchaser may not acquire shares of the company from shareholders who accepted the full tender offer to the extent that following such acquisition, the purchaser would own more than 90% of the company&#146;s issued and
outstanding share capital or more than 90% of the particular class of shares with respect to which the full tender offer was made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A
shareholder that had his or her shares so transferred, whether he or she accepted the full tender offer or not, has the right, within six months from the date of acceptance of the full tender offer, to petition the court to determine that the full
tender offer was for less than fair value and that the fair value should be paid as determined by the court. However, subject to certain conditions, the purchaser may provide in its offer that shareholders who accept the full tender offer will not
be entitled to such rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors consists of three classes of directors plus the chief executive officer, who is not part of any class. One of the
classes is elected each year by the shareholders at our annual meeting for a term of approximately three years. Elected directors cannot be removed from office by the shareholders until the expiration of their term of office, unless they violate
their duties of care or loyalty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the Companies Law, we have elected to comply with SEC and NYSE requirements for
independent directors on the Board and audit and compensation committees, in lieu of the Israeli requirements for statutory independent directors and audit committee and compensation committee composition. Following such election, we no longer
designate any of our directors as statutory independent directors or designated independent directors under Israeli law. Our directors who were previously designated as statutory independent directors continue to serve their current term as members
of the Board until the earlier of the remainder of their three-year term or until the 2018 annual meeting of shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of
our ordinary shares representing a majority of the voting power represented at a shareholders&#146; meeting and voting at the meeting have the power to elect all of the directors up for election. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, the board of directors formulates company policy and supervises the performance of the chief executive officer. Subject to the
provisions of the Companies Law and the Articles, any Teva power that has not been conferred upon another body may be exercised by the board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither our Memorandum or Articles, nor Israeli law, mandate retirement of directors at a certain age, or share ownership for a
director&#146;s qualification. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conflicts of Interest </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Approval of Related Party Transactions </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Companies Law requires that an &#147;office holder&#148; (as defined in the Companies Law) of a company promptly disclose any personal
interest that he or she may have and all related material information known to him or her, in connection with any existing or proposed transaction of the company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Companies Law, any transaction with an office holder or in which the
office holder has a personal interest (other than with respect to such office holder&#146;s Terms of Office and Employment) must be brought before the audit committee, in order to determine whether such transaction is an &#147;extraordinary
transaction&#148; (defined as a transaction not in the ordinary course of business, not on market terms or likely to have a material impact on the company&#146;s profitability, assets or liabilities). The term &#147;Terms of Office and
Employment,&#148; as defined in the Companies Law, includes compensation, equity-based awards, releases from liability, indemnification and insurance, severance and other benefits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Companies Law, the Articles and Teva policy, in the event the audit committee determines that the transaction is not an
extraordinary transaction, the transaction will require only audit committee approval; if, however, it is determined to be an extraordinary transaction, board of directors approval is also required, and in some circumstances shareholder approval may
also be required. Such a transaction may only be approved if it is determined to be in the best interests of Teva. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A person with a
personal interest in the matter generally may not be present at meetings of the board of directors or certain committees where the matter is being considered and, if a member of the board of directors or a committee, may generally not vote on the
matter. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Transactions with Controlling Shareholders </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Israeli law, extraordinary transactions with a controlling shareholder or in which the controlling shareholder has a personal interest
and any engagement with a controlling shareholder or a controlling shareholder&#146;s relative with respect to the provision of services to the company or with their Terms of Office and Employment as an office holder or their employment, if they are
not office holders, generally require the approval of the audit committee (or with respect to Terms of Office and Employment, the compensation committee), the board of directors and the shareholders. If required, shareholder approval must include at
least a majority of the shareholders who do not have a personal interest in the transaction and are present and voting at the meeting (abstentions are disregarded), or, alternatively, that the total shareholdings of the disinterested shareholders
who vote against the transaction cannot represent more than two percent of the voting rights in the company. Transactions for a period of more than three years generally need to be brought for approval in accordance with the above procedures every
three years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A shareholder who holds 25% or more of the voting rights in a company is considered a controlling shareholder for these
purposes if no other shareholder holds more than 50% of the voting rights. If two or more shareholders are interested parties in the same transaction, their shareholdings are combined for the purposes of calculating percentages. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Approval of Director and Executive Officer Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As required by the Companies Law, we have adopted a compensation policy regarding the Terms of Office and Employment of our office holders (the
&#147;Compensation Policy&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Companies Law, arrangements between Teva and its office holders must generally be
consistent with the Compensation Policy. However, under certain circumstances, we may approve an arrangement that is not consistent with the Compensation Policy, if such arrangement is approved by a special disinterested majority of our
shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, pursuant to the Companies Law, the Terms of Office and Employment of office holders generally require the
approval of the compensation committee and the Board of Directors. The Terms of Office and Employment of directors (including those of a chief executive officer who is a director) further require the approval of the shareholders by a simple
majority; with respect to a chief executive officer who is not a director, the approval of the shareholders by the special disinterested majority is also generally required. Pursuant to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regulations promulgated under the Companies Law, shareholder approval is not required with respect to the remuneration granted to a director or a chief executive officer for the period following
his or her appointment until the next general meeting of shareholders, provided such remuneration is approved by the compensation committee and the Board of Directors, is consistent with the Compensation Policy and is on similar or less favorable
terms than those of such person&#146;s predecessor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under certain circumstances, if the Terms of Office and Employment of office holders
who are not directors are not approved by the shareholders (where such approval is required), the compensation committee and the Board of Directors may nonetheless approve such terms. In addition, non-material amendments of the Terms of Office and
Employment of office holders who are not directors may be approved by the compensation committee only and non-material amendments of the Terms of Office and Employment of executive officers other than the chief executive officer may be approved by
the chief executive officer only, provided such approval is permitted under the Compensation Policy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Insurance, Exemption and Indemnification of
Directors and Executive Officers </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Companies Law provides that a company may not exempt or indemnify a director or an executive
officer, or enter into an insurance contract, which would provide coverage for any liability incurred as a result of any of the following: (i)&nbsp;a breach by the director and/or executive officer of his or her duty of loyalty unless, with respect
to insurance coverage or indemnification, due to a breach of his or her duty of loyalty to the company committed in good faith and with reasonable grounds to believe that such act would not prejudice the interests of the company; (ii)&nbsp;a breach
by the director and/or the executive officer of his or her duty of care to the company committed intentionally or recklessly (other than if solely done in negligence); (iii)&nbsp;any act or omission done with the intent of unlawfully realizing
personal gain; or (iv)&nbsp;a fine, monetary sanction, forfeit or penalty imposed upon a director and/or executive officer. In addition, the Companies Law provides that directors and executive officers can be exempted in advance with respect to
liability for damages caused as a result of a breach of their duty of care to the company (but not for such breaches committed intentionally or recklessly, as noted above, or in connection with a distribution (as defined in the Companies Law)). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to indemnification and release agreements, we release our directors and executive officers from liability and indemnify them to the
fullest extent permitted by law and the Articles. Under these agreements, our undertaking to indemnify each director and executive officer for certain payments and expenses as well as monetary liabilities imposed by a court judgment (including a
settlement or an arbitrator&#146;s award that was approved by a court), which indemnification of monetary liabilities (i)&nbsp;shall be limited to matters that are connected or otherwise related to certain events or circumstances set forth therein,
and (ii)&nbsp;shall not exceed $200 million in the aggregate per director or executive officer. Under Israeli law, indemnification is subject to other limitations, including those described above. Subject to applicable law, we may also indemnify our
directors and officers following specific events. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our directors and executive officers are also covered by directors&#146; and
officers&#146; liability insurance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividends </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Companies Law, dividends may generally be distributed only out of profits, provided that there is no reasonable concern that the
distribution will prevent us from satisfying our existing and anticipated obligations when they become due. In accordance with the Companies Law and the Articles, the decision to distribute dividends and the amount to be distributed is made by the
board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, subject to certain exceptions, so long as any mandatory convertible preferred shares remain outstanding,
no dividend or distribution may be declared or paid on our ordinary shares or ADSs, and we may not purchase any such ordinary shares or ADSs, unless all accumulated and unpaid dividends for all preceding dividend periods have been declared and paid,
or a sufficient sum of cash has been set apart for the payment of such dividends, for all outstanding mandatory convertible preferred shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CEO and Center of Management </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Articles, our chief executive officer and a majority of the members of the board of directors are required to be residents of Israel,
unless our center of management has been transferred to another country in accordance with the Articles. The Articles require that our center of management remain in Israel, unless the board of directors otherwise resolves, by a supermajority of
three-quarters of the participating votes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exchange Controls </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Non-residents of Israel who purchase ADSs with U.S. dollars or other non-Israeli currency will be able to receive dividends, if any, and any
amounts payable upon the dissolution, liquidation or winding up of the affairs of Teva, in U.S. dollars at the rate of exchange prevailing at the time of conversion. Dividends to non-Israeli residents are subject to withholding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc552144_7b"></A>DESCRIPTION OF AMERICAN DEPOSITARY SHARES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Set forth below is a summary of the deposit agreement, as amended, among Teva, JPMorgan Chase Bank, N.A., as depositary, which we refer to
as the depositary, and the holders from time to time of ADSs. This summary is not complete and is qualified in its entirety by the amended and restated deposit agreement, a copy of which has been filed as an exhibit to the Registration Statement on
Form F-6 filed with the SEC on October&nbsp;30, 2012, as amended on February&nbsp;29, 2016 (the &#147;Deposit Agreement&#148;). Additional copies of the deposit agreement are available for inspection at the principal office of the depositary, 4 New
York Plaza, 12<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor, New York, New York 10004. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>American Depositary Shares and Receipts
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each ADS represents one ordinary share of Teva deposited with the custodian. ADSs may be issued in uncertificated form or may be
evidenced by an American Depositary Receipt, or ADR. ADRs evidencing a specified number of ADSs are issuable by the depositary pursuant to the deposit agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Deposit and Withdrawal of Ordinary Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary has agreed that, upon deposit with the custodian of ordinary shares of Teva accompanied by an appropriate confirmation or
confirmations of a book-entry transfer or instrument or instruments of transfer or endorsement in form satisfactory to the custodian and any certificates as may be required by the depositary or the custodian, the depositary will execute and deliver
at its corporate trust office, upon payment of the fees, charges and taxes provided in the deposit agreement, to or upon the written order of the person or persons entitled thereto, uncertificated securities or an ADR registered in the name of such
person or persons for the number of ADSs issuable with respect to such deposit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Every person depositing ordinary shares under the deposit
agreement shall be deemed to represent and warrant that such ordinary shares are validly issued, fully paid and non-assessable ordinary shares and that such person is duly authorized to make such deposit, and the deposit of such ordinary shares or
sale of ADSs by that person is not restricted under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon surrender of ADSs at the corporate trust office of the
depositary, and upon payment of the fees provided in the deposit agreement, ADS holders are entitled to delivery to them or upon their order at the principal office of the custodian or at the corporate trust office of the depositary of certificates
representing the ordinary shares and any other securities, property or cash represented by the surrendered ADSs. Delivery to the corporate trust office of the depositary shall be made at the risk and expense of the ADS holder surrendering ADSs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary may deliver ADSs prior to the receipt of ordinary shares or &#147;pre-release.&#148; The depositary may deliver ordinary shares
upon the receipt and surrender of ADSs that have been pre-released, whether or not such surrender is prior to the termination of such pre-release or the depositary knows that such ADSs have been pre-released. Each pre-release will be: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">accompanied by a written representation from the person to whom ordinary shares or ADSs are to be delivered that such person, or its customer, (i)&nbsp;owns the ordinary shares or ADSs to be remitted, as the case may
be, (ii)&nbsp;assigns all beneficial rights, title and interest in such ordinary shares or ADSs, as the case may be, to the depositary in its capacity as such and for the benefit of the holders of the ADSs, and (iii)&nbsp;will not take any action
with respect to such ordinary shares or ADSs, as the case may be, that is inconsistent with the transfer of beneficial ownership (including, without the consent of the depositary, disposing of such ordinary shares or ADSs, as the case may be), other
than in satisfaction of such pre-release; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at all times fully collateralized with cash or such other collateral as the depositary deems appropriate; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">terminable by the depositary with no more than five business days&#146; notice; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">subject to such further indemnities and credit regulations as the depositary deems appropriate. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of ADSs outstanding at any time as a result of pre-releases will not normally exceed 30% of the ordinary shares outstanding with
the depositary; provided, however, that the depositary reserves the right to disregard such limit from time to time as it deems appropriate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividends, Other Distributions and Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary shall, as promptly as practicable, convert or cause to be converted into U.S. dollars, to the extent that in its judgment it can
reasonably do so and transfer the resulting U.S. dollars to the United States, all cash dividends and other cash distributions denominated in a currency other than U.S. dollars that it or the custodian receives in respect of the deposited ordinary
shares, and to distribute the amount received, net of any fees of the depositary and expenses incurred by the depositary in connection with conversion, to the holders of ADSs. The amount distributed will be reduced by any amounts to be withheld by
Teva or the depositary for applicable taxes, net of expenses of conversion into U.S. dollars. If the depositary determines that any foreign currency received by it or the custodian cannot be so converted on a reasonable basis and transferred, or if
any required approval or license of any government or agency is denied or not obtained within a reasonable period of time, the depositary may distribute such foreign currency received by it or hold such foreign currency uninvested and without
liability for interest thereon for the respective accounts of the ADS holders. If any conversion of foreign currency, in whole or in part, cannot be effected for distribution to some of the holders of ADSs entitled thereto, the depositary may make
such conversion and distribution in U.S. dollars to the extent permissible to such holders of ADSs and may distribute the balance of the currency received by the depositary to, or hold such balance uninvested and without liability for interest
thereon for, the respective accounts of such holders of ADSs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any distribution upon any ordinary shares deposited or deemed deposited
under the deposit agreement consists of a dividend in, or free distribution of, additional ordinary shares, the depositary shall, only if Teva so requests, distribute to the holders of outstanding ADSs, on a pro rata basis, additional ADSs that
represent the number of additional ordinary shares received as such dividend or free distribution subject to the terms and conditions of the deposit agreement and net of any fees and expenses of the depositary. In lieu of delivering fractional ADSs
in the event of any such distribution, the depositary will sell the amount of additional ordinary shares represented by the aggregate of such fractions and will distribute the net proceeds to holders of ADSs. If additional ADSs are not so
distributed, each ADS shall thereafter also represent the additional ordinary shares distributed together with the ordinary shares represented by such ADS prior to such distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Teva offers or causes to be offered to the holders of ordinary shares any rights to subscribe for additional ordinary shares or any rights
of any other nature, the depositary, after consultation with Teva, shall have discretion as to the procedure to be followed in making such rights available to holders of ADSs or in disposing of such rights for the benefit of such holders and making
the net proceeds available to such holders or, if the depositary may neither make such rights available to such holders nor dispose of such rights and make the net proceeds available to such holders, the depositary shall allow the rights to lapse;
provided, however, that the depositary will, if requested by Teva, take action as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if at the time of the offering of any rights the depositary determines in its discretion that it is lawful and feasible to make such rights available to all holders of ADSs or to certain holders of ADSs but not other
holders of ADSs, the depositary may distribute to any holder of ADSs to whom it determines the distribution to be lawful and feasible, on a pro rata basis, warrants or other instruments therefor in such form as it deems appropriate to facilitate the
exercise of such rights by such holder of ADSs; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the depositary determines in its discretion that it is not lawful and feasible to make such rights available
to certain holders of ADSs, it may sell the rights, warrants or other instruments in proportion to the number of ADSs held by the holder of ADSs to whom it has determined it may not lawfully or
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
feasibly make such rights available, and allocate the net proceeds of such sales (net of the fees of the depositary and all taxes and governmental charges) for the account of such holders of ADSs
otherwise entitled to such rights, warrants or other instruments, upon an averaged or other practical basis without regard to any distinctions among such holders of ADSs because of exchange restrictions or the date of delivery of any ADS or
otherwise. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In circumstances in which rights would not otherwise be distributed, if a holder of ADSs requests the
distribution of warrants or other instruments in order to exercise the rights allocable to the ADSs of such holder, the depositary will make such rights available to such holder upon written notice from Teva to the depositary that (i)&nbsp;Teva has
elected in its sole discretion to permit such rights to be exercised, and (ii)&nbsp;such holder has executed such documents as Teva has determined in its sole discretion are reasonably required under applicable law. If the depositary has distributed
warrants or other instruments for rights to all or certain holders of ADSs, then upon instruction pursuant to such warrants or other instruments to the depositary from such holder to exercise such rights, upon payment by such holder to the
depositary for the account of such holder of an amount equal to the purchase price of the ordinary shares to be received upon the exercise of the rights, and upon payment of the fees of the depositary as set forth in such warrants or other
instruments, the depositary shall, on behalf of such holder, exercise the rights and purchase the ordinary shares, and Teva shall cause the ordinary shares so purchased to be delivered to the depositary on behalf of such holder. As agent for such
holder, the depositary will cause the ordinary shares so purchased to be deposited under the deposit agreement, and shall issue and deliver to such holder legended ADRs or confirmations with respect to uncertificated ADSs, subject to the appropriate
restrictions on sale, deposit, cancellation and transfer under applicable securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary will not offer to the holders
of ADSs any rights to subscribe for additional ordinary shares or rights of any other nature, unless and until such a Registration Statement is in effect with respect to the rights and the securities to which they relate, or unless the offering and
sale of such securities to the holders of such ADSs are exempt from registration under the provisions of the Securities Act and an opinion of counsel satisfactory to the depositary and Teva has been obtained. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary shall not be responsible for any failure to determine that it may be lawful and feasible to make such rights available to
holders of ADSs in general or any holder in particular. If the depositary determines that any distribution of property is subject to any tax or other governmental charge that the depositary is obligated to withhold, the depositary may by public or
private sale in Israel dispose of all or a portion of such property in such amounts and in such manner as the depositary deems necessary and practicable to pay any such taxes or charges, and the depositary will distribute the net proceeds of any
such sale after deduction of any taxes or charges to the ADS holders entitled thereto on a pro rata basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon any change in par value,
split-up, consolidation or any other reclassification of ordinary shares, or upon any recapitalization, reorganization, merger or consolidation or sale of assets affecting Teva or to which it is a party, any securities that shall be received by the
depositary or the custodian in exchange for or in conversion of or in respect of ordinary shares shall be treated as newly deposited ordinary shares under the deposit agreement, and ADSs shall thenceforth represent, in addition to the existing
deposited securities, the right to receive the new ordinary shares so received in respect of ordinary shares, unless additional ADSs are delivered or the depositary calls for the surrender of outstanding ADSs to be exchanged for new ADSs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Record Dates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever any cash dividend
or other cash distribution shall become payable, any distribution other than cash shall be made or rights shall be issued with respect to the ordinary shares, or whenever for any reason the depositary causes a change in the number of ordinary shares
that are represented by each ADS, or whenever the depositary shall receive notice of any meeting of holders of ordinary shares, the depositary shall fix a record date which shall be as close as practicable to the record date applicable to the
ordinary shares, provided that the record </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
date established by Teva or the depositary shall not occur on a day on which the shares or ADSs are not traded in Israel or the U.S.: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">for the determination of the holders of ADSs who shall be: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">entitled to receive such dividend, distribution or rights, or the net proceeds of the sale thereof; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">entitled to give instructions for the exercise of voting rights at any such meeting; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on or after which each ADS will represent the changed number of ordinary shares. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reports and Other
Communications </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva will furnish to the depositary and the custodian all notices of shareholders&#146; meetings, proxy soliciting
material and other reports and communications that are made generally available to the holders of ordinary shares and English translations of the same. The depositary will make such notices, reports and communications available for inspection by ADS
holders at its corporate trust office when furnished by Teva pursuant to the deposit agreement and, upon request by Teva, will mail such notices, reports and communications to ADS holders at Teva&#146;s expense. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting of the Underlying Ordinary Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon receipt of notice of any meeting or solicitation of consents or proxies of holders of ordinary shares, if requested in writing, the
depositary shall, as soon as practicable thereafter, mail to the ADS holders a notice containing: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">such information as is contained in the notice received by the depositary; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a statement that the holders of ADSs as of the close of business on a specified record date will be entitled, subject to applicable law and the provisions of Teva&#146;s Memorandum and Articles, as amended, to instruct
the depositary as to the exercise of voting rights, if any, pertaining to the amount of ordinary shares represented by their respective ADSs; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a statement as to the manner in which such instructions may be given. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the written
request of an ADS holder on such record date, received on or before the date established by the depositary for such purpose, the depositary shall endeavor, insofar as is practicable and permitted under applicable law and the provisions of
Teva&#146;s Memorandum and Articles, as amended, to vote or cause to be voted the amount of ordinary shares represented by the ADSs in accordance with the instructions set forth in such request. The depository shall not itself exercise any voting
discretion over any ordinary shares represented by ADSs. If instructions are not received by the depositary by the deadline, the ordinary shares represented by such uninstructed ADSs shall not be voted. The depositary may, to the extent not
prohibited by the deposit agreement, law or regulation or by the requirements of the stock exchange on which the ADSs are listed, in lieu of distribution of the materials provided to the depositary in connection with any meeting of, or solicitation
of consents or proxies from, holders of deposited securities, distribute to the owners a notice that provides owners with instructions on how to retrieve such materials or receive such materials upon request. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amendment and Termination of the Deposit Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The form of the ADRs and the terms of the deposit agreement may at any time be amended by written agreement between Teva and the depositary,
without the consent of the ADS holders. Any amendment that imposes or increases any fees or charges (other than taxes or other governmental charges, registration fees, cable, telex or facsimile transmission costs, delivery costs or other such
expenses), or that otherwise prejudices any substantial existing right of holders of ADSs shall, however, not become effective until the expiration of 30 days after notice of such amendment has been given to the holders of outstanding ADSs. Every
holder of an ADS at </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the time such amendment becomes effective will be deemed, by continuing to hold such ADS, to consent and agree to such amendment and to be bound by the deposit agreement as amended thereby. In no
event will any amendment impair the right of any ADS holder to surrender the ADSs held by such holder and receive therefor the underlying ordinary shares and any other property represented thereby, except in order to comply with mandatory provisions
of applicable law. However, if any governmental body or regulatory body should adopt new laws, rules or regulations which would require amendment or supplement of the deposit agreement or any receipt to ensure compliance therewith, Teva and the
depositary may amend or supplement the deposit agreement and the receipts at any time in accordance with such changed laws, rules or regulations. Such amendment or supplement to the deposit agreement in such circumstances may become effective before
a notice of such amendment or supplement is given to owners or within any other period of time as required for compliance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever so
directed by Teva, the depositary has agreed to terminate the deposit agreement by mailing notice of such termination to the holders of all ADSs then outstanding at least 30 days prior to the date fixed in such notice for such termination. The
depositary may likewise terminate the deposit agreement by mailing notice of such termination to Teva and the holders of all ADSs then outstanding if at any time 60 days shall have expired after the depositary shall have delivered to Teva a written
notice of its election to resign and a successor depositary shall not have been appointed and accepted its appointment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any ADSs
remain outstanding after the date of termination, the depositary thereafter will discontinue the registration of transfers of ADSs, will suspend the distribution of dividends to the holders and will not give any further notices or perform any
further acts under the deposit agreement, except: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the collection of dividends and other distributions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the sale of rights and other property; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the delivery of ordinary shares, together with any dividends or other distributions received with respect thereto and the net proceeds of the sale of any rights or other property, in exchange for surrendered ADSs,
subject to the terms of the deposit agreement. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any time after the expiration of one year from the date of termination,
the depositary may sell the underlying ordinary shares and hold uninvested the net proceeds, together with any cash then held by it under the deposit agreement, unsegregated and without liability for interest, for the pro rata benefit of the holders
of ADSs that have not theretofore surrendered their ADSs and such holders shall become general creditors of the depositary with respect to such net proceeds. After making such sale, the depositary shall be discharged from all obligations under the
deposit agreement, except to account for net proceeds and other cash (after deducting any applicable fees of the depositary, expenses and taxes) and except for obligations for indemnification set forth in the deposit agreement. Upon the termination
of the deposit agreement, Teva will also be discharged from all obligations thereunder, except for certain obligations to the depositary. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Charges of
Depositary </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva will pay the fees and out-of-pocket expenses of the depositary and those of any registrar only in accordance with
agreements in writing entered into between the depositary and Teva from time to time. The following charges shall be incurred by any party depositing or withdrawing ordinary shares or by any party surrendering ADSs or to whom ADSs are issued
(including, without limitation, issuance pursuant to a stock dividend or stock split declared by Teva or an exchange of stock regarding the ADSs or deposited ordinary shares or a distribution of ADSs pursuant to the terms of the deposit agreement):
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any applicable taxes and other governmental charges; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any applicable transfer or registration fees; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">certain cable, telex and facsimile transmission charges as provided in the deposit agreement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any expenses incurred in the conversion of foreign currency; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a fee of $5.00 or less per 100 ADSs (or a portion of such amount of ADSs) for the delivery of ADSs in connection with the deposit of ordinary shares, distributions in ordinary shares or the distribution of rights on the
ordinary shares; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a fee of $0.02 or less per ADS for any cash distributions on the ordinary shares; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a fee of $5.00 or less per 100 ADSs (or a portion of such amount of ADSs) for the distribution of securities on the ordinary shares (other than ordinary shares or rights thereon); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a fee of $0.02 or less per ADS annually for depositary services performed by the depositary and/or the custodians (which may be charged directly to the owners or which may be withheld from cash distributions, at the
sole discretion of the depositary);&nbsp;and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a fee (which may be charged directly to the owners or which may be withheld from cash distributions, at the sole discretion of the depositary) for the reimbursement of such fees, charges and expenses as are incurred by
the depositary and/or any of its agents (including the custodian and expenses incurred on behalf of holders of the ADSs in connection with compliance with foreign exchange control regulations or any law or regulation relating to foreign investment)
in connection with the servicing of the ordinary shares, the sale of ordinary shares, the delivery of ADSs or otherwise in connection with the depositary&#146;s or its custodian&#146;s compliance with applicable law. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary may own and deal in any class of securities of Teva and its affiliates and in ADSs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer of American Depositary Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ADSs are transferable on the books of the depositary, except during any period when the transfer books of the depositary are closed, or if
any such action is deemed necessary or advisable by the depositary or Teva at any time or from time to time because of any requirement of law or of any government or governmental body or commission or under any provision of the deposit agreement.
The surrender of outstanding ADSs and withdrawal of deposited ordinary shares may not be suspended subject only to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">temporary delays caused by closing the transfer books of the depositary or Teva, the deposit of ordinary shares in connection with voting at a shareholders&#146; meeting or the payment of dividends; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the payment of fees, taxes and similar charges; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">compliance with the U.S. or foreign laws or governmental regulations relating to the ADSs or to the withdrawal of the deposited ordinary shares. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary shall not knowingly accept for deposit under the deposit agreement any ordinary shares required to be registered under the
provisions of the Securities Act, unless a Registration Statement is in effect as to such ordinary shares. As a condition to the delivery, registration of transfer, split-up, combination or surrender of any ADS or withdrawal of ordinary shares, the
depositary, the custodian or the registrar may require payment from the person presenting the ADS or the depositor of the ordinary shares of a sum sufficient to reimburse it for any tax or other governmental charge and any stock transfer or
registration fee with respect thereto, payment of any applicable fees payable by the holders of ADSs, may require the production of proof satisfactory to the depositary as to the identity and genuineness of any signature and may also require
compliance with any regulations the depositary may establish consistent with the provisions of the deposit agreement. The depositary may refuse to deliver ADSs, register the transfer of any ADS or make any distribution on, or related to, ordinary
shares until it or the custodian has received proof of citizenship or residence, exchange control approval or other information as it may deem necessary or proper. Holders of ADSs may inspect the transfer books of the depositary at any reasonable
time and the list of recipients, provided that such inspection shall not be for the purpose of communicating with holders of ADSs in the interest of a business or object other than Teva&#146;s business or a matter related to the deposit agreement or
ADSs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither the depositary nor Teva nor any of their directors, employees, agents or affiliates will be liable to the holders of ADSs if by reason
of any present or future law or regulation of the United States or any other country or of any government or regulatory authority or any stock exchange, any provision, present or future, of Teva&#146;s Memorandum and Articles, as amended, or any
circumstance beyond its control, the depositary or Teva or any of their respective directors, employees, agents or affiliates is prevented or delayed in performing its obligations or exercising its discretion under the deposit agreement or is
subject to any civil or criminal penalty on account of performing its obligations. The obligations of Teva and the depositary under the deposit agreement are expressly limited to performing their obligations specifically set forth in the deposit
agreement without negligence, bad faith or willful misconduct. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc552144_8"></A>DESCRIPTION OF DEBT SECURITIES AND GUARANTEES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We or any of the other finance subsidiaries may elect to offer debt securities. The following description of debt securities sets forth the
material terms and provisions of the debt securities to which any prospectus supplement may relate. Our senior debt securities would be issued under a senior indenture between Teva and The Bank of New York Mellon, as trustee. Teva&#146;s
subordinated debt securities would be issued under a subordinated indenture between Teva and The Bank of New York Mellon, as trustee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
senior debt securities of each finance subsidiary would be issued under a senior indenture among that entity, Teva, as guarantor, and The Bank of New York Mellon, as trustee. The subordinated debt securities of each finance subsidiary would be
issued under a subordinated indenture among that entity, Teva, as guarantor, and The Bank of New York Mellon, as trustee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of the
indentures are sometimes referred to in this prospectus collectively as the &#147;indentures&#148; and each, individually, as an &#147;indenture.&#148; All senior indentures are sometimes referred to in this prospectus collectively as the
&#147;senior indentures&#148; and each, individually, as a &#147;senior indenture.&#148; All subordinated indentures are sometimes referred to in this prospectus collectively as the &#147;subordinated indentures&#148; and each, individually, as a
&#147;subordinated indenture.&#148; The particular terms of the debt securities offered by any prospectus supplement, and the extent to which the general provisions described below may apply to the offered debt securities, will be described in the
applicable prospectus supplement. The indentures will be qualified under the Trust Indenture Act of 1939, as amended. The terms of the debt securities will include those stated in the indentures and those made part of the indentures by reference to
the Trust Indenture Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because the following summaries of the material terms and provisions of the indentures and the related debt
securities are not complete, you should refer to the forms of the indentures and the debt securities for complete information on some of the terms and provisions of the indentures, including definitions of some of the terms used below, and the debt
securities. The senior indentures and subordinated indentures are substantially identical to one another, except for specific provisions relating to subordination contained in the subordinated indentures. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provisions of the indentures
do not limit the aggregate principal amount of debt securities which may be issued thereunder. Unless otherwise provided in a prospectus supplement, the senior debt securities will be the issuer&#146;s direct, unsecured and unsubordinated general
obligations and will have the same rank in liquidation as all of the issuer&#146;s other unsecured and unsubordinated debt. The subordinated debt securities will be unsecured obligations of the issuer, subordinated in right of payment to the prior
payment in full of all senior indebtedness of the issuer with respect to such series, as described below under &#147;Subordination of the Subordinated Debt Securities&#148; and in the applicable prospectus supplement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Payments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The issuer may issue debt
securities from time to time in one or more series. The provisions of the indentures allow the issuer to &#147;reopen&#148; a previous issue of a series of debt securities and issue additional debt securities of that series, as well as debt
securities of other series. The debt securities may be denominated and payable in U.S. dollars or foreign currencies. The issuer may also issue debt securities from time to time with the principal amount or interest payable on any relevant payment
date to be determined by reference to one or more currency exchange rates, securities or baskets of securities, commodity prices or indices. Holders of these types of debt securities will receive payments of principal or interest that depend upon
the value of the applicable currency, security or basket of securities, commodity or index on the relevant payment dates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Debt securities
may bear interest at a fixed rate, which may be zero, a floating rate, or a rate which varies during the lifetime of the debt security. Debt securities bearing no interest or interest at a rate that at the time of issuance is below the prevailing
market rate may be sold at a discount below their stated principal amount. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Terms Specified in the Applicable Prospectus Supplement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement will contain, where applicable, the following terms of and other information relating to any offered debt
securities: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the specific designation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any limit on the aggregate principal amount of the debt securities, their purchase price and denomination; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the currency in which the debt securities are denominated and/or in which principal, premium, if any, and/or interest, if any, is payable; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the date of maturity; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the interest rate or rates or the method by which the calculation agent will determine the interest rate or rates, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the interest payment dates, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the place or places for payment of the principal of and any premium and/or interest on the debt securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any repayment, redemption, prepayment or sinking fund provisions, including any redemption notice provisions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether we will issue the debt securities in definitive form and under what terms and conditions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms on which holders of the debt securities may convert or exchange these securities into or for ADSs or other of our securities or of an entity unaffiliated with us, any specific terms relating to the adjustment
of the conversion or exchange feature and the period during which the holders may make the conversion or exchange; </TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">information as to the methods for determining the amount of principal or interest payable on any date and/or the currencies, securities or baskets of securities, commodities or indices to which the amount payable on
that date is linked; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any agents for the debt securities, including trustees, depositaries, authenticating or paying agents, transfer agents or registrars; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether and under what circumstances the issuer will pay additional amounts on debt securities for any tax, assessment or governmental charge withheld or deducted and, if so, whether we will have the option to redeem
those debt securities rather than pay the additional amounts; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any material Israeli, U.S. federal and, if applicable, Cura&ccedil;ao or Dutch income tax consequences, including, but not limited to: </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">tax considerations applicable to any discounted debt securities or to debt securities issued at par that are treated as having been issued at a discount for United States federal income tax purposes; and
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">tax considerations applicable to any debt securities denominated and payable in foreign currencies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether certain payments on the debt securities will be guaranteed under a financial insurance guaranty policy and the terms of that guaranty; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the debt securities will be secured; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any applicable selling restrictions; and </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any other specific terms of the debt securities, including any modifications to or additional events of default, covenants or modified or eliminated acceleration rights, and any terms required by or advisable under
applicable laws or regulations, including laws and regulations relating attributes required for the debt securities to be afforded certain capital treatment for bank regulatory or other purposes. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of the debt securities may be issued as original issue discount securities. Original issue discount securities bear no interest or bear
interest at below-market rates and may be sold at a discount below their stated principal amount. The applicable prospectus supplement will contain information relating to income tax, accounting, and other special considerations applicable to
original issue discount securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration and Transfer of Debt Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders may present debt securities for exchange, and holders of registered debt securities may present these securities for transfer, in the
manner, at the places and subject to the restrictions stated in the debt securities and described in the applicable prospectus supplement. The issuer will provide these services without charge except for any tax or other governmental charge payable
in connection with these services and subject to any limitations or requirements provided in the applicable indenture or the supplemental indenture or issuer order under which that series of debt securities is issued. If any of the securities are
held in global form, the procedures for transfer of interests in those securities will depend upon the procedures of the depositary for those global securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Events of Default </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each indenture
provides holders of debt securities with remedies if the issuer and/or guarantor, as the case may be, fails to perform specific obligations, such as making payments on the debt securities, or if the issuer and/or guarantor, as the case may be,
becomes bankrupt. Holders should review these provisions and understand which actions trigger an event of default and which actions do not. Each indenture permits the issuance of debt securities in one or more series, and, in many cases, whether an
event of default has occurred is determined on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">series-by-series</FONT></FONT> basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An event of default is defined under the indentures, with respect to any series of debt securities issued under that indenture, as any one or
more of the following events, subject to modification in a supplemental indenture, each of which we refer to in this prospectus as an event of default, having occurred and be continuing: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">default is made in the payment of principal in respect of the securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">default is made for more than 30 days in the payment of interest in respect of the securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the issuer and/or guarantor, as the case may be, fails to perform any of its other obligations under the securities and this failure has continued for the period of 90 days following service of notice on the issuer
and/or guarantor requiring the same to be remedied; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">issuer&#146;s and/or guarantor&#146;s, as the case may be, bankruptcy, insolvency or reorganization under any applicable bankruptcy, insolvency or insolvency related reorganization law; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an order is made or an effective resolution is passed for the winding up or liquidation of the issuer and/or guarantor, as the case may be; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any other event of default provided in the supplemental indenture or issuer order, if any, under which that series of debt securities is issued. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Acceleration of Debt Securities Upon an Event of Default </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each indenture provides that, unless otherwise set forth in a supplemental indenture: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if an event of default occurs due to the default in payment of principal of, or any premium or interest on, any
series of debt securities issued under the indenture, or due to the default in the performance or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
breach of any other covenant or warranty of the issuer and/or guarantor, as the case may be, applicable to that series of debt securities but not applicable to all outstanding debt securities
issued under that indenture occurs and is continuing, either the trustee or the holders of not less than 25% in aggregate principal amount of the outstanding debt securities of each affected series, voting as one class, by notice in writing to the
issuer and guarantor, as the case may be, may declare the principal of and accrued interest on the debt securities of such affected series (but not any other debt securities issued under that indenture) to be due and payable immediately;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if an event of default occurs due to specified events of bankruptcy, insolvency or reorganization of the issuer and/or the guarantor, as the case may be, the principal of all debt securities and interest accrued on the
debt securities to be due and payable immediately; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if an event of default due to a default in the performance of any other of the covenants or agreements in the indenture applicable to all outstanding debt securities issued under the indenture occurs and is continuing,
either the trustee or the holders of not less than 25% in aggregate principal amount of all outstanding debt securities issued under the indenture for which any applicable supplemental indenture does not prevent acceleration under the relevant
circumstances, voting as one class, by notice in writing to the issuer and/or guarantor, as the case may be, may declare the principal of all debt securities and interest accrued on the debt securities to be due and payable immediately.
</TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Annulment of Acceleration and Waiver of Defaults </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some circumstances, if any and all events of default under the indenture, other than the <FONT STYLE="white-space:nowrap">non-payment</FONT>
of the principal of the securities that has become due as a result of an acceleration, have been cured, waived or otherwise remedied, then the holders of a majority in aggregate principal amount of all series of outstanding debt securities affected,
voting as one class, may annul past declarations of acceleration or waive past defaults of the debt securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification of Trustee for Actions
Taken on Your Behalf </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each indenture provides that the trustee shall not be liable with respect to any action taken or omitted to be
taken by it in good faith in accordance with the direction of the holders of debt securities issued under that indenture relating to the time, method and place of conducting any proceeding for any remedy available to the trustee, or exercising any
trust or power conferred upon the trustee. In addition, each indenture contains a provision entitling the trustee, subject to the duty of the trustee to act with the required standard of care during a default, to be indemnified to its reasonable
satisfaction by the holders of debt securities issued under the indenture before proceeding to exercise any right or power at the request of holders. Subject to these provisions and specified other limitations, the holders of a majority in aggregate
principal amount of each series of outstanding debt securities of each affected series, voting as one class, may direct the time, method and place of conducting any proceeding for any remedy available to the trustee, or exercising any trust or power
conferred on the trustee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitation on Actions by You as an Individual Holder </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each indenture provides that no individual holder of debt securities may institute any action against us under that indenture, except actions
for payment of overdue principal and interest, unless the following actions have occurred: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the holder must have previously given written notice to the trustee of the continuing default; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the holders of not less than 25% in aggregate principal amount of the outstanding debt securities of each affected series, treated as one class, must have: </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">requested the trustee to institute that action; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">offered the trustee reasonable indemnity; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the trustee must have not instituted that action within 60 days after receipt of the request referred to above; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the holders of a majority in principal amount of the outstanding debt securities of each affected series, voting as one class, must not have given directions to the trustee inconsistent with those of the holders
referred to above. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each indenture contains a covenant that the issuer and guarantor, if applicable, will file annually with
the trustee a certificate of no default or a certificate specifying any default that exists. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Discharge, Defeasance and Covenant Defeasance </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The issuer has the ability to eliminate most or all of its obligations on any series of debt securities prior to maturity if it complies with
the following provisions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Discharge of Indenture</I></B>. The issuer may discharge all of its obligations, other than as to
transfers and exchanges, under the indenture after it has: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">paid or caused to be paid the principal of and interest on all of the outstanding debt securities in accordance with their terms; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delivered to the applicable trustee for cancellation all of the outstanding debt securities; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">irrevocably deposited with the applicable trustee cash or, in the case of a series of debt securities payable only in U.S. dollars, U.S. government obligations in trust for the benefit of the holders of any series of
debt securities issued under the indenture that have either become due and payable, or are by their terms due and payable, or are scheduled for redemption, within one year, in an amount certified to be sufficient to pay on each date that they become
due and payable, the principal of and interest on, and any mandatory sinking fund payments for, those debt securities. However, the deposit of cash or U.S. government obligations for the benefit of holders of a series of debt securities that are due
and payable, or are scheduled for redemption, within one year will discharge obligations under the applicable indenture relating only to that series of debt securities. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Defeasance of a Series of Securities at Any Time</I></B>. The issuer may also discharge all of its obligations, other than as to
transfers and exchanges, under any series of debt securities at any time, which we refer to as defeasance in this prospectus. The issuer may be released with respect to any outstanding series of debt securities from the obligations imposed by the
covenants described above limiting consolidations, mergers, asset sales and leases, and elect not to comply with those sections without creating an event of default. Discharge under those procedures is called covenant defeasance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Defeasance or covenant defeasance may be effected only if, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the issuer irrevocably deposits with the relevant trustee cash or, in the case of debt securities payable only in U.S. dollars, U.S. government obligations, as trust funds in an amount certified to be sufficient to pay
on each date that they become due and payable, the principal of and interest on, and any mandatory sinking fund payments for, all outstanding debt securities of the series being defeased; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the issuer delivers to the relevant trustee an opinion of counsel to the effect that: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the holders of the series of debt securities being defeased will not recognize income, gain or loss for United States federal income tax purposes as a result of the defeasance or covenant defeasance; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the defeasance or covenant defeasance will not otherwise alter those holders&#146; United States federal income tax treatment of principal and interest payments on the series of debt securities being defeased; and
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in the case of a defeasance, this opinion must be based on a ruling of the Internal Revenue Service or a change in United States federal income tax law occurring after the date of this prospectus, since that result
would not occur under current tax law. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Modification of the Indenture </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Modification without Consent of Holders</I></B>. The issuer and the relevant trustee may enter into supplemental indentures without the
consent of the holders of debt securities issued under each indenture to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">secure any debt securities or to confirm and evidence the release of security when such release is permitted under such indenture; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">evidence the assumption by a successor corporation of our obligations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">add covenants for the protection of the holders of debt securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delete or modify any Events of Default with respect to a new series being established; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">add or change any provisions of such indenture regarding restrictions on the payment of principal or premium if such modification does not adversely affect holders of such debt securities in any material respect;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">change or eliminate any provisions of such indenture if such change or elimination becomes effective when no securities affected are outstanding; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">cure any ambiguity, omission, mistake, defect or error or correct any inconsistency; or to surrender any right or power of an issuer or guarantors; or to make such other provisions that shall not adversely affect the
interests of the holders in any material respect; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish the forms or terms of debt securities of any series or to authorize the issuance of additional securities of a series; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">evidence the assumption by the guarantor of all obligations and release of issuer; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">evidence the acceptance of appointment by a successor trustee; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">supplement such indenture to permit defeasance; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">add, change or eliminate provisions of such indenture to qualify under the Trust Indenture Act; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduce the minimum denomination of any series; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">prohibit the authentication and delivery of additional series; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">add guarantors or <FONT STYLE="white-space:nowrap">co-obligors</FONT> to a series or to release guarantors in accordance with such indenture; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">make such provisions as necessary to exchange securities pursuant to a registration rights or similar agreement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">conform provisions of such indenture with respect to a series to the provisions of the applicable &#147;Description of Notes&#148;; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">make any other change that does not adversely affect in any material respect the interests of holders of such securities. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Modification with Consent of Holders</I></B>. Each issuer and the trustee, with the consent of the holders of not less than a majority
in aggregate principal amount of each affected series of outstanding debt securities, voting as one class, may add any provisions to, or change in any manner or eliminate any of the provisions of, the indenture or modify in any manner the rights of
the holders of those debt securities. However, the issuer and the trustee may not make any of the following changes to any outstanding debt security without the consent of each holder that would be affected by the change: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">extend the final maturity of the security; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduce the principal amount; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduce the rate or extend the time of payment of interest; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduce any amount payable on redemption; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">change the currency in which the principal, including any amount of original issue discount, premium, or interest on the security is payable; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">modify or amend the provisions for conversion of any currency into another currency; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduce the amount of any original issue discount security payable upon acceleration or provable in bankruptcy; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">alter the terms on which holders of the debt securities may convert or exchange debt securities for stock or other securities or for other property or the cash value of the property, other than in accordance with the
antidilution provisions or other similar adjustment provisions included in the terms of the debt securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">impair the right of any holder to institute suit for the enforcement of any payment on any debt security when due; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduce the percentage of debt securities the consent of whose holders is required for modification of the Indenture. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Form of Debt Security </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each debt security
will be represented either by a certificate issued in definitive form to a particular investor or by one or more global securities representing the entire issuance of securities. Both certificated securities in definitive form and global securities
may be issued in registered form, where the issuer&#146;s obligation runs to the holder of the security named on the face of the security. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Definitive securities name you or your nominee as the owner of the security and in order to transfer or exchange these securities or to
receive payments other than interest or other interim payments, you or your nominee must physically deliver the securities to the trustee, registrar, paying agent or other agent, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Global securities name a depositary or its nominee as the owner of the debt securities represented by these global securities. The depositary
maintains a computerized system that will reflect each investor&#146;s beneficial ownership of the securities through an account maintained by the investor with its broker/dealer, bank, trust company or other representative, as we explain more fully
below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Global Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Registered Global Securities</I></B>. The issuer may issue the debt securities in the form of one or more fully registered global
securities that will be deposited with a depositary or its nominee identified in the applicable prospectus supplement and registered in the name of that depositary or nominee. In those cases, one or more registered global securities will be issued
in a denomination or aggregate denominations equal to the portion of the aggregate principal or face amount of the securities to be represented by registered global securities. Unless and until it is exchanged in whole for securities in definitive
registered form, a registered global security may not be transferred except as a whole by and among the depositary for the registered global security, the nominees of the depositary or any successors of the depositary or those nominees. If not
described below, any specific terms of the depositary arrangement with respect to any securities to be represented by a registered global security will be described in the prospectus supplement relating to those securities. We anticipate that the
following provisions will apply to all depositary arrangements: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ownership of beneficial interests in a registered global security will be
limited to persons, called participants, that have accounts with the depositary or persons that may hold interests through participants. Upon </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the issuance of a registered global security, the depositary will credit, on its book-entry registration and transfer system, the participants&#146; accounts with the respective principal or face
amounts of the securities beneficially owned by the participants. Any dealers, underwriters or selling agents participating in the distribution of the securities will designate the accounts to be credited. Ownership of beneficial interests in a
registered global security will be shown on, and the transfer of ownership interests will be effected only through, records maintained by the depositary, with respect to interests of participants, and on the records of participants, with respect to
interests of persons holding through participants. The laws of some states may require that some purchasers of securities take physical delivery of these securities in definitive form. These laws may impair your ability to own, transfer or pledge
beneficial interests in registered global securities. So long as the depositary, or its nominee, is the registered owner of a registered global security, that depositary or its nominee, as the case may be, will be considered the sole owner or holder
of the securities represented by the registered global security for all purposes under the applicable indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as described
below, owners of beneficial interests in a registered global security will not be entitled to have the securities represented by the registered global security registered in their names, will not receive or be entitled to receive physical delivery
of the securities in definitive form and will not be considered the owners or holders of the securities under the applicable indenture. Accordingly, each person owning a beneficial interest in a registered global security must rely on the procedures
of the depositary for that registered global security and, if that person is not a participant, on the procedures of the participant through which the person owns its interest, to exercise any rights of a holder under the applicable indenture. We
understand that under existing industry practices, if we request any action of holders or if an owner of a beneficial interest in a registered global security desires to give or take any action that a holder is entitled to give or take under the
applicable indenture, the depositary for the registered global security would authorize the participants holding the relevant beneficial interests to give or take that action, and the participants would authorize beneficial owners owning through
them to give or take that action or would otherwise act upon the instructions of beneficial owners holding through them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Principal,
premium, if any, and interest payments on debt securities represented by a registered global security registered in the name of a depositary or its nominee will be made to the depositary or its nominee, as the case may be, as the registered owner of
the registered global security. None of the issuer, the guarantor, if applicable, the trustee or any other agent of the issuer, guarantor or agent of the trustee will have any responsibility or liability for any aspect of the records relating to
payments made on account of beneficial ownership interests in the registered global security or for maintaining, supervising or reviewing any records relating to those beneficial ownership interests. We expect that the depositary for any of the
securities represented by a registered global security, upon receipt of any payment of principal, premium, interest or other distribution of underlying securities or other property to holders on that registered global security, will immediately
credit participants&#146; accounts in amounts proportionate to their respective beneficial interests in that registered global security as shown on the records of the depositary. We also expect that payments by participants to owners of beneficial
interests in a registered global security held through participants will be governed by standing customer instructions and customary practices, as is now the case with the securities held for the accounts of customers registered in &#147;street
name,&#148; and will be the responsibility of those participants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the depositary for any of these securities represented by a
registered global security is at any time unwilling or unable to continue as depositary or ceases to be a clearing agency registered under the Exchange Act, and a successor depositary registered as a clearing agency under the Exchange Act is not
appointed by the issuer within 90 days, the issuer will issue securities in definitive form in exchange for the registered global security that had been held by the depositary. In addition, the issuer may, at any time and in its sole discretion,
decide not to have any of the securities represented by one or more registered global securities. If the issuer makes that decision, it will issue securities in definitive form in exchange for all of the registered global security or securities
representing those securities. Any securities issued in definitive form in exchange for a registered global security will be registered in the name or names that the depositary gives to the relevant trustee or other relevant agent of ours or theirs.
It is expected that the depositary&#146;s instructions will be based upon directions </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
received by the depositary from participants with respect to ownership of beneficial interests in the registered global security that had been held by the depositary. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Guarantees </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva will fully and
unconditionally guarantee payment in full to the holders of the debt securities issued by the finance subsidiaries pursuant to this prospectus. The guarantee is set forth in, and forms part of, the finance subsidiary indenture under which the debt
securities will be issued. If, for any reason, the issuer does not make any required payment in respect of its debt securities when due, the guarantor will cause the payment to be made to or to the order of the trustee. The guarantee will be on a
senior basis when the guaranteed debt securities are issued under the senior indenture, and on a subordinated basis to the extent the guaranteed debt securities are issued under the subordinated indenture. The extent to which the guarantee is
subordinated to other indebtedness of the guarantor will be substantially the same as the extent to which the subordinated debt issued by the issuer is subordinated to the other indebtedness of the issuer as described below under
&#147;&#151;Subordination of the Subordinated Debt Securities.&#148; The holder of the guaranteed security may sue the guarantor to enforce its rights under the guarantee without first suing any other person or entity. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Subordination of the Subordinated Debt Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subordinated debt securities issued by an issuer will, to the extent set forth in the applicable subordinated indenture, be subordinate in
right of payment to the prior payment in full of all senior indebtedness of the issuer, whether outstanding at the date of the subordinated indenture or incurred after that date. In the event of: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any insolvency or bankruptcy case or proceeding, or any receivership, liquidation, reorganization or other similar case or proceeding in connection therewith, relative to the issuer or to its creditors, as such, or to
its assets; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any voluntary or involuntary liquidation, dissolution or other winding up of the issuer, whether or not involving insolvency or bankruptcy; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any assignment for the benefit of creditors or any other marshalling of assets and liabilities of the issuer, then the holders of senior indebtedness of the issuer will be entitled to receive payment in full of all
amounts due or to become due on or in respect of all its senior indebtedness, or provision will be made for the payment in cash, before the holders of the subordinated debt securities of the issuer are entitled to receive or retain any payment on
account of principal of, or any premium or interest on, or any additional amounts with respect to, the subordinated debt securities. The holders of senior indebtedness of the issuer will be entitled to receive, for application to the payment of the
senior indebtedness, any payment or distribution of any kind or character, whether in cash, property or securities, including any payment or distribution which may be payable or deliverable by reason of the payment of any other indebtedness of the
issuer being subordinated to the payment of its subordinated debt securities. This payment may be payable or deliverable in respect of its subordinated debt securities in any case, proceeding, dissolution, liquidation or other winding up event.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By reason of subordination, in the event of liquidation or insolvency of the issuer, holders of senior indebtedness of the
issuer and holders of other obligations of the issuer that are not subordinated to its senior indebtedness may recover more ratably than the holders of subordinated debt securities of the issuer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the payment in full of all senior indebtedness of the issuer, the rights of the holders of subordinated debt securities of the
issuer will be subrogated to the rights of the holders of its senior indebtedness to receive payments or distributions of cash, property or securities of the issuer applicable to its senior indebtedness until the principal of, any premium and
interest on, and any additional amounts with respect to, its subordinated debt securities have been paid in full. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No payment of principal, including redemption and sinking fund payments, of, or any premium
or interest on, or any additional amounts with respect to the subordinated debt securities of the issuer, or payments to acquire these securities, other than pursuant to their conversion, may be made: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if any senior indebtedness of the issuer is not paid when due and any applicable grace period with respect to the default has ended and the default has not been cured or waived or ceased to exist; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if the maturity of any senior indebtedness of the issuer has been accelerated because of a default. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The subordinated indentures do not limit or prohibit the issuer from incurring additional senior indebtedness, which may include indebtedness
that is senior to its subordinated debt securities, but subordinate to the issuer&#146;s other obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The subordinated indentures
provide that these subordination provisions, insofar as they relate to any particular issue of subordinated debt securities by the issuer, may be changed prior to the issuance. Any change would be described in the applicable prospectus supplement.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>New York Law to Govern </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
indentures and the debt securities will be governed by the laws of the State of New York. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Concerning the Trustee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Bank of New York Mellon, as trustee under the indenture, has been appointed by us as paying agent, conversion agent, registrar and
custodian with regard to the debt securities. The trustee or its affiliates may from time to time in the future provide banking and other services to us in the ordinary course of their business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc552144_9"></A>DESCRIPTION OF PURCHASE CONTRACTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva may issue purchase contracts for the purchase or sale of debt or equity securities issued by Teva, a basket of such securities, an index
or indices of such securities or any combination of the above as specified in the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each purchase
contract will entitle the holder thereof to purchase or sell, and obligate us to sell or purchase, on specified dates, such securities at a specified purchase price, which may be based on a formula, all as set forth in the applicable prospectus
supplement. The applicable prospectus supplement will also specify the methods by which the holders may purchase or sell such securities and any acceleration, cancellation or termination provisions or other provisions relating to the settlement of a
purchase contract and any security arrangements or requirements with respect thereto. Alternatively, if provided in the applicable prospectus supplement, purchase contracts may require holders to satisfy their obligations thereunder when the
purchase contracts are issued. Any purchase contracts we issue will be physically settled by delivery of our ordinary shares or other securities to which they relate. Teva&#146;s obligation to settle such
<FONT STYLE="white-space:nowrap">pre-paid</FONT> purchase contacts on the relevant settlement date may constitute indebtedness. Accordingly, <FONT STYLE="white-space:nowrap">pre-paid</FONT> purchase contracts will be issued under either the senior
indenture or the subordinated indenture. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc552144_10"></A>DESCRIPTION OF UNITS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As specified in the applicable prospectus supplement, Teva may issue units consisting of one or more purchase contracts, debt securities,
ordinary shares, ADSs or any combination of such securities. The applicable prospectus supplement will describe: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms of the units and of the purchase contracts, debt securities, ordinary shares and/or ADSs comprising the units, including whether and under what circumstances the securities comprising the units may be traded
separately; </TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a description of the terms of any unit agreement governing the units; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a description of the provisions for the payment, settlement, transfer or exchange of the units. </TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc552144_11"></A>TAXATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The material Israeli, U.S. federal and, if applicable, Cura&ccedil;ao or Dutch income tax consequences relating to the purchase, ownership and
disposition of any of the securities offered by this prospectus will be set forth in the prospectus supplement offering those securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc552144_12"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell our securities in any one or more of the following ways from time to time: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to or through underwriters; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to or through dealers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">through agents; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">directly to purchasers, including our affiliates. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prospectus supplement with respect to
any offering of our securities will set forth the terms of the offering, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the name or names of any underwriters, dealers or agents; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the purchase price of the securities and the proceeds to us from the sale; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any underwriting discounts and commissions or agency fees and other items constituting underwriters&#146; or agents&#146; compensation; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any delayed delivery arrangements. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The distribution of the securities may be effected from
time to time in one or more transactions at a fixed price or prices, which may be changed, at market prices prevailing at the time of sale, at prices related to the prevailing market prices or at negotiated prices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If securities are sold by means of an underwritten offering, we will execute an underwriting agreement with an underwriter or underwriters,
and the names of the specific managing underwriter or underwriters, as well as any other underwriters, and the terms of the transaction, including commissions, discounts and any other compensation of the underwriters and dealers, if any, will be set
forth in the prospectus supplement which will be used by the underwriters to sell the securities. If underwriters are utilized in the sale of the securities, the securities will be acquired by the underwriters for their own account and may be resold
from time to time in one or more transactions, including negotiated transactions, at fixed public offering prices or at varying prices determined by the underwriters at the time of sale. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities to be sold by us may be offered to the public either through underwriting syndicates represented by managing underwriters or
directly by the managing underwriters. If any underwriter or underwriters are utilized in the sale of the securities, unless otherwise indicated in the prospectus supplement, the underwriting agreement will provide that the obligations of the
underwriters are subject to conditions precedent and that the underwriters with respect to a sale of securities will be obligated to purchase all of those securities if they purchase any of those securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may grant to the underwriters options to purchase additional securities to cover over-allotments, if any, at the public offering price with
additional underwriting discounts or commissions. If we grant any over-allotment option, the terms of any over-allotment option will be set forth in the prospectus supplement relating to those securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a dealer is utilized in the sales of securities in respect of which this prospectus is delivered, we will sell those securities to the
dealer as principal. The dealer may then resell those securities to the public at varying prices to be determined by the dealer at the time of resale. Any reselling dealer may be deemed to be an underwriter, as the term is defined in the Securities
Act, of the securities so offered and sold. The name of the dealer and the terms of the transaction will be set forth in the related prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Offers to purchase securities may be solicited by agents designated by us from time to time. Any agent involved in the offer or sale of the
securities in respect of which this prospectus is delivered will be named, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any commissions payable by us to the agent will be set forth, in the applicable prospectus supplement. Unless otherwise indicated in the prospectus supplement, any agent will be acting on a
reasonable best efforts basis for the period of its appointment. Any agent may be deemed to be an underwriter, as that term is defined in the Securities Act, of the securities so offered and sold. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Offers to purchase securities may be solicited directly by us and the sale of those securities may be made by us directly to institutional
investors or others, who may be deemed to be underwriters within the meaning of the Securities Act with respect to any resale of those securities. The terms of any sales of this type will be described in the related prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Underwriters, dealers, agents and remarketing firms may be entitled under relevant agreements entered into with us to indemnification by us
against certain civil liabilities, including liabilities under the Securities Act, that may arise from any untrue statement or alleged untrue statement of a material fact or any omission or alleged omission to state a material fact in this
prospectus, any supplement or amendment hereto, or in the Registration Statement of which this prospectus forms a part, or to contribution with respect to payments which the agents, underwriters or dealers may be required to make. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If so indicated in the prospectus supplement, we will authorize underwriters or other persons acting as our agents to solicit offers by
institutions to purchase securities from us pursuant to contracts providing for payments and delivery on a future date. Institutions with which contracts of this type may be made include commercial and savings banks, insurance companies, pension
funds, investment companies, educational and charitable institutions and others, but in all cases those institutions must be approved by us. The obligations of any purchaser under any contract of this type will be subject to the condition that the
purchase of the securities shall not at the time of delivery be prohibited under the laws of the jurisdiction to which the purchaser is subject. The underwriters and other persons acting as our agents will not have any responsibility in respect of
the validity or performance of those contracts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One or more firms, referred to as &#147;remarketing firms,&#148; may also offer or sell
the securities, if the prospectus supplement so indicates, in connection with a remarketing arrangement upon their purchase. Remarketing firms will act as principals for their own accounts or as agents for Teva or any of its subsidiaries. These
remarketing firms will offer or sell the securities in accordance with a redemption or repayment pursuant to the terms of the securities. The prospectus supplement will identify any remarketing firm and the terms of its agreement, if any, with Teva
or any of its subsidiaries and will describe the remarketing firm&#146;s compensation. Remarketing firms may be deemed to be underwriters in connection with the securities they remarket. Remarketing firms may be entitled under agreements that may be
entered into with Teva or any of its subsidiaries to indemnification by Teva or any of its subsidiaries against certain civil liabilities, including liabilities under the Securities Act, and may engage in transactions with or perform services for
Teva or any of its subsidiaries in the ordinary course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Disclosure in the prospectus supplement of our use of delayed
delivery contracts will include the commission that underwriters and agents soliciting purchases of the securities under delayed contracts will be entitled to receive in addition to the date when we will demand payment and delivery of the securities
under the delayed delivery contracts. These delayed delivery contracts will be subject only to the conditions that we describe in the prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any ADSs will be listed on the NYSE, but any other securities may or may not be listed on a national securities exchange. In connection with
the offering of securities, persons participating in the offering, such as any underwriters, may purchase and sell securities in the open market. These transactions may include over-allotment and stabilizing transactions and purchases to cover
syndicate short positions created in connection with the offering. Stabilizing transactions consist of bids or purchases for the purpose of preventing or retarding a decline in the market price of the securities, and syndicate short positions
involve the sale by underwriters of a greater number of securities than they are required to purchase from any issuer in the offering. Underwriters also </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may impose a penalty bid, whereby selling concessions allowed to syndicate members or other broker-dealers in respect of the securities sold in the offering for their account may be reclaimed by
the syndicate if the securities are repurchased by the syndicate in stabilizing or covering transactions. These activities may stabilize, maintain or otherwise affect the market price of the securities, which may be higher than the price that might
prevail in the open market, and these activities, if commenced, may be discontinued at any time. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc552144_13"></A>EXPERTS
</B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements and management&#146;s assessment of the effectiveness of internal control over financial reporting
(which is included in management&#146;s report on internal control over financial reporting) incorporated in this prospectus by reference to the Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> of Teva Pharmaceutical Industries
Limited for the year ended December&nbsp;31, 2017, have been so incorporated in reliance on the reports of Kesselman &amp; Kesselman, an independent registered public accounting firm in Israel and a member of PricewaterhouseCoopers International
Limited, given on the authority of said firm as experts in auditing and accounting. </P>  <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc552144_14"></A>LEGAL MATTERS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain legal matters with respect to United States and New York law with respect to the validity of certain of the offered
securities will be passed upon for the issuers by Kirkland&nbsp;&amp; Ellis LLP, New York, New York. Certain legal matters with respect to Israeli law with respect to the validity of certain of the offered securities will be passed upon for the
issuers by Tulchinsky Stern Marciano Cohen Levitski&nbsp;&amp; Co., Israel. Certain legal matters with respect to Cura&ccedil;ao law will be passed upon for the issuers by VanEps Kunneman VanDoorne, Cura&ccedil;ao. Certain legal matters with respect
to Dutch law will be passed upon for the issuers by Van Doorne N.V., Netherlands. Any underwriters will be advised about other issues relating to any offering by their own counsel. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc552144_15"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Available Information </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This
prospectus is part of a Registration Statement that we filed with the SEC. The Registration Statement, including the attached exhibits, contains additional relevant information about us. The rules and regulations of the SEC allow us to omit some of
the information included in the Registration Statement from this prospectus. In addition, we file annual and quarterly reports and other information with the SEC. You may read and copy such material at the public reference facilities maintained by
the SEC at 100 F Street, N.E., Room 1580, Washington, D.C. 20549, as well as at the SEC&#146;s regional offices. You may also obtain copies of such material from the SEC at prescribed rates by writing to the Public Reference Section of the SEC, 100
F Street, N.E., Room 1580, Washington, D.C. 20549. Please call the SEC at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-SEC-0330</FONT></FONT></FONT> for further information on the public
reference rooms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC maintains an Internet website at <U>http://www.sec.gov</U> that contains reports, proxies, information
statements and other material that are filed through the SEC&#146;s Electronic Data Gathering, Analysis and Retrieval (EDGAR) system and filed electronically with the SEC. We began filing through the EDGAR system on October&nbsp;31, 2002. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information about us is also available on our website at <U>http://www.tevapharm.com</U>. Such information on our website is not part of this
prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Incorporation by Reference </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rules of the SEC allow us to incorporate by reference information into this prospectus. The information incorporated by reference is
considered to be a part of this prospectus, and information that we file later with the SEC will automatically update and supersede this information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following documents filed with the SEC are incorporated into this prospectus by reference: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Our Annual Report on Form 10-K for the year ended December 31, 2017; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Our Current Report on Form 8-K filed with the SEC on February 1, 2018 (with respect to Item 1.01 and Item 9.01 only) and March 14, 2018. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also incorporate by reference into this prospectus all documents (other than current reports furnished under Items 2.02 or Item 7.01 of
Form <FONT STYLE="white-space:nowrap">8-K</FONT> and exhibits filed on such form that are related to such items) that are filed by us with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (i)&nbsp;after the date of the
initial filing of the Registration Statement of which this prospectus is a part and prior to the effectiveness of the Registration Statement, or (ii)&nbsp;after the date of this prospectus until we sell all of the securities covered by this
prospectus or the sale of securities by us pursuant to this prospectus is terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any statement contained in a document incorporated
or deemed to be incorporated by reference shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in this prospectus or in any other subsequently filed document which is
incorporated or deemed to be incorporated by reference modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may also obtain copies of these documents free of charge through our website at <U>http://www.tevapharm.com</U> or by contacting us
at our address or telephone number set forth below. Other than the documents incorporated by reference herein as specified above, the documents and other information on our website are not incorporated by reference herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Teva Pharmaceutical Industries Limited </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Investor Relations </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>5
Basel Street </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>P.O. Box 3190 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Petach Tikva 4951033 Israel </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+972-3-926-7267</FONT></FONT></FONT>
</B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc552144_16"></A>ENFORCEMENT OF CIVIL LIABILITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Teva Pharmaceutical Industries Limited </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva is organized under the laws of Israel and certain of Teva&#146;s directors and officers reside outside of the United States. As a result,
service of process on them may be difficult to effect in the United States. Furthermore, a substantial portion of Teva&#146;s assets are located outside of the United States. Therefore, any judgment obtained in the United States against us or any of
our directors and officers may not be collectible within the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to various time limitations, an Israeli court may
declare a judgment rendered by a foreign court in a civil matter, including judgments awarding monetary or other damages in non civil matters, enforceable if it finds that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">the judgment was rendered by a court which was, according to the foreign country&#146;s law, competent to render it; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">the judgment is no longer appealable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">the obligation in the judgment is enforceable according to the rules relating to the enforceability of judgments in Israel and the substance of the judgment is not contrary to public policy in Israel; and
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">the judgment can be executed in the state in which it was given. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A foreign judgment will not
be declared enforceable by Israeli courts if it was given in a state, the laws of which do not provide for the enforcement of judgments of Israeli courts (subject to exceptional cases) or if its enforcement is likely to prejudice the sovereignty or
security of Israel. An Israeli court also will not declare a foreign judgment enforceable if it is proven to the Israeli court that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">the judgment was obtained by fraud; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">there was no due process; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">the judgment was given by a court not competent to render it according to the laws of private international law in Israel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">the judgment conflicts with another judgment that was given in the same matter between the same parties and which is still valid; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">at the time the action was brought to the foreign court a claim in the same matter and between the same parties was pending before a court or tribunal in Israel. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Teva Finance Company BV, Teva Finance IV BV, Teva Finance V BV, Teva Finance NV, Teva Finance Netherlands II, Teva Finance Netherlands III and Teva
Finance Netherlands IV </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the BVs is organized under the laws of Cura&ccedil;ao and each of the Netherlands BVs is organized
under the laws of the Netherlands, and its managing directors and supervisory directors reside outside the United States, and all or a significant portion of the assets of such person may be, and substantially all of the assets of each of the BVs
and the Netherlands BVs are, located outside the United States. As a result, it may not be possible to effect service of process within the United States upon any of the BVs or the Netherlands BVs or any such person or to enforce against any of the
BVs or the Netherlands BVs or any such person judgments obtained in United States courts predicated upon the civil liability provisions of the federal securities laws of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The United States and Cura&ccedil;ao and the United States and the Netherlands do not currently have a treaty providing for reciprocal
recognition and enforcement of judgments in civil and commercial matters. Therefore, a final judgment for the payment of money rendered by any federal or state court in the United States based on civil liability, whether or not predicated solely
upon the federal securities laws of the United States, would not be directly enforceable in Cura&ccedil;ao or the Netherlands. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the party in whose favor such a final judgment is rendered brings a new suit in a
competent court in Cura&ccedil;ao or the Netherlands, that party may submit to the Cura&ccedil;ao or Dutch court the final judgment that has been rendered in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A foreign judgment would be enforceable in Cura&ccedil;ao generally, without any <FONT STYLE="white-space:nowrap">re-examination</FONT> of the
merits of the original judgment provided that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">the judgment is valid and enforceable in the jurisdiction where rendered; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">the judgment has been rendered by a foreign court that has accepted jurisdiction in accordance with an international accepted ground for jurisdiction; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">no principles of due process were violated in the proceedings that resulted in the foreign judgment; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">the recognition and enforcement of the judgment does not violate Cura&ccedil;ao principles of public order; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">the judgment is not contrary to a prior or simultaneous judgment between the same parties of a Cura&ccedil;ao court or of a foreign court which judgement can be recognized and enforced in Cura&ccedil;ao; and
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">the judgment has not been rendered in proceedings of a penal, revenue or other public law nature. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Dutch court will generally grant the same judgment without <FONT STYLE="white-space:nowrap">re-litigation</FONT> on the merits if: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">that judgment results from legal proceedings compatible with Dutch notions of due process; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">that judgment does not contravene public policy of the Netherlands; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">the jurisdiction of the relevant federal or state court in the United States has been based on internationally accepted principles of international civil law. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the foregoing and provided that service of process occurs in accordance with applicable treaties, investors should be able to
enforce in the Netherlands final judgments in civil and commercial matters obtained from U.S. federal or state courts. However, it is doubtful whether a Dutch court would accept jurisdiction and impose civil liability in an original action commenced
in the Netherlands and predicated solely upon U.S. securities laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:19pt; font-family:Times New Roman" ALIGN="center"><B>TEVA&nbsp;PHARMACEUTICAL
INDUSTRIES&nbsp;LIMITED </B></P>  <P STYLE="margin-top:45pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>American Depositary Shares, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>each representing one Ordinary Share, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Debt Securities, </B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Purchase Contracts and Units </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>TEVA PHARMACEUTICAL FINANCE IV, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>TEVA PHARMACEUTICAL FINANCE V, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>TEVA PHARMACEUTICAL FINANCE VI, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>TEVA PHARMACEUTICAL FINANCE COMPANY B.V. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>TEVA PHARMACEUTICAL FINANCE IV B.V. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>TEVA PHARMACEUTICAL FINANCE V B.V. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>TEVA PHARMACEUTICAL FINANCE N.V. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>TEVA PHARMACEUTICAL FINANCE NETHERLANDS II B.V. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>TEVA PHARMACEUTICAL FINANCE NETHERLANDS III B.V. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>TEVA PHARMACEUTICAL FINANCE NETHERLANDS IV B.V. </B></P>
<P STYLE="margin-top:30pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Debt Securities, fully and unconditionally guaranteed by </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>TEVA PHARMACEUTICAL INDUSTRIES LIMITED </B></P> <P STYLE="font-size:45pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:45pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>You should rely only on the information contained or incorporated by reference in this prospectus. We have not authorized anyone to provide
you with different information.&nbsp;You should not assume that the information contained or incorporated by reference in this prospectus is accurate as of any date other than the date of this prospectus.&nbsp;We are not making an offer of these
securities in any state where the offer is not permitted. </B></P> <P STYLE="margin-top:50pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus
is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018. </B></P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II. INFORMATION NOT REQUIRED IN PROSPECTUS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM&nbsp;14. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth all costs and expenses in connection with the offer and sale of the securities being registered. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="90%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">622,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer agent and trustee fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Estimated expenses are not presently known. The foregoing sets forth the general categories of expenses (other than underwriting discounts and commissions) that we anticipate we will incur in connection with the
offering of securities under this Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3.</FONT> An estimate of the aggregate expenses in connection with the issuance and distribution of the securities being offered will be included in
the applicable prospectus supplement. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM&nbsp;15. INDEMNIFICATION OF DIRECTORS AND OFFICERS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Teva Pharmaceutical Industries Limited </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Israeli Companies Law, 5759-1999 (the &#147;Companies Law&#148;) provides that a company may not exempt or indemnify a director or an
executive officer (collectively, an &#147;Officer&#148;), or enter into an insurance contract, which would provide coverage for any liability incurred as a result of any of the following: (i)&nbsp;a breach by the Officer of his or her duty of
loyalty unless, with respect to insurance coverage or indemnification, due to a breach of his or her duty of loyalty to the company committed in good faith and with reasonable grounds to believe that such act would not prejudice the interests of the
company; (ii)&nbsp;a breach by the Officer of his or her duty of care to the company committed intentionally or recklessly; (iii)&nbsp;any act or omission done with the intent of unlawfully realizing personal gain; or (iv)&nbsp;a fine, monetary
sanction, forfeit or penalty imposed upon an Officer. In addition, the Companies Law provides that Officers can only be exempted in advance with respect to liability for damages caused as a result of a breach of their duty of care to the company
(but not for such breaches committed intentionally or recklessly, as noted above, or in connection with a distribution (as defined in the Companies Law)). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva&#146;s Articles include provisions under which Officers of Teva are or may be insured, exempted or indemnified against liability which
they may incur in their capacities as such, subject to the Companies Law. Articles 102 through 105 of Teva&#146;s Articles provide as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">102.</TD>
<TD ALIGN="left" VALIGN="top">Subject to the provisions of applicable law, the Company shall be entitled to engage in a contract for insurance of the liability of any Officer of the Company, in whole or in part, in respect of any liability or
expense imposed on an Officer or expended by him or her as a result of any action which was performed by said Officer in his or her capacity as an Officer of the Company for which insurance may be provided under applicable law, including in respect
of any liability imposed on any Officer with respect to any of the following: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">Breach of a duty of care <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">vis-&agrave;-vis</FONT></FONT> the Company or
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">vis-&agrave;-vis</FONT></FONT> another person; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Breach of a duty of loyalty <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">vis-&agrave;-vis</FONT></FONT> the Company, provided that the Officer acted in good faith and had reasonable grounds to
believe that the action in question would not adversely affect the Company; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">Financial liability which shall be imposed upon said Officer in favor of another person as a result of any action which was performed by said Officer in his or her capacity as an Officer of the Company; including (c1) A
payment which said Officer is obligated to make to an injured party as set forth in Section&nbsp;52(54)(a)(1)(a) of the Securities Law and expenses that said Officer incurred in connection with a proceeding under Chapters H&#146;3, H&#146;4 or
I&#146;1 of the Securities Law, including reasonable legal expenses, which term includes attorney fees, or in connection with Article D of Chapter Four of Part Nine of the Companies Law. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">103.</TD>
<TD ALIGN="left" VALIGN="top">Subject to the provisions of applicable law, the Company shall be entitled to indemnify <I>post factum </I>and/or undertake in advance to indemnify any Officer of the Company, as a result of any liability or an expense
imposed on him or her or expended by him or her as a result of any action which was performed by said Officer in his or her capacity as an Officer of the Company, in respect of any liability or expense for which indemnification may be provided under
applicable law, including in respect of any liability or an expense imposed on the Officer as follows: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">Financial liability imposed upon said Officer in favor of another person by virtue of a decision by a court of law, including a decision by way of settlement or a decision in arbitration which has been confirmed by a
court of law, provided that the undertaking to indemnify in advance shall be limited to events which, in the opinion of the Board of Directors of the Company, are foreseeable, in light of the Company&#146;s activities at the time that the
undertaking to indemnify was given, and shall further be limited to amounts or criteria that the Board of Directors has determined to be reasonable under the circumstances, and provided further that in the undertaking to indemnify in advance the
events that the Board of Directors believes to be foreseeable in light of the Company&#146;s activities at the time that the undertaking to indemnify was given are mentioned, as is the amount or criteria that the Board of Directors determined to be
reasonable under the relevant circumstances, including (a1) A payment which said Officer is obligated to make to an injured party as set forth in Section&nbsp;52(54)(a)(1)(a) of the Securities Law and expenses that said Officer incurred in
connection with a proceeding under Chapters H&#146;3, H&#146;4 or I&#146;1 of the Securities Law, including reasonable legal expenses, which term includes attorney fees, or in connection with Article D of Chapter Four of Part Nine of the Companies
Law. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Reasonable litigation expenses, including attorney fees, expended by the Officer as a result of an inquiry or a proceeding conducted in respect of such Officer by an authority authorized to conduct same, which was
concluded without the submission of an indictment against said Officer and without any financial penalty being imposed on said Officer instead of a criminal proceeding (as such term is defined in the Companies Law), or which was concluded without
the submission of an indictment against said Officer with a financial penalty being imposed on said Officer instead of a criminal proceeding, in respect of a criminal charge which does not require proof of criminal intent or in connection with a
financial sanction. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">Reasonable litigation expenses, including attorney fees, which said Officer shall have expended or shall have been obligated to expend by a court of law, in any proceedings which shall have been filed against said
Officer by or on behalf of the Company or by another person, or with regard to any criminal charge of which said Officer was acquitted, or with regard to any criminal charge of which said Officer was convicted which does not require proof of
criminal intent. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">104.</TD>
<TD ALIGN="left" VALIGN="top">Subject to the provisions of applicable law, the Company shall be entitled, in advance, to exempt any Officer of the Company from liability, in whole or in part, with regard to damage incurred as a result of the breach
of duty of care <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">vis-&agrave;-vis</FONT></FONT> the Company. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">105.</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Notwithstanding the foregoing, the Company shall be entitled to insure, indemnify and exempt from liability any
Officer of the Company to the fullest extent permitted by applicable law. Accordingly, (i)&nbsp;any amendment to the Companies Law, the Securities Law or any other applicable law expanding the right of any Officer to be insured, indemnified or
exempted from liability in comparison to the provisions of these Articles shall, to the extent permitted by applicable law, immediately apply to the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
fullest extent permitted by applicable law, and (ii)&nbsp;any amendment to the Companies Law, the Securities Law or any other applicable law adversely affecting the right of any Officer to be
insured, indemnified or exempted from liability in comparison to the provision of these Articles shall not be in effect <I>post factum </I>and shall not affect the Company&#146;s obligation or ability to insure, indemnify or exempt from liability an
Officer for any act or omission occurring prior to such amendment, unless otherwise provided by applicable law. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to
indemnification and release agreements, Teva releases its Officers from liability and indemnifies them to the fullest extent permitted by law and the Articles. Under these agreements, Teva undertakes to indemnify each Officer for monetary
liabilities imposed by a court judgment (including a settlement or an arbitrator&#146;s award that were approved by a court), provided that such undertaking (i)&nbsp;shall be limited to matters that are connected or otherwise related to certain
events or circumstances set forth therein, and (ii)&nbsp;shall not exceed $200&nbsp;million in the aggregate per Officer. Under Israeli law, indemnification is subject to other limitations, including those described above. Subject to applicable law,
Teva may also indemnify its Officers following specific events. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva&#146;s Officers are also covered by directors&#146; and
officers&#146; liability insurance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Teva Pharmaceutical Finance IV, LLC, Teva Pharmaceutical Finance V, LLC and Teva Pharmaceutical Finance VI, LLC
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Section&nbsp;18-108</FONT> of the Delaware Limited Liability Company Act provides that
&#147;subject to such standards and restrictions, if any, as are set forth in its limited liability company agreement, a limited liability company may, and shall have the power to, indemnify and hold harmless any member or manager or other person
from and against any and all claims and demands whatsoever.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;3.3 of the operating agreement of each of the LLCs
provides as follows (with the references therein to the &#147;Company&#148; referring to the applicable LLC): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any Person made, or
threatened to be made, a party to any action or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that such Person is or was (i)&nbsp;a Member, or (ii)&nbsp;an employee, officer, director, manager,
shareholder or partner of a Member, or (iii)&nbsp;a Manager, or (iv)&nbsp;such other Persons (including employees of the Company) as the Majority in Interest of the Members may designate from time to time, in their sole and absolute discretion
(collectively, the &#147;Indemnified Persons&#148;), shall be indemnified by the Company for any losses or damage sustained with respect to such action or proceeding, and the Company shall advance such Indemnified Person&#146;s reasonable related
expenses to the fullest extent permitted by law. The Company shall have the power to purchase and maintain insurance on behalf of the Indemnified Persons against any liability asserted against or incurred by them. The duty of the Company to
indemnify the Indemnified Persons under this Section&nbsp;3.3 shall not extend to actions or omissions of any Indemnified Person which are grossly negligent or which involve fraud, misrepresentation, bad faith, or other willful misconduct by such
Indemnified Person or which are in material breach or violation by such Indemnified Person of this Agreement or which are in derogation of the fiduciary duties owed by such Indemnified Person to the Company and the Members, in each case as
determined by a court of competent jurisdiction. No Indemnified Person shall be liable to the Company or any other Member for actions taken in good faith. The duty of the Company to indemnify the Indemnified Persons under this Section&nbsp;3.3 shall
be limited to the assets of the Company, and no recourse shall be available against any Member for satisfaction of such indemnification obligations of the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Teva Pharmaceutical Finance Company B.V., Teva Pharmaceutical Finance IV B.V., Teva Pharmaceutical Finance V B.V. and Teva Pharmaceutical Finance N.V.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the laws of Cura&ccedil;ao, indemnification by a company of its officers and directors for liability incurred in their
capacity as such is not permitted where the liability results from the gross negligence or willful malfeasance of the officers or directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Article 13 of the articles of incorporation of each of the BVs (other than Teva Finance
Company BV and Teva Finance NV) provides as follows (with the references therein to the &#147;Company&#148; referring to the applicable BV): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The Company shall indemnify to the fullest extent permitted under the laws of Cura&ccedil;ao or any other applicable law any person who was or is a party or is threatened to be made a party to any threatened, pending or
contemplated claims, actions, suits or proceedings by reason of the fact that he is or was a Supervisory Director, Managing Director, officer, employee or agent, other service provider, manager or advisor of the Company, or was serving at the
request of the Company as a Supervisory Director, Managing Director, officer, employee, agent, other service provider, manager or advisor of another Company, partnership, joint venture, trust or other enterprise against any and all losses,
judgments, fines, amounts paid in settlements and expenses (including attorney&#146;s fees) actually and reasonably incurred by him in connection with the defense or settlement of such claim, action, suit or proceeding if he acted in good faith and
in a manner he reasonably believed to be in or not opposed to the best interest of the Company and except that no indemnification shall be made in respect of any claim, action, suit or proceeding as to which such person shall have been adjudged to
be liable for gross negligence or willful misconduct or that such person did not act in good faith and could not reasonably have presumed that his actions were in the best interests of the Company in the performance of his duty to the Company
unless, and only to the extent that a court of competent jurisdiction in Cura&ccedil;ao or the court in which such action or suit was brought shall determine in view of all the circumstances of the case, such person is fairly and reasonably entitled
to indemnity for such expenses which such court shall deem proper. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">To the extent that a Supervisory Director, Managing Director, officer, employee, agent, other service provider, manager or advisor of the Company has been successful on the merits or otherwise in defense of any action,
suit or proceedings of the kind referred to in paragraph 1 of this Article 13, or in defense of any claim, issue or matter related thereto, he shall be indemnified against expenses (including attorney&#146;s fees) actually and reasonably incurred by
him in connection therewith. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Any indemnification (unless ordered by a court of competent jurisdiction) shall be made by the Company only as authorized in the specific case upon a determination that indemnification of the Supervisory Director,
Managing Director, officer, employee, agent, other service provider, manager or advisor is proper in the circumstances because he has met the applicable standard of conduct set forth in this Article 13. Such determination shall be made (i)&nbsp;by
the Supervisory Board, provided the relevant Supervisory Director seeking indemnification is not a party to such action, suit or proceedings, (ii)&nbsp;if the sole Supervisory Director or all the Supervisory Directors in office are a party to such
action, suit or proceedings, by independent legal counsel in a written opinion, or (iii)&nbsp;by resolution adopted at a General Meeting of Shareholders. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">Expenses incurred in defending any such suit or proceedings may be paid by the Company in advance of the final disposition of such action, suit or proceeding, upon receipt of an undertaking by or on behalf of the
Supervisory Director, Managing Director, officer, employee, agent, other service provider, manager or advisor to repay such amount if it shall ultimately be determined that he is not entitled to be indemnified. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The indemnification provided by this Article 13 shall not be deemed exclusive of any other right to which those indemnified may be entitled under any agreement, vote of Shareholders or disinterested Supervisory Director
or otherwise, both as to action in his official capacity while holding such office, and shall continue as to a person who has ceased to be a Supervisory Director, Managing Director, officer, employee, agent, other service provider, manager or
advisor. The indemnification shall inure to the benefit of the heirs, executors and administrators or successors in interest of those persons indemnified. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Article 30 of the articles of association of Teva Finance Company BV provides as follows:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The Company shall indemnify to the fullest extent permitted under the laws of Cura&ccedil;ao or any other applicable law any person who was or is a party or is threatened to be made a party to any threatened, pending or
contemplated claims, actions, suits or proceedings by reason of the fact that he is or was a Supervisory Director, Managing Director, officer, employee or agent, other service provider, manager or advisor of the Company, or was serving at the
request of the Company as a Supervisory Director, Managing Director, officer, employee, agent, other service provider, manager or advisor of another Company, partnership, joint venture, trust or other enterprise against any and all losses,
judgments, fines, amounts paid in settlements and expenses (including attorney&#146;s fees) actually and reasonably incurred by him in connection with the defense or settlement of such claim, action, suit or proceeding if he acted in good faith and
in a manner he reasonably believed to be in or not opposed to the best interest of the Company and except that no indemnification shall be made in respect of any claim, action, suit or proceeding as to which such person shall have been adjudged to
be liable for gross negligence or willful misconduct or that such person did not act in good faith and could not reasonably have presumed that his actions were in the best interests of the Company in the performance of his duty to the Company
unless, and only to the extent that a court of competent jurisdiction in Cura&ccedil;ao or the court in which such action or suit was brought shall determine in view of all the circumstances of the case, such person is fairly and reasonably entitled
to indemnity for such expenses which such court shall deem proper. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">To the extent that a Supervisory Director, Managing Director, officer, employee, agent, other service provider, manager or advisor of the Company has been successful on the merits or otherwise in defense of any action,
suit or proceedings of the kind referred to in paragraph 1 of this Article 30, or in defense of any claim, issue or matter related thereto, he shall be indemnified against expenses (including attorney&#146;s fees) actually and reasonably incurred by
him in connection therewith. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Any indemnification (unless ordered by a court of competent jurisdiction) shall be made by the Company only as authorized in the specific case upon a determination that indemnification of the Supervisory Director,
Managing Director, officer, employee, agent, other service provider, manager or advisor is proper in the circumstances because he has met the applicable standard of conduct set forth in this Article 30. Such determination shall be made (i)&nbsp;by
the Supervisory Board, provided the relevant Supervisory Director seeking indemnification is not a party to such action, suit or proceedings, (ii)&nbsp;if the sole Supervisory Director or all the Supervisory Directors in office are a party to such
action, suit or proceedings, by independent legal counsel in a written opinion, or (iii)&nbsp;by resolution adopted at a General Meeting of Shareholders. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">Expenses incurred in defending any such suit or proceedings may be paid by the Company in advance of the final disposition of such action, suit or proceeding, upon receipt of an undertaking by or on behalf of the
Supervisory Director, Managing Director, officer, employee, agent, other service provider, manager or advisor to repay such amount if it shall ultimately be determined that he is not entitled to be indemnified. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The indemnification provided by this Article 30 shall not be deemed exclusive of any other right to which those indemnified may be entitled under any agreement, vote of Shareholders or disinterested Supervisory Director
or otherwise, both as to action in his official capacity while holding such office, and shall continue as to a person who has ceased to be a Supervisory Director, Managing Director, officer, employee, agent, other service provider, manager or
advisor. The indemnification shall inure to the benefit of the heirs, executors and administrators or successors in interest of those persons indemnified. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The articles of incorporation of Teva Finance NV do not contain such indemnification provisions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Teva Pharmaceutical Finance Netherlands II B.V., Teva Pharmaceutical Finance Netherlands III B.V. and
Teva Pharmaceutical Finance Netherlands IV B.V. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the laws of the Netherlands, indemnification by a company of its officers
and directors for liability incurred in their capacity as such is not permitted where the liability results from the gross negligence or willful malfeasance of the officers or directors. Subject to the foregoing, the general meeting of shareholders
of the Netherlands BVs can grant an indemnity or an annual discharge to a managing director of the Netherlands BVs. As for the indemnity, article 16(3) of the articles of association of the Netherlands BVs provides that &#147;the remuneration and
the other employment conditions of each managing director are determined by the general meeting.&#148; As for the annual discharge, the relevant clauses of Article 21 of the articles of association of each of the Netherlands BVs provide as follows:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The general meeting adopts the financial statements. The management board adopts the annual report. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Adoption of the financial statements does not discharge a managing director, unless the provisions of paragraph 3 apply. By separate resolution the general meeting can discharge a managing director for the management
conducted in the financial year in question, insofar as that management is apparent from the financial statements or has been made known to the general meeting. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">If all the shareholders are also managing directors of the Company, signing of the financial statements by all the managing directors also serves as adoption of the financial statements, provided that all the parties
entitled to attend meetings have been given the opportunity to take note of the drafted financial statements and have agreed to this manner of adoption. Adoption of the financial statements in this manner discharges the managing directors.
</TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM&nbsp;16. EXHIBITS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exhibits listed below in the &#147;Exhibit Index&#148; are part of this Registration Statement and are numbered in accordance with Item 601
of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ITEM&nbsp;17. UNDERTAKINGS </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">The undersigned registrants hereby undertake: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">To include any prospectus required by Section&nbsp;10(a)(3) of the Securities Act of 1933; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a
fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or any decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which
was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent
no more than a 20% change in the maximum aggregate offering price set forth in the &#147;Calculation of Registration Fee&#148; table in the effective Registration Statement; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top">To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>provided, however</I>, that paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) of this section do not apply if
the information required to be included in a post-effective amendment by those paragraphs is contained in </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
periodic reports filed with or furnished to the SEC by the registrants pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the Securities Exchange Act of 1934 that are incorporated by reference
in the Registration Statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the Registration Statement. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new Registration Statement relating to the securities offered therein, and
the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top">Each prospectus filed by the registrants pursuant to Rule 424(b)(3) shall be deemed to be part of the Registration Statement as of the date the filed prospectus was deemed part of and included in the Registration
Statement; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top">Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a Registration Statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or
(x)&nbsp;for the purpose of providing the information required by section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the Registration Statement as of the earlier of the date such form of prospectus is first
used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such
date shall be deemed to be a new effective date of the Registration Statement relating to the securities in the Registration Statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the
initial bona fide offering thereof. Provided, however, that no statement made in a Registration Statement or prospectus that is part of the Registration Statement or made in a document incorporated or deemed incorporated by reference into the
Registration Statement or prospectus that is part of the Registration Statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the Registration Statement or
prospectus that was part of the Registration Statement or made in any such document immediately prior to such effective date; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">That, for the purpose of determining liability of the registrants under the Securities Act of 1933 to any purchaser in the initial distribution of the securities: </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The undersigned registrants undertake that in a primary offering of securities of the undersigned registrants pursuant to this Registration Statement, regardless of the underwriting method used to sell the securities to
the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrants will be a seller to the purchaser and will be considered to offer or sell such securities to such
purchaser: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">Any preliminary prospectus or prospectus of the undersigned registrants relating to the offering required to be filed pursuant to Rule 424; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrants or used or referred to by the undersigned registrants; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrants or its securities provided by or on behalf of the undersigned registrants; and
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top">Any other communication that is an offer in the offering made by the undersigned registrants to the purchaser. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">The undersigned registrants hereby undertake that, for purposes of determining any liability under the Securities Act of 1933, each filing of any registrants&#146; annual report pursuant to Section&nbsp;13(a) or
Section&nbsp;15(d) of the Securities Exchange Act of 1934 that is incorporated by reference in the Registration Statement shall be deemed to be a new Registration Statement relating to the securities offered therein, and the offering of such
securities at that time shall be deemed to be the initial bona fide offering thereof. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrants pursuant to the foregoing provisions, the
registrants have been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against
such liabilities (other than the payment by the registrants of expenses incurred or paid by a director, officer or controlling person of the registrants in the successful defense of any action, suit or proceeding) is asserted by such director,
officer or controlling person in connection with the securities being registered, the registrants will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the
question whether such indemnification by it is against public policy as expressed in the Act will be governed by the final adjudication of such issue. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">The undersigned registrants hereby undertake to file an application for the purpose of determining the eligibility of the trustee to act under Subsection (a)&nbsp;of Section&nbsp;310 of the Trust Indenture Act in
accordance with the rules and regulations prescribed by the SEC under Section&nbsp;305(b)(2) of the Trust Indenture Act. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="91%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*1.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Underwriting Agreement relating to ordinary shares issued by Teva Pharmaceutical Industries Limited</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*1.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Underwriting Agreement relating to purchase contracts issued by Teva Pharmaceutical Industries Limited</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*1.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Underwriting Agreement relating to units issued by Teva Pharmaceutical Industries Limited</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*1.4</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Underwriting Agreement relating to debt securities issued by Teva Pharmaceutical Industries Limited</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*1.5</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Underwriting Agreement relating to debt securities issued by Teva Pharmaceutical Finance IV, LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*1.6</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Underwriting Agreement relating to debt securities issued by Teva Pharmaceutical Finance V, LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*1.7</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Underwriting Agreement relating to debt securities issued by Teva Pharmaceutical Finance VI, LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*1.8</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Underwriting Agreement relating to debt securities issued by Teva Pharmaceutical Finance Company B.V.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*1.9</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Underwriting Agreement relating to debt securities issued by Teva Pharmaceutical Finance IV B.V.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*1.10</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Underwriting Agreement relating to debt securities issued by Teva Pharmaceutical Finance V B.V.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*1.11</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Underwriting Agreement relating to debt securities issued by Teva Pharmaceutical Finance N.V.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*1.12</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Underwriting Agreement relating to debt securities issued by Teva Pharmaceutical Finance Netherlands II B.V.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*1.13</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Underwriting Agreement relating to debt securities issued by Teva Pharmaceutical Finance Netherlands III B.V.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*1.14</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Underwriting Agreement relating to debt securities issued by Teva Pharmaceutical Finance Netherlands IV B.V.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Memorandum of Association of Teva Pharmaceutical Industries Limited <SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP> (incorporated by reference to Exhibit 3.1 to Registration Statement on Form F-1 (Reg. No.
33-15736))</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex32.htm">Amendment to Memorandum of Association of Teva Pharmaceutical Industries Limited <SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP> (incorporated
 by reference to Exhibit 3.2 to Form 10-K filed on February 12, 2018) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518039076/d529462dex33.htm">Articles of Association of Teva Pharmaceutical Industries Limited <SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP> (incorporated by reference
 to Exhibit 3.3 to Form 10-K filed on February 12, 2018) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000114544312001217/d29912_exa.htm">Amended and Restated Deposit Agreement, dated November 5, 2012, among Teva Pharmaceutical Industries Limited, JPMorgan Chase Bank N.A., as depository,
 and the holders from time to time of ADSs (incorporated by reference to Teva Pharmaceutical Industries Limited&#146;s Registration Statement on Form F-6 (Reg. No. 333-184652)) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000114544312001217/d29912_exd.htm">Form of American Depositary Receipt (incorporated by reference to Teva Pharmaceutical Industries Limited&#146;s Registration Statement on Form F-6
(Reg. No. 333-184652)) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119380516002720/e614709_ex99-a2.htm">Amendment to Amended and Restated Deposit Agreement, dated February 29, 2016, among Teva Pharmaceutical Industries Limited, JPMorgan Chase Bank
 N.A., as depository, and the holders from time to time of ADSs (incorporated by reference to Teva Pharmaceutical Industries Limited&#146;s Post-Effective Amendment to Registration Statement on Form F-6 (Reg. No. 333-208239)) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#134;4.4</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0000818686/000119312518023821/d532134dex41.htm">Form of Senior Teva Pharmaceutical Industries Limited Indenture</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#134;4.5</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0000818686/000119312518023821/d532134dex42.htm">Form of Guaranteed Senior Finance Subsidiary Indenture</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#134;4.6</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0000818686/000119312518023821/d532134dex43.htm">Form of Subordinated Teva Pharmaceutical Industries Limited Indenture </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#134;4.7</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0000818686/000119312518023821/d532134dex44.htm">Form of Guaranteed Subordinated Finance Subsidiary Indenture</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*4.8</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Form of Purchase Contract Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;**5.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d552144dex51.htm">Opinion of Tulchinsky Stern Marciano Cohen Levitski&nbsp;&amp; Co. (Israeli law) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;**5.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d552144dex52.htm">Opinion of Kirkland&nbsp;&amp; Ellis LLP (New York law) </A></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="91%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;&#134;5.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0000818686/000119312518023821/d532134dex53.htm">Opinion of VanEps Kunneman VanDoorne (Cura&ccedil;ao law) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;&#134;5.4</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0000818686/000119312518023821/d532134dex54.htm">Opinion of Van Doorne N.V. (Dutch law) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&#134;12.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518023821/d532134dex121.htm">Statement regarding the computation of consolidated ratio of earnings to fixed charges </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>**23.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d552144dex231.htm">Consent of Kesselman&nbsp;&amp; Kesselman </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;23.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518023821/d532134dex51.htm">Consent of Tulchinsky Stern Marciano Cohen Levitski&nbsp;&amp; Co. (included in Exhibit 5.1) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;23.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518023821/d532134dex52.htm">Consent of Kirkland&nbsp;&amp; Ellis LLP (included in Exhibit 5.2) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;23.4</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518023821/d532134dex53.htm">Consent of VanEps Kunneman VanDoorne (included in Exhibit 5.3) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;23.5</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518023821/d532134dex54.htm">Consent of Van Doorne, N.V. (included in Exhibit 5.4) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;24.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/818686/000119312518023821/d532134ds3.htm#sig">Power of Attorney of Teva Pharmaceutical Industries Limited (included on the signature pages of this Registration Statement on Form S-3, filed
 on January 29, 2018) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&#134;25.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0000818686/000119312518023821/d532134dex251.htm">Statement of Eligibility of The Bank of New York Mellon on Form <FONT STYLE="white-space:nowrap">T-1,</FONT> as Trustee for the form of the
Teva Pharmaceutical Industries Limited Senior Indenture</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&#134;25.2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0000818686/000119312518023821/d532134dex252.htm">Statement of Eligibility of The Bank of New York Mellon on Form <FONT STYLE="white-space:nowrap">T-1,</FONT> as Trustee for the form of the
Teva Pharmaceutical Industries Limited Subordinated Indenture </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&#134;25.3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0000818686/000119312518023821/d532134dex253.htm">Statement of Eligibility of The Bank of New York Mellon on Form <FONT STYLE="white-space:nowrap">T-1,</FONT> as Trustee for the form of the
Teva Pharmaceutical Finance IV, LLC Senior Indenture </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&#134;25.4</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0000818686/000119312518023821/d532134dex254.htm">Statement of Eligibility of The Bank of New York Mellon on Form <FONT STYLE="white-space:nowrap">T-1,</FONT> as Trustee for the form of the
Teva Pharmaceutical Finance IV, LLC Subordinated Indenture </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&#134;25.5</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0000818686/000119312518023821/d532134dex255.htm">Statement of Eligibility of The Bank of New York Mellon on Form <FONT STYLE="white-space:nowrap">T-1,</FONT> as Trustee for the form of the
Teva Pharmaceutical Finance V, LLC Senior Indenture </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&#134;25.6</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0000818686/000119312518023821/d532134dex256.htm">Statement of Eligibility of The Bank of New York Mellon on Form <FONT STYLE="white-space:nowrap">T-1,</FONT> as Trustee for the form of the
Teva Pharmaceutical Finance V, LLC Subordinated Indenture </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&#134;25.7</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0000818686/000119312518023821/d532134dex257.htm">Statement of Eligibility of The Bank of New York Mellon on Form <FONT STYLE="white-space:nowrap">T-1,</FONT> as Trustee for the form of the
Teva Pharmaceutical Finance VI, LLC Senior Indenture </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&#134;25.8</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0000818686/000119312518023821/d532134dex258.htm">Statement of Eligibility of The Bank of New York Mellon on Form <FONT STYLE="white-space:nowrap">T-1,</FONT> as Trustee for the form of the
Teva Pharmaceutical Finance VI, LLC Subordinated Indenture </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&#134;25.9</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0000818686/000119312518023821/d532134dex259.htm">Statement of Eligibility of The Bank of New York Mellon on Form <FONT STYLE="white-space:nowrap">T-1,</FONT> as Trustee for the form of the
Teva Pharmaceutical Finance Company B.V. Senior Indenture </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&#134;25.10</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0000818686/000119312518023821/d532134dex2510.htm">Statement of Eligibility of The Bank of New York Mellon on Form <FONT STYLE="white-space:nowrap">T-1,</FONT> as Trustee for the form of the
 Teva Pharmaceutical Finance Company B.V. Subordinated Indenture</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&#134;25.11</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0000818686/000119312518023821/d532134dex2511.htm">Statement of Eligibility of The Bank of New York Mellon on Form <FONT STYLE="white-space:nowrap">T-1,</FONT> as Trustee for the form of the
 Teva Pharmaceutical Finance IV B.V. Senior Indenture </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&#134;25.12</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0000818686/000119312518023821/d532134dex2512.htm">Statement of Eligibility of The Bank of New York Mellon on Form <FONT STYLE="white-space:nowrap">T-1,</FONT> as Trustee for the form of the
 Teva Pharmaceutical Finance IV B.V. Subordinated Indenture </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&#134;25.13</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0000818686/000119312518023821/d532134dex2513.htm">Statement of Eligibility of The Bank of New York Mellon on Form <FONT STYLE="white-space:nowrap">T-1,</FONT> as Trustee for the form of the
 Teva Pharmaceutical Finance V B.V. Senior Indenture </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&#134;25.14</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0000818686/000119312518023821/d532134dex2514.htm">Statement of Eligibility of The Bank of New York Mellon on Form <FONT STYLE="white-space:nowrap">T-1,</FONT> as Trustee for the form of the
 Teva Pharmaceutical Finance V B.V. Subordinated Indenture </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&#134;25.15</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0000818686/000119312518023821/d532134dex2515.htm">Statement of Eligibility of The Bank of New York Mellon on Form <FONT STYLE="white-space:nowrap">T-1,</FONT> as Trustee for the form of the
 Teva Pharmaceutical Finance N.V. Senior Indenture </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&#134;25.16</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0000818686/000119312518023821/d532134dex2516.htm">Statement of Eligibility of The Bank of New York Mellon on Form <FONT STYLE="white-space:nowrap">T-1,</FONT> as Trustee for the form of the
 Teva Pharmaceutical Finance N.V. Subordinated Indenture</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&#134;25.17</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0000818686/000119312518023821/d532134dex2517.htm">Statement of Eligibility of The Bank of New York Mellon on Form <FONT STYLE="white-space:nowrap">T-1,</FONT> as Trustee for the form of the
 Teva Pharmaceutical Finance Netherlands II B.V. Senior Indenture</A></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="89%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&#134;25.18</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0000818686/000119312518023821/d532134dex2518.htm">Statement of Eligibility of The Bank of New York Mellon on Form <FONT STYLE="white-space:nowrap">T-1,</FONT> as Trustee for the form of the
 Teva Pharmaceutical Finance Netherlands II B.V. Subordinated Indenture</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&#134;25.19</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0000818686/000119312518023821/d532134dex2519.htm">Statement of Eligibility of The Bank of New York Mellon on Form <FONT STYLE="white-space:nowrap">T-1,</FONT> as Trustee for the form of the
 Teva Pharmaceutical Finance Netherlands III B.V. Senior Indenture</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&#134;25.20</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0000818686/000119312518023821/d532134dex2520.htm">Statement of Eligibility of The Bank of New York Mellon on Form <FONT STYLE="white-space:nowrap">T-1,</FONT> as Trustee for the form of the
 Teva Pharmaceutical Finance Netherlands III B.V. Subordinated Indenture </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&#134;25.21</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0000818686/000119312518023821/d532134dex2521.htm">Statement of Eligibility of The Bank of New York Mellon on Form <FONT STYLE="white-space:nowrap">T-1,</FONT> as Trustee for the form of the
 Teva Pharmaceutical Finance Netherlands IV B.V. Senior Indenture</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&#134;25.22</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0000818686/000119312518023821/d532134dex2522.htm">Statement of Eligibility of The Bank of New York Mellon on Form <FONT STYLE="white-space:nowrap">T-1,</FONT> as Trustee for the form of the
 Teva Pharmaceutical Finance Netherlands IV B.V. Subordinated Indenture</A></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">English translation or summary from Hebrew original, which is the official version. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">English translation or summary from Hebrew original, which is the official version, except as to Exhibit&nbsp;A thereto, the official version of which is in English. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top">Previously filed. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">To be filed, if necessary, subsequent to the effectiveness of this Registration Statement by an amendment to the Registration Statement or incorporated by reference to a Current Report on Form <FONT
STYLE="white-space:nowrap">8-K.</FONT> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top">Filed herewith. </TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="sig"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of
the requirements for filing on Form <FONT STYLE="white-space:nowrap">S-3</FONT> and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Petach Tikva, Israel, on March
28, 2018. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">TEVA PHARMACEUTICAL INDUSTRIES LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;/s/ Deborah Griffin</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Deborah Griffin</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Senior Vice President and Chief<BR>&nbsp;&nbsp;Accounting Officer</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has
been signed by the following persons in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:15.95pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:16.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" align="left">&nbsp;&nbsp;Dr.&nbsp;Sol&nbsp;J. Barer</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Chairman</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>March 28,&nbsp;2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" align="left">&nbsp;&nbsp;K&aring;re Schultz</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">President and Chief Executive Officer and</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">March 28,&nbsp;2018</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:24pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:24pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" align="left">&nbsp;&nbsp;Michael McClellan</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Executive Vice President and Chief</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial Officer</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Principal Financial Officer)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">March 28,&nbsp;2018</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:24pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:24pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;/s/ Deborah Griffin</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Deborah Griffin</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Senior Vice President and Chief</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accounting Officer</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Principal Accounting Officer)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">March 28,&nbsp;2018</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" align="left">&nbsp;&nbsp;Rosemary A. Crane</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">March 28,&nbsp;2018</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" align="left">&nbsp;&nbsp;Amir Elstein</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">March 28,&nbsp;2018</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" align="left">&nbsp;&nbsp;Murray A. Goldberg</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">March 28,&nbsp;2018</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" align="left">&nbsp;&nbsp;Jean-Michel Halfon</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">March 28,&nbsp;2018</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" align="left">&nbsp;&nbsp;Gerald M. Lieberman</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">March 28,&nbsp;2018</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" align="left">&nbsp;&nbsp;Galia Maor</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">March 28,&nbsp;2018</P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:15.95pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:16.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" align="left">&nbsp;&nbsp;Roberto A. Mignone</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">March 28,&nbsp;2018</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" align="left">&nbsp;&nbsp;Dr.&nbsp;Perry&nbsp;D. Nisen</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">March 28,&nbsp;2018</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" align="left">&nbsp;&nbsp;Nechemia (Chemi) J. Peres</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">March 28,&nbsp;2018</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" align="left">&nbsp;&nbsp;Dan S. Suesskind</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">March 28,&nbsp;2018</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" align="left">&nbsp;&nbsp;Gabrielle Sulzberger</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">March 28,&nbsp;2018</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;/s/ Deborah Griffin</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Deborah Griffin</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Authorized U.S. Representative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">March 28,&nbsp;2018</P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*By: /s/ Deborah Griffin </P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:4%;border-bottom:1px solid #000000; width:36%">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deborah Griffin </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Attorney-in-Fact </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe
that it meets all of the requirements for filing on Form <FONT STYLE="white-space:nowrap">S-3</FONT> and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in North Wales,
Pennsylvania on March 28,&nbsp;2018. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">TEVA PHARMACEUTICAL FINANCE IV, LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;/s/ Deborah Griffin</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Deborah Griffin</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;President, Chief Executive Officer and</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Manager</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, the Registration Statement has
been signed by the following persons in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:15.95pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:16.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;/s/ Deborah Griffin</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Deborah Griffin</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">President, Chief Executive Officer</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">and
Manager</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>March 28,&nbsp;2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;/s/ Gudjon Gustafsson</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Gudjon Gustafsson</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Vice President and Treasurer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>March 28,&nbsp;2018</TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe
that it meets all of the requirements for filing on Form <FONT STYLE="white-space:nowrap">S-3</FONT> and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in North Wales,
Pennsylvania on March 28,&nbsp;2018. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">TEVA PHARMACEUTICAL FINANCE V, LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;/s/ Deborah Griffin</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Deborah Griffin</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;President, Chief Executive Officer and</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Manager</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, the Registration Statement has
been signed by the following persons in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:15.95pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:16.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;/s/ Deborah Griffin</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Deborah Griffin</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">President, Chief Executive Officer</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">and
Manager</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>March 28,&nbsp;2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;/s/ Gudjon Gustafsson</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Gudjon Gustafsson</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Vice President and Treasurer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>March 28,&nbsp;2018</TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe
that it meets all of the requirements for filing on Form <FONT STYLE="white-space:nowrap">S-3</FONT> and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in North Wales,
Pennsylvania on March 28,&nbsp;2018. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">TEVA PHARMACEUTICAL FINANCE VI, LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;/s/ Deborah Griffin</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Deborah Griffin</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;President, Chief Executive Officer and</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Manager</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, the Registration Statement has
been signed by the following persons in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:15.95pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:16.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;/s/ Deborah Griffin</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Deborah Griffin</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">President, Chief Executive Officer</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">and
Manager</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>March 28,&nbsp;2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;/s/ Gudjon Gustafsson</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Gudjon Gustafsson</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Vice President and Treasurer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>March 28,&nbsp;2018</TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe
that it meets all of the requirements for filing on Form <FONT STYLE="white-space:nowrap">S-3</FONT> and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Curacao on March
28,&nbsp;2018. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TEVA PHARMACEUTICAL FINANCE</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">COMPANY
B.V.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Teva Pharmaceutical Finance Netherlands III</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;B.V., its Managing Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Teva Pharmaceuticals Europe B.V.,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;its Managing Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;/s/ David Vrhovec</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name:&nbsp;&nbsp;&nbsp;&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;David Vrhovec</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Managing Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;/s/ John Nason</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;John Nason</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Managing
Director</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, the Registration Statement has
been signed by the following persons in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:15.95pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:16.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;/s/ Werner Kormelink</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Werner Kormelink</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Supervisory Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>March 28,&nbsp;2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;/s/ Iseline Gouverneur</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Iseline Gouverneur</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Local Representative</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>March 28,&nbsp;2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;/s/ Deborah Griffin</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Deborah Griffin</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Authorized U.S. Representative</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>March 28,&nbsp;2018</TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe
that it meets all of the requirements for filing on Form <FONT STYLE="white-space:nowrap">S-3</FONT> and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Curacao on March
28,&nbsp;2018. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">TEVA PHARMACEUTICAL FINANCE IV B.V.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Teva Pharmaceutical Finance Netherlands II</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;B.V., its Managing Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Teva Pharmaceuticals Europe B.V.,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;its Managing Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;/s/ David Vrhovec</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name:&nbsp;&nbsp;&nbsp;&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;David Vrhovec</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Managing Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;/s/ John Nason</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;John Nason</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Managing
Director</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, the Registration Statement has
been signed by the following persons in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:15.95pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:16.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;/s/ Werner Kormelink</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Werner Kormelink</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Supervisory Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>March 28,&nbsp;2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;/s/ Iseline Gouverneur</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Iseline Gouverneur</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Local Representative</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>March 28,&nbsp;2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;/s/ Deborah Griffin</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Deborah Griffin</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Authorized U.S. Representative</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>March 28,&nbsp;2018</TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe
that it meets all of the requirements for filing on Form <FONT STYLE="white-space:nowrap">S-3</FONT> and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Curacao on March
28,&nbsp;2018. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">TEVA PHARMACEUTICAL FINANCE V B.V.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Teva Pharmaceutical Finance Netherlands IV</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;B.V., its Managing Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Teva Pharmaceuticals Europe B.V.,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;its Managing Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;/s/ David Vrhovec</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name:&nbsp;&nbsp;&nbsp;&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;David Vrhovec</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Managing Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;/s/ John Nason</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;John Nason</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Managing
Director</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, the Registration Statement has
been signed by the following persons in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:15.95pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:16.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;/s/ Werner Kormelink</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Werner Kormelink</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Supervisory Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>March 28,&nbsp;2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;/s/ Iseline Gouverneur</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Iseline Gouverneur</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Local Representative</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>March 28,&nbsp;2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;/s/ Deborah Griffin</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Deborah Griffin</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Authorized U.S. Representative</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>March 28,&nbsp;2018</TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe
that it meets all of the requirements for filing on Form <FONT STYLE="white-space:nowrap">S-3</FONT> and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Curacao on March
28,&nbsp;2018. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">TEVA PHARMACEUTICAL FINANCE N.V.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;/s/ Iseline Gouverneur</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Iseline Gouverneur</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Managing Director A</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;/s/ Werner Kormelink</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name:&nbsp;&nbsp;&nbsp;&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Werner Kormelink</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Managing Director B</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, the Registration Statement has
been signed by the following person in the capacity and on the date indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:15.95pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:16.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;/s/ Deborah Griffin</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Deborah Griffin</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Authorized U.S. Representative</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>March 28,&nbsp;2018</TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe
that it meets all of the requirements for filing on Form <FONT STYLE="white-space:nowrap">S-3</FONT> and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in The Netherlands on
March 28, 2018. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TEVA PHARMACEUTICAL FINANCE</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">NETHERLANDS II B.V.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Teva Pharmaceuticals Europe B.V.,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;its Managing Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;/s/ David Vrhovec</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name:&nbsp;&nbsp;&nbsp;&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;David Vrhovec</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Managing Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;/s/ John Nason</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;John Nason</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Managing
Director</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, the Registration Statement has
been signed by the following persons in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:15.95pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:16.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;/s/ John Nason</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;John Nason</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Managing Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>March 28,&nbsp;2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;/s/ David Vrhovec</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;David Vrhovec</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Managing Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">March 28,&nbsp;2018</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;/s/ Deborah Griffin</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Deborah Griffin</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Authorized U.S. Representative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">March 28,&nbsp;2018</P></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe
that it meets all of the requirements for filing on Form <FONT STYLE="white-space:nowrap">S-3</FONT> and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in The Netherlands on
March 28, 2018. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TEVA PHARMACEUTICAL FINANCE</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">NETHERLANDS III B.V.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Teva Pharmaceuticals Europe B.V.,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;its Managing Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;/s/ David Vrhovec</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name:&nbsp;&nbsp;&nbsp;&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;David Vrhovec</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Managing Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;/s/ John Nason</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;John Nason</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Managing
Director</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, the Registration Statement has
been signed by the following persons in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:15.95pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:16.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;/s/ John Nason</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;John Nason</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Managing Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>March 28,&nbsp;2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;/s/ David Vrhovec</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;David Vrhovec</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Managing Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">March 28,&nbsp;2018</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;/s/ Deborah Griffin</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Deborah Griffin</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Authorized U.S. Representative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">March 28,&nbsp;2018</P></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe
that it meets all of the requirements for filing on Form <FONT STYLE="white-space:nowrap">S-3</FONT> and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in The Netherlands on
March 28, 2018. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TEVA PHARMACEUTICAL FINANCE</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">NETHERLANDS IV B.V.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Teva Pharmaceuticals Europe B.V.,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;its Managing Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;/s/ David Vrhovec</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name:&nbsp;&nbsp;&nbsp;&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;David Vrhovec</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Managing Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;/s/ John Nason</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;John Nason</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Managing
Director</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, the Registration Statement has
been signed by the following persons in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:15.95pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:16.00pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;/s/ John Nason</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;John Nason</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>Managing Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>March 28,&nbsp;2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;/s/ David Vrhovec</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;David Vrhovec</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Managing Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">March 28,&nbsp;2018</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;/s/ Deborah Griffin</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Deborah Griffin</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Authorized U.S. Representative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">March 28,&nbsp;2018</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>d552144dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g552144ex5_1.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">March 28, 2018 </P> <P STYLE="margin-top:0pt;margin-bottom:0pt;page-break-before:always"></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Teva Pharmaceutical Industries Limited </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Teva Pharmaceutical
Finance IV, LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Teva Pharmaceutical Finance V, LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Teva
Pharmaceutical Finance VI, LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Teva Pharmaceutical Finance Company B.V. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Teva Pharmaceutical Finance IV B.V. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Teva Pharmaceutical Finance
V B.V. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Teva Pharmaceutical Finance N.V. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Teva Pharmaceutical
Finance Netherlands II B.V. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Teva Pharmaceutical Finance Netherlands III B.V. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Teva Pharmaceutical Finance Netherlands IV B.V. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Teva
Pharmaceutical Industries Limited </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5 Basel Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">P.O. Box
3190 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Petach Tikva 4951033 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Israel </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Re: <U>Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT></U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 1 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g552144ex5_01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>T<SMALL>ULCHINSKY</SMALL> S<SMALL>TERN</SMALL> M<SMALL>ARCIANO</SMALL> C<SMALL>OHEN</SMALL>
L<SMALL>EVITSKI</SMALL> &amp; C<SMALL>O</SMALL>. </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have acted as Israeli counsel for Teva Pharmaceutical Industries Limited, an Israeli corporation (&#147;<U>Teva</U>&#148; or the
&#147;<U>Company</U>&#148;), in connection with the preparation and filing by Teva with the United States Securities and Exchange Commission pursuant to the Securities Act of 1933, as amended (the &#147;<U>Act</U>&#148;), of the Registration
Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (the &#147;<U>Registration Statement</U>&#148;) by Teva, Teva Pharmaceutical Finance IV, LLC, a Delaware limited liability company (&#147;<U>Teva Finance IV LLC</U>&#148;), Teva
Pharmaceutical Finance V, LLC, a Delaware limited liability company (&#147;<U>Teva Finance V LLC</U>&#148;), Teva Pharmaceutical Finance VI, LLC, a Delaware limited liability company (&#147;<U>Teva Finance VI LLC</U>&#148; and, together with Teva
Finance IV LLC and Teva Finance V LLC, the &#147;<U>LLCs</U>&#148;), Teva Pharmaceutical Finance Company B.V., a Cura&ccedil;ao private limited liability company (&#147;<U>Teva Finance Company BV</U>&#148;), Teva Pharmaceutical Finance IV B.V., a
Cura&ccedil;ao private limited liability company (&#147;<U>Teva Finance IV BV</U>&#148;), Teva Pharmaceutical Finance V B.V., a Cura&ccedil;ao private limited liability company (&#147;<U>Teva Finance V BV</U>&#148; and, together with Teva Finance
Company BV and Teva Finance IV BV, the &#147;<U>Teva BVs</U>&#148;), Teva Pharmaceutical Finance N.V., a Cura&ccedil;ao public limited liability company (&#147;<U>Teva Finance NV</U>&#148;); Teva Pharmaceutical Finance Netherlands II B.V., a Dutch
private limited liability company (&#147;<U>Teva Netherlands II</U>&#148;), Teva Pharmaceutical Finance Netherlands III B.V., a Dutch private limited liability company (&#147;<U>Teva Netherlands III</U>&#148;), and Teva Pharmaceutical Finance
Netherlands IV B.V., a Dutch private limited liability company (&#147;<U>Teva Netherlands IV</U>&#148; and, together with Teva Netherlands II and Teva Netherlands III, the &#147;<U>Netherlands BVs</U>&#148; and, together with the Teva BVs, Teva
Finance NV and the LLCs, the &#147;<U>Finance Subsidiaries</U>&#148;) relating to the registration of the sale from time to time of: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(A) by Teva,
(i)&nbsp;American Depositary Shares (&#147;<U>ADSs</U>&#148;), each representing one ordinary share, par value NIS 0.10 per share, of Teva (the &#147;<U>Ordinary Shares</U>&#148;); (ii)&nbsp;senior debt securities (the &#147;<U>Teva Senior Debt
Securities</U>&#148;), which may be issued pursuant to an indenture (the &#147;<U>Teva Senior Indenture</U>&#148;) to be executed by Teva and The Bank of New York Mellon, as trustee; and (iii)&nbsp;subordinated debt securities (the &#147;<U>Teva
Subordinated Debt Securities</U>&#148; and, together with the Teva Senior Debt Securities, the &#147;<U>Teva Debt Securities</U>&#148;), which may be issued pursuant to an indenture (the &#147;<U>Teva Subordinated Indenture</U>&#148; and, together
with the Teva Senior Indenture, the &#147;<U>Teva Indentures</U>&#148;) to be executed by Teva and The Bank of New York Mellon, as trustee; (iv)&nbsp;purchase contracts (the &#147;<U>Purchase Contracts</U>&#148;) for the purchase and sale of
Teva&#146;s securities or securities of third parties, a basket of such securities, an index or indices of such securities or any combination of the above; and (v)&nbsp;units (the &#147;<U>Units</U>&#148;) consisting of one or more Purchase
Contracts, Teva Debt Securities, Subsidiary Debt Securities, Ordinary Shares, ADSs, other equity securities or any combination of such securities; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(B) by
each of the Finance Subsidiaries, (i)&nbsp;senior debt securities (the &#147;<U>Subsidiary Senior Debt Securities</U>&#148;), guaranteed by Teva, which may be issued pursuant to an indenture (each, a &#147;<U>Subsidiary Senior Indenture</U>&#148;)
to be executed by the applicable Finance Subsidiary, Teva and The Bank of New York Mellon, as trustee; and (ii)&nbsp;subordinated debt securities (the &#147;<U>Subsidiary Subordinated Debt Securities</U>&#148;, and together with the Subsidiary
Senior Debt Securities, the &#147;<U>Subsidiary Debt Securities</U>&#148;), guaranteed by Teva, which may be issued pursuant to an indenture (each, a &#147;<U>Subsidiary Subordinated Indenture</U>&#148; and together with the Subsidiary Senior
Indentures, the &#147;<U>Subsidiary Indentures</U>&#148;) to be executed by the applicable Finance Subsidiary, Teva, as guarantor and The Bank of New York Mellon, as trustee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of the opinions hereinafter expressed, we have examined originals or copies, certified and otherwise identified to our satisfaction, of such
documents, corporate records, certificates of public officials and other instruments as we have deemed necessary as a basis for the opinions expressed herein. Insofar as the opinions expressed herein involve factual matters, we have relied (without
independent factual investigation), to the extent we deemed proper or necessary, upon certificates of, and other communications with, officers and employees of Teva and upon certificates of public officials. We have also considered such questions of
Israeli law as we have deemed relevant and necessary as a basis for the opinions hereinafter expressed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 2 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g552144ex5_01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>T<SMALL>ULCHINSKY</SMALL> S<SMALL>TERN</SMALL> M<SMALL>ARCIANO</SMALL> C<SMALL>OHEN</SMALL>
L<SMALL>EVITSKI</SMALL> &amp; C<SMALL>O</SMALL>. </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In making our examination, we have assumed the genuineness of all signatures, the legal capacity of natural
persons, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified, photostatic or facsimile copies and the authenticity of the originals of such copies and the
legal capacity and due authenticity of all persons executing such documents. We have assumed the same to have been properly given and to be accurate, and we have assumed the truth of all facts communicated to us by the Company, and have assumed that
all consents, minutes and protocols of meetings of the Company&#146;s board of directors and shareholders which have been provided to us are true, accurate and have been properly prepared in accordance with the Company&#146;s incorporation documents
and all applicable laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the opinions as to enforceability expressed below, such enforceability may be limited by bankruptcy,
insolvency, reorganization, moratorium and other similar laws relating to or affecting creditors&#146; rights generally, subject to general principles of equity and to limitations on availability of equitable relief, including specific performance
(regardless of whether such enforceability is considered in a proceeding in equity or at law) or by an implied covenant of good faith and fair dealing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with all of the opinions expressed below, we have assumed that, at or prior to the time of the delivery of any such security, (i)&nbsp;the
Ordinary Shares or such other securities have been specifically authorized and approved for issuance and sale by the Company by all necessary corporate action, and such authorization shall not have been modified or rescinded; (ii)&nbsp;the Ordinary
Shares or such other securities will be issued, sold and delivered as contemplated by the Registration Statement, the prospectuses included therein and one or more purchase, underwriting or similar agreements, if applicable, and such agreements have
been duly authorized, executed and delivered by the Company and the other parties thereto and; (iii)&nbsp;the Company has received the consideration provided for pursuant to the relevant corporate action and, if applicable, the underwriting
agreements; (iv)&nbsp;the Registration Statement (including any post-effective amendments) is effective under the Act, and such effectiveness shall not have been terminated or rescinded; and (v)&nbsp;there shall not have occurred any change in law
affecting the validity or enforceability of any such security. We have also assumed that none of the terms of any security to be established subsequent to the date hereof, nor the issuance and delivery of such security, nor the compliance by Teva
with the terms of such security will violate any applicable law or will result in a violation of any provision of any instrument or agreement then binding upon the relevant company (including Teva), or any restriction imposed by any court or
governmental body having jurisdiction over Teva. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our opinions expressed below are based upon our consideration of only those statutes, rules and
regulations of the State of Israel which, in our experience, are normally applicable to guarantors or issuers of securities of the nature of the Ordinary Shares, ADSs, Teva Debt Securities, Purchase Contracts, Units and Subsidiary Debt Securities.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on and subject to the foregoing, we are of the opinion that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">The Amended and Restated Deposit Agreement, dated as of November&nbsp;5, 2012, among Teva, JPMorgan Chase Bank N.A., as depositary, and the Owners and Holders (each as defined therein) from time to time of ADSs issued
thereunder, as amended on February&nbsp;29, 2016 (the &#147;Deposit Agreement&#148;) has been duly authorized, executed and delivered by Teva. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">When the Ordinary Shares, including the Ordinary Shares underlying the ADSs or any Purchase Contracts or Units, are issued in accordance with the assumptions above, such Ordinary Shares will be validly issued, fully
paid and non-assessable. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">When the Teva Indentures have been duly authorized, executed and delivered by the parties thereto in accordance with applicable law, and when the specific terms of a particular series of Teva Debt Securities have been
duly authorized and established by the parties in accordance with the relevant Teva Indenture and such Teva Debt Securities have been duly authorized, executed, authenticated, issued and delivered in accordance with the relevant Teva Indenture and
any applicable underwriting or other agreement, such Teva Debt Securities will constitute valid and binding obligations of Teva, enforceable against Teva in accordance with their terms. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">When the Purchase Contracts and related agreements have been duly authorized, executed, issued and delivered by the parties thereto in accordance with applicable law and with the specific terms of such related purchase
contract agreement, such Purchase Contracts will constitute valid and binding obligations of Teva, enforceable against Teva in accordance with their terms. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">When the Units and the related unit agreement have been duly authorized, executed, issued and delivered by the parties thereto in accordance with applicable law and with the specific terms of such related unit
agreement, such Units will constitute valid and binding obligations of Teva, enforceable against Teva in accordance with their terms. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 3 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g552144ex5_01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>T<SMALL>ULCHINSKY</SMALL> S<SMALL>TERN</SMALL> M<SMALL>ARCIANO</SMALL> C<SMALL>OHEN</SMALL>
L<SMALL>EVITSKI</SMALL> &amp; C<SMALL>O</SMALL>. </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top">When the Subsidiary Indentures have been duly authorized, executed and delivered by the parties thereto (including Teva as guarantor) in accordance with applicable law, and when the specific terms of a particular series
of Subsidiary Debt Securities have been duly authorized and established in accordance with the relevant Subsidiary Indenture and such Subsidiary Debt Securities have been duly authorized, executed, authenticated, issued and delivered in accordance
with the relevant Subsidiary Indenture and any applicable underwriting or other agreement, Teva&#146;s guarantee under each Subsidiary Indenture with respect to such Subsidiary Debt Securities will constitute a valid and binding obligation of Teva,
enforceable against Teva in accordance with its terms. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top">Under the choice of law or conflicts of law doctrines of Israel, a court, tribunal or other competent authority sitting in Israel has discretion, but should apply to any claim or controversy arising under a Teva
Indenture, a Subsidiary Indenture or the Deposit Agreement, the law of the State of New York, which is the local law governing the Teva Indentures, the Subsidiary Indentures and the Deposit Agreement, designated therein by the parties thereto, if
properly brought to the attention of the court, tribunal or other competent authority in accordance with the laws of the State of Israel, provided there are no reasons for declaring such designation void on the grounds of public policy or as being
contrary to Israeli law and provided further that, the choice of law is <I>bona fide</I> and is not made for the purpose of evading the laws of another jurisdiction. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to our opinions as to the Ordinary Shares, we have assumed that, at the time of issuance and sale, a sufficient number of Ordinary Shares are
registered (authorized) and available for issuance under the Company&#146;s Memorandum of Association and Articles of Association as then in effect and that the consideration for the issuance and sale of any such Ordinary Shares is in an amount that
is not less than the nominal (par) value thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not purport to be expert on the laws of any jurisdiction other than the laws of the State of
Israel, and we express no opinion herein as to the effect of any other laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the filing of this opinion as an exhibit to the
Registration Statement. By giving our consent, we do not admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Act or the rules and regulations issued or promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion is being delivered to you for your information in connection with the above matter and addresses matters only as of the date hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Very truly yours, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Tulchinsky
Stern Marciano Cohen Levitski&nbsp;&amp; Co., </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Law Offices </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Tulchinsky Stern Marciano Cohen Levitski&nbsp;&amp; Co. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Law Offices </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 4 - </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.2
<SEQUENCE>3
<FILENAME>d552144dex52.htm
<DESCRIPTION>EX-5.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g552144img01.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">601 Lexington Avenue</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">New York, NY 10022</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(212) 446-4800</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">www.kirkland.com</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Facsimile: <FONT STYLE="white-space:nowrap">(212)&nbsp;446-4900</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">March 28, 2018 </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Teva Pharmaceutical Industries Limited </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5 Basel Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">P.O. Box 3190 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Petach Tikva, 4951033 Israel </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"><U>Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT></U> </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are issuing this opinion letter in our capacity as special U.S. counsel to Teva Pharmaceutical Industries Limited, an&nbsp;Israeli
corporation (&#147;<U>Teva</U>&#148;) and the LLCs (as defined below) in connection with the Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (the &#147;<U>Registration Statement</U>&#148;) to be filed with the Securities
and Exchange Commission (the &#147;<U>Commission</U>&#148;) by Teva, Teva Pharmaceutical Finance&nbsp;IV, LLC, a Delaware limited liability company (&#147;<U>Teva Finance IV LLC</U>&#148;), Teva Pharmaceutical Finance V, LLC, a Delaware limited
liability company (&#147;<U>Teva Finance V LLC</U>&#148;), Teva Pharmaceutical Finance VI, LLC, a Delaware limited liability company (&#147;<U>Teva Finance VI LLC</U>&#148; and, together with Teva Finance IV LLC and Teva Finance V LLC, the
&#147;<U>LLCs</U>&#148;), Teva Pharmaceutical Finance Company B.V., a Cura&ccedil;ao private limited liability company (&#147;<U>Teva Finance Company BV</U>&#148;), Teva Pharmaceutical Finance IV B.V., a Cura&ccedil;ao private limited liability
company (&#147;<U>Teva Finance IV BV</U>&#148;), Teva Pharmaceutical Finance V B.V., a Cura&ccedil;ao private limited liability company (&#147;<U>Teva Finance V BV</U>&#148;), Teva Pharmaceutical Finance N.V., a Cura&ccedil;ao public limited
liability company (&#147;<U>Teva Finance NV</U>,&#148; and, together with Teva Finance Company BV, Teva Finance IV BV, and Teva Finance V BV, the &#147;Cura&ccedil;ao<U> Finance Subsidiaries</U>&#148;), Teva Pharmaceutical Finance Netherlands II
B.V., a Dutch private limited liability company (&#147;<U>Teva Finance Netherlands II</U>&#148;), Teva Pharmaceutical Finance Netherlands III B.V. (&#147;<U>Teva Finance Netherlands III&#148;</U>), Teva Pharmaceutical Finance Netherlands IV B.V.
(&#147;<U>Teva Finance Netherlands IV</U>&#148; and, together with Teva Finance Netherlands II and Teva Finance Netherlands III the &#147;<U>Netherlands Finance Subsidiaries</U>&#148; and, together with the LLCs and the Cura&ccedil;ao Finance
Subsidiaries, the &#147;<U>Finance Subsidiaries,</U>&#148; and together with Teva, the &#147;<U>Companies</U>&#148;), to register: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) by
Teva, (i) American Depositary Shares (&#147;ADSs&#148;), each representing one ordinary share, par value NIS 0.10 per share, of Teva (&#147;Ordinary Shares&#148;); (ii)&nbsp;senior debt securities (the &#147;<U>Teva Senior Debt
Securities</U>&#148;), which may be issued pursuant to an indenture (the &#147;<U>Teva Senior Indenture</U>&#148;) to be executed by Teva and The Bank of New York Mellon, as trustee; and subordinated debt securities (the &#147;<U>Teva Subordinated
Debt Securities</U>&#148; and, together with the Teva Senior Debt Securities, the &#147;<U>Teva Debt Securities</U>&#148;), which may be issued pursuant to an indenture (the &#147;<U>Teva Subordinated Indenture</U>&#148; and, together with the Teva
Senior Indenture, the &#147;<U>Teva Indentures</U>&#148;) to be executed by Teva and The Bank of </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beijing&nbsp;&nbsp;&nbsp;&nbsp;Boston&nbsp;&nbsp;&nbsp;&nbsp;Chicago&nbsp;&nbsp;&nbsp;&nbsp;Hong&nbsp;Kong&nbsp;&nbsp;&nbsp;&nbsp;Houston&nbsp;&nbsp;&nbsp;
&nbsp;London&nbsp;&nbsp;&nbsp;&nbsp;Los&nbsp;Angeles&nbsp;&nbsp;&nbsp;&nbsp;Munich&nbsp;&nbsp;&nbsp;&nbsp;Palo&nbsp;Alto&nbsp;&nbsp;&nbsp;&nbsp;San&nbsp;Francisco&nbsp;&nbsp;&nbsp;&nbsp;Shanghai&nbsp;&nbsp;&nbsp;&nbsp;Washington,&nbsp;D.C.
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g552144img01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Teva Pharmaceutical Industries Limited </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March 28, 2018 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 2
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
New York Mellon, as trustee; (iii)&nbsp;purchase contracts (the &#147;<U>Purchase Contracts</U>&#148;) for the purchase or sale of Teva&#146;s securities or securities of third parties, a basket
of such securities, an index or indices of such securities or any combination of the above; and (iv)&nbsp;units (the &#147;<U>Units</U>&#148;) consisting of one or more Purchase Contracts, Ordinary Shares, ADSs, Teva Debt Securities, Finance
Subsidiary Debt Securities, other equity securities or any combination of such securities; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) &nbsp;&nbsp;&nbsp;&nbsp;by each of the
Finance Subsidiaries, (i)&nbsp;senior debt securities (the &#147;<U>Finance Subsidiary Senior Debt Securities</U>&#148;), guaranteed by Teva, which may be issued pursuant to an indenture (each, a &#147;<U>Finance Subsidiary Senior
Indenture</U>&#148;) to be executed by the applicable Finance Subsidiary, Teva and The Bank of New York Mellon, as trustee; and (ii)&nbsp;subordinated debt securities (the &#147;<U>Finance Subsidiary Subordinated Debt Securities</U>,&#148; and
together with the Finance Subsidiary Senior Debt Securities, the &#147;<U>Finance Subsidiary Debt Securities</U>&#148;), guaranteed by Teva, which may be issued pursuant to an indenture (each, a &#147;<U>Finance Subsidiary Subordinated
Indenture</U>,&#148; and together with the Finance Subsidiary Senior Indentures, the &#147;<U>Finance Subsidiary Indentures</U>&#148;) to be executed by the applicable Finance Subsidiary, Teva and The Bank of New York Mellon, as trustee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of the opinions hereinafter expressed, we have examined copies of the Certificate of Formation and the Operating Agreement of
each of the LLCs, the Amended and Restated Deposit Agreement, dated as of November 5, 2012, among Teva, JPMorgan Chase Bank N.A., as depositary (the &#147;Depositary&#148;), and the holders from time to time of ADSs issued thereunder, as amended on
February 29, 2016 (the &#147;Deposit Agreement&#148;), the forms of the Teva Indentures and the Finance Subsidiary Indentures, the Registration Statement and originals or copies, certified and otherwise identified to our satisfaction, of such other
documents, corporate or limited liability company records, certificates of public officials and other instruments as we have deemed necessary as a basis for the opinions expressed herein. Insofar as the opinions expressed herein involve factual
matters, we have relied (without independent factual investigation), to the extent we deemed proper or necessary, upon certificates of, and other communications with, officers and employees of the Companies and upon certificates of public officials.
In addition, our opinions in paragraph (1)&nbsp;below are based solely upon certificates of good standing issued by the Secretary of State of Delaware. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this opinion, we have assumed that (a)&nbsp;the Registration Statement, and any amendments thereto (including
post-effective amendments), relating to the offered securities will have become effective under the Securities Act of 1933, as amended (the &#147;<U>Act</U>&#148;); (b) a prospectus supplement will have been prepared and filed with the Commission
describing the securities offered thereby; (c)&nbsp;all offered securities will be issued and sold in compliance with applicable federal and state securities laws and in the manner stated in the Registration Statement and the applicable prospectus
supplement; (d)&nbsp;a definitive purchase, underwriting, sales agency or similar agreement with respect to the offered securities will have been duly authorized and validly executed and delivered by the applicable Company and the other parties
thereto; (e)&nbsp;any applicable indenture and indenture trustee will have been qualified under the Trust Indenture Act of 1939, as amended; (f)&nbsp;with respect to any Units, consisting of one or more Purchase Contracts, Ordinary Shares, ADSs Teva
Debt Securities, Finance Subsidiary Debt Securities, other equity securities or any combination of such securities, such Units will be authorized, validly issued, fully paid and nonassessable (to the extent applicable); and (g) the Deposit Agreement
will not have been terminated or modified subsequent to the date thereof and remains in full force and effect;. We have also assumed that Teva is and will be a company duly incorporated and validly existing as an Israeli corporation in Israel and in
good standing under the laws of Israel. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g552144img01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Teva Pharmaceutical Industries Limited </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March 28, 2018 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 3
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the foregoing, and having regard for such legal considerations as we have deemed
relevant, we advise you that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;Each of the LLCs is validly existing in good standing as a limited liability
company under the Delaware Limited Liability Company Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. &nbsp;&nbsp;&nbsp;&nbsp;Assuming the Deposit Agreement has been duly
authorized, executed and delivered by the parties thereto, when ADSs are issued in accordance with the Deposit Agreement against the deposit of duly authorized, validly issued, fully paid and non-assessable Ordinary Shares, such ADSs will be validly
issued and will entitle the holders thereof to the rights specified therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;When the Teva Debt Securities and
the applicable Teva Indenture have been authorized by appropriate corporate authorization, the applicable Teva Indenture has been duly executed by the parties thereto, and the Teva Debt Securities have been executed, authenticated and delivered in
accordance with the applicable Teva Indenture against payment therefor, the Teva Debt Securities will be validly issued and the Teva Debt Securities will constitute binding obligations of Teva in accordance with their terms and the terms of the
applicable Teva Indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;When the Finance Subsidiary Debt Securities and the applicable Finance Subsidiary
Indenture have been authorized by appropriate corporate authorization, the applicable Finance Subsidiary Indenture has been duly executed by the parties thereto, and the Finance Subsidiary Debt Securities have been executed, authenticated and
delivered in accordance with the applicable Finance Subsidiary Indenture against payment therefor, the Finance Subsidiary Debt Securities will be validly issued and the Finance Subsidiary Debt Securities will constitute binding obligations of such
Finance Subsidiary in accordance with their terms and the terms of the applicable Finance Subsidiary Indenture and Teva&#146;s guarantee under each Finance Subsidiary Indenture with respect to such Finance Subsidiary Debt Securities will constitute
the valid and binding obligation of Teva. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;When the Purchase Contracts and the related purchase contract
agreement have been duly authorized by appropriate corporate authorization , and the Purchase Contracts have been duly executed and issued in accordance with the related purchase contract agreement, the Purchase Contracts will constitute valid and
binding obligations of Teva, enforceable against Teva in accordance with their terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&nbsp;&nbsp;&nbsp;&nbsp;When the Units and the
related unit agreement have been duly authorized by appropriate corporate authorization, and the Units have been duly executed and issued in accordance with the related unit agreement, the Unit will constitute valid and binding obligations of Teva,
enforceable against Teva in accordance with their terms. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g552144img01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Teva Pharmaceutical Industries Limited </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March 28, 2018 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 4
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each opinion (an &#147;<U>enforceability opinion</U>&#148;) in this letter that any security
is a valid and binding obligation or is enforceable in accordance with its terms is subject to: (i)&nbsp;the effect of bankruptcy, insolvency, fraudulent conveyance and other similar laws and judicially developed doctrines in this area such as
substantive consolidation and equitable subordination; (ii)&nbsp;the effect of general principles of equity; and (iii)&nbsp;other commonly recognized statutory and judicial constraints on enforceability including statutes of limitations. In
addition, we do not express any opinion as to the enforceability of any rights to contribution or indemnification which may be violative of public policy underlying any law, rule or regulation (including any federal or state securities law, rule or
regulation). &#147;General principles of equity&#148; include, but are not limited to: principles limiting the availability of specific performance and injunctive relief; principles which limit the availability of a remedy under certain
circumstances where another remedy has been elected; principles requiring reasonableness, good faith and fair dealing in the performance and enforcement of an agreement by the party seeking enforcement; principles which may permit a party to cure a
material failure to perform its obligations; and principles affording equitable defenses such as waiver, laches and estoppel. We express no opinion with respect to the enforceability of any provision which purports to waive the benefit of usury
laws. It is possible that terms in a particular contract covered by our enforceability opinion may not prove enforceable for reasons other than those explicitly cited in this letter should an actual enforcement action be brought, but (subject to all
the exceptions, qualifications, exclusions and other limitations contained in this letter) such unenforceability would not in our opinion prevent the party entitled to enforce that contract from realizing the principal benefits purported to be
provided to that party by the terms in that contract which are covered by our enforceability opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This opinion does not cover the law
of any jurisdiction other than the law of the State of New York and the Delaware Limited Liability Company Act. We did not find it necessary for the purposes of this opinion, and accordingly we do not purport to cover herein, the application of the
securities or &#147;Blue Sky&#148; laws of the various states. We undertake no responsibility to update or supplement this opinion in response to changes in law or future events or other circumstances. We have assumed the indentures, purchase
contract agreement and unit agreement referenced in the numbered paragraphs above will be governed by the law of the State of New York. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This opinion is being furnished in accordance with the requirements of Item 601 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT>
promulgated under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement, other than as to the specific issues addressed herein, and no opinion may be inferred or implied beyond that
expressly stated herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the reference
to this opinion in the Registration Statement in the section &#147;Legal Matters.&#148; In giving this consent, we do not thereby admit that we are &#147;experts&#148; within the meaning of the Act. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g552144img01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Teva Pharmaceutical Industries Limited </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March 28, 2018 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 5
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Yours very truly,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ KIRKLAND&nbsp;&amp; ELLIS LLP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">KIRKLAND&nbsp;&amp; ELLIS LLP</TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>d552144dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g552144g80l77.gif" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the incorporation by reference in this Registration Statement on Form S-3 (No. 333-222767) of Teva Pharmaceutical Industries Limited of
our reports dated February 12, 2018 relating to the financial statements, financial statement Schedule II &#150; Valuation and Qualifying Accounts and the effectiveness of internal control over financial reporting, which appear in Teva
Pharmaceutical Industries Limited Annual Report on Form 10-K for the year ended December 31, 2017. We also consent to the reference to us under the heading &#147;Experts&#148; in such Registration Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Kesselman &amp; Kesselman </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certified Public Accountants
(lsr.) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A member firm of PricewaterhouseCoopers International Limited </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tel-Aviv, Israel </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March 26, 2018 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g552144ex5_01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g552144ex5_01.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ $P%0 P$1  (1 0,1 ?_$ '4   (" @,! 0
M       )!P@&"@$"!0L$ 0$                     $   !@(! @8! 0<#
M!0     " P0%!@<!" D %!$2$Q46"A<R(3$B(R48&4(D)D%18E4X$0$
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M[8\:47K*6*8:WO=@,C;&MO:-23.4M2EK;#%463+XX%Q4NN$/;H4S>,X(\!3
MSX![?)E4]=[$V%7?'G&M?:U+F6]D*N!VNG9Q^J6.O1U04/7*>)MUD/$8?1,)
MJESV#F8IFB:X@:I5DIV12,;P>([*%.A6@Z5I:T;(U-C*W%Y);VAO1-: G(Q&
M9*1H$Q:1*7DP><C'D!!0<>.<YSGP\<] H;G;=8+#>.>P[-GL'B4W8J]N'41X
M>T<JCC8_@!#3]PZ$23Q(C$X)CS6[+O$C528TTG(!^F9G'C^[H(5JRQI_M!8O
M,S,K?U[J)/$M6YM(:9U3EC]0D=<G23K*MJ5\72J9N$_EC6[+K$6AEW8@]$@
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B[E_Q_P GI>/:^V?Z/-W/\SPZ!HG0'0'0'0'0'0'0'0?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g552144ex5_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g552144ex5_1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@"J +& P$1  (1 0,1 ?_$ (,  0 " P # 0$!
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ML:H0@PZQ)=)(@@NY%K,WKN*#WK%!7"+S?; 0W\,O;',?R$_*O7<WY4^-9CP
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M!X'@\-$DT_K]B>FGU_T_9IKK]?\ ]?TQCZ^!^/3[/Q_9I^/Z?3[/MQ]GT_\
MI]OT^GT\#=--3Z?D3TW^G^C[]==OI]?]/T^N,_3Z_3P-$TT_K^-/33Z_Z?LU
MUU^OT_T?7Z8Q]?I]?!Y?;K]WW?;C[OI]OW?3'W?;C.<XU^O^GZ8SG_1X/WP?
MF<?7&<?_ %Q]/!6KD#EZ$\:\W4]S3 2IR21NG(8WA@F3RO\ C5)0:;)OWY9R
M[++"V(YEKLX)DUU-4D4M$DM=L:ZX_I]<A9'*"&V<YV12SG.?KG.4],YSG/\
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M3RI]FNV=L!],CJGI^H/EUY&^:&<\Z6T5H_I/B<!3?45?5[!Y-8UN\=3R01]
MT)S*JCC;0Q81.+"E&XEF;6$,B#@4]2+;KHZXPVT<!WIE'18.W*HO',$KF[7\
M,'TU+5$)V8IVPHHA)Y,;$OA0J%0*"RB/";5FYG;\NRCARP!*#$-LIHZN55]E
M4D0_BSKSX^[<8_\ 2_6I29GF/L=IW(ZG[@8#H7^W>L&A4AJ^Z<B<Q;$$:0;N
M4:U(C,5LT=/U""@A1MINCG?93][73P=#OE8J&[;;X'^"2&5E070<ZF-$WKQK
M8%S1.,T1;1:25?%*HJI&*6"0FX=K#U'L>6CD@TV;;MG&FCE?;7.Z&BB>/O\
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M,$ZFD</7T936OX?"A!HFP==/RX:"4(:[(ZMTMXVRV5W1QG?.0V#_ *?9[?O
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MN!<=$X7_  ,V^[A?=%OIIKG??./NR&K?\,TG_P QWY/_ />4B/\ \/\ @?\
M#-)_\QWY/_\ >4B/_P /^!_PS2?_ #'?D_\ ]Y2(_P#P_P"!_P ,TG_S'?D_
M_P!Y2(__  _X'_#-)_\ ,=^3_P#WE(C_ /#_ ('_  S2?_,=^3__ 'E(C_\
M#_@?\,TG_P QWY/_ />4B/\ \/\ @?\ #-)_\QWY/_\ >4B/_P /^!_PS2?_
M #'?D_\ ]Y2(_P#P_P"!_P ,TG_S'?D__P!Y2(__  _X'_#-)_\ ,=^3_P#W
ME(C_ /#_ ('_  S2?_,=^3__ 'E(C_\ #_@?\,TG_P QWY/_ />4B/\ \/\
M@?\ #-)_\QWY/_\ >4B/_P /^!_PS2?_ #'?D_\ ]Y2(_P#P_P"!_P ,TG_S
M'?D__P!Y2(__  _X'_#-)_\ ,=^3_P#WE(C_ /#_ ('_  S2?_,=^3__ 'E(
MC_\ #_@?\,TG_P QWY/_ />4B/\ \/\ @?\ #-)_\QWY/_\ >4B/_P /^!_P
MS2?_ #'?D_\ ]Y2(_P#P_P"!_P ,TG_S'?D__P!Y2(__  _X'_#-)_\ ,=^3
M_P#WE(C_ /#_ ('_  S2?_,=^3__ 'E(C_\ #_@?\,TG_P QWY/_ />4B/\
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M,,AUW0I9)QG5^V7=?=NVU#/?*WS!T?W9\7O0G+L&CU=!;VO(/%0XX83G3]*
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M (=X'^557_\ MO O_)\>_P##O _RJJ__ -MX%_Y/CW_AW@?Y55?_ .V\"_\
M)\>_\.\#_*JK_P#VW@7_ )/CW_AW@?Y55?\ ^V\"_P#)\>_\.\#_ "JJ_P#]
MMX%_Y/CW_AW@?Y55?_[;P+_R?'O_  [P/\JJO_\ ;>!?^3X]_P"'>#[1U>0
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M]=V"B;)=)C^R$6\V7?UK-U8W6<"L9A.;'O\ ^(ZE.P!DOM@F54A<)Z?L<Z3
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MUM'2^% ^&0<ST%)]X1DU5$/<(UR!#Q.'L&PW^,$"XA'BP ]'H<L%%J,A)>'
M#L5&OF(EZBY'-'C%%=)'15/7; 9O-%U)FRO\W\P4-FQ?W]#.9%_WOZYD244W
M@2<MR*_9_A,S5.!J; M366W\K@)G]##C]3_4^#8W==PY]88*UG0?\L^C41DL
M$"GOY KI^E%)>6C)V1"OXM-]H%<_R!6'#5?SK-E'*/Z_VI*::**Z[A =N<,\
MFWQ55?4C;=)QB:5;5+MD^KR)OW9]FWBKM@"(1I!8<1$F!YG.VP(JX;*_D<J8
M<:*[95QOM],^"Q+^$0TM#U:^+Q2.%X&X!IQES#"X4<4BSN.)--&.@)X!?MW
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MTE\DQ*/Y4G^NLNAOO.E0SB>+L [E=8(&=SYU'F"QY9FV;JFUF:*CW9?=/7;
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MEWB \2%"!V:Q J6*/W6Z39B.',6ZBRZRFVJ:26FVVV<8QG/@Y>VW\QG(=,C
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MUQ]H-@G4/X4L:690F'&-ULKJ;4;8>R.Z><)?KZI(XZ&UW2W3SC?[\YWWQO\
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M>,GM)5!BA5FS(*AU&\IT8N45?S[-B+)QI^;?&,?:$H=4S;Y%X?>M>1;GZ?\
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M$[[?_P H_=1>2D&&RFO^++5XMI]?IOM]0.HC&7IM:2N@K!<^XCCB(K%]TO\
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M#PL"?%B[ ;O"4&\J4V6/$56#+9N*>.6_[#?]51T'AI\MW+#CG7FWIE@.MPE
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MFMSQ1\WC<J=2>ZV,8E\GKMFW*GIZ^756;!T @4!^5VKE3*>ZBZJH1?\ '_\
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MH2X8&5NF;6*^":7U"K28&0\"ELAAFCB9/TIU:[HDJ@HB"%M$$]VS'31'"&F
MN=9]6]+=+\+=4T7<*%6UG=-V5;U#3D0?53)Y3(8:'C\]"SF$5%)B!B0@@AM
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MPU5<(.QXG%HU9P=]!4I]JT>-&+'5=_KATU^_]5SMO@,18/Q'V-7W#'QZ<?\
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MHA.W&TBQK93JXR4 =U&2F)$HHQ4!D,OZB?*17<>J.V%: L:-DVVGXDMM E"
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M$?O:;Z((ZZ!O9RG(7*+)B-IRI$C)9#7>2#FN6!A_NM&8&:,!WD>,2J.QU'1
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MH<2J>O,PF/0_5M"RSE\](A9T\U!IJ/C[=70@^PS8?GW4V9I[>#?.=>9H'S0
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MVOX(.KYE5MRR%OM,;2;AW<#CCN<1NO2]>#"A]F?9K83<ED<MT7&NZ_XM?KG
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M85C5U><ZPFC+4YTB#Z$VT+E%AU<X,1[8CD>S;JL=V+5+3&SU?.NV ]\=Y/\
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M6>@&+4%/)M85D5;>3G9[.'YF2Q-L%>,16X])NW.I/'N<*-MMDMOO"!O^H?\
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M#M%@P;[O'RR#;1=\^<IHHZ9V^Y553737&=ML8R&5\#P/ \#P/ \#P/ \#P/
M\#P/ \#P/!&S>XZH=V6\IIK8T,<6R/&+&G];HR$8I-&8ANU"/ER3F.ZN,E$6
M2+.2CU=E-D\:X3>H[?7Z*:_4))\#P/ \&LP^:1*P8^SED&D@671@@N3:L3\>
M(M2PEVX"E7P(N@W?LU%6ZJHTR-<-5]==LY371WTV^FVN<>#9O!CRQ88!%$SI
ML@T$A@H]Z6+E"#A-JP&C!S91X_(/72VVB+9HS:H[J**;YQKIIKG.<XQCP>D
M>"RD$%D\;*L#L=D8D<> &Q3I%\+,A2[-$@**C7K?;=!XP(,7":R*NFV=%$]\
M;8SG&<>#+>!X'@>!X'@>!X'@>!X'@C>=7%5-8E(B$L6Q89"#$^))AX2,E$A&
M!'TL*K&H['$AT?;/W""I5ZH?EXMGA-'&^V7)!NG]/N5TQD)(\#P/ \&L#9I$
M3$HDT)%24(1F$+9QXA+HPS)-7!R-,9:F35B[LV,25V=C6\@2"N]F>ZNNNKC#
M93.GU^S;Z![8S+HO-&+XG$I (D@\9(I1$2+T*_;D6K*40F0DHG+X^Y6;**)H
MEXS)P[L>^;[9PHV>-E$E,:[Z;8P&Q>!X'@>#^;F84C<,=%]^5M65;6$0YB[M
M ]BVQ8S@''Y"*=5G<4"E<^ALOC06,K#F$E?I=NU81@B(? ENOHLJ,.OTON4<
MZ;;!Z-+<[F@W/XBO*O4NFE))3'"E6R6E(='N.9'9P:WMQ/'#EO(XR2DI",O8
MU7%K0CI1BBS4#$]4RVB+!BV;B7R9E3;4)0NKH[MBOP5[ (6<Z3F9Z(32QS])
MRU#FC^;8RX0'YPYAM4=$C:\.I-WJ=;8M"8SP4!8MQ;'0F@)>LWAI)V(03?!B
M)%(.@^BC7-1:PW'2<)G$.[4'(69#%.9UQ,<YU>B!'4D>%614UCR"KWP^4163
M5N:!(HD%]Y$)21<-';S=H0>*-%0UG/3GR/26GTW#LQ>%77)&N0@]G1-@,XMD
M$W8WU+F_/D[2L >?)K1#^T*GMD!T&-8[Y#/4&KC":+!$>)?MC6^FH67KNT.Q
MAO041''9]=TTKG?K6 UZ_'2:BX^*CA&DK/X44M652,J>CM1QU^T&0/J5ND%&
MEDGK5 6HIN((;NE-L9U":/EDJH1/N2Y0^859BQ;#2L/F0>$R&KUQ/IHA&A?5
ME,3"8-Q344%-'40;2/ '9 EA'3"'ZS/91;ZZIXS@-)[CG][<Y(O17+4;GP6*
MG^1.K)+ (]35$ZV")3ZP!3JFYO5^NPJ/U[)\A2TP GYLNLU(80&FOL<9^W+U
M-/;(0(VF5X578U]A(N!OFJJKO#MKI9V1N*JN<SUERZ-SI[SYSFC0!_,#(0.2
M;E*PFLU&2-!^9_BU!:QP4T'O7S5%XOOL$.H&NK:BJ/H4)6[*WMFLSB_RS64'
MK=[S0)D4?$7"'[; 2?GQ<!'7M4GOY5[>4*LF4/L#'KHP..#T]5AZ>FK/"^X6
M.FMW=L"[EM/>-S:UTH;M=_4E=09H5YH<2Z Q2M!'$L2M"G['T9Q"L&,[FJ /
MI9)T(9KZ%5]3NJS@3KHZ>82WT"#T[.ZD9=&<^W+,J>NP0CO3UCT]T'9,&BCF
MT9A%8&Y[$A:<.E%3D&U(QQE95=']F+1570C'1<S'5VN1,_QJK]ENYV"]4+NZ
MYZHLOI5'HB73XO27+;^1V)BR M?#9.O9U:7ID%(JCBJD1K&$$IEDWS8,82$6
M=U9L6[MVSP)+NMU]'3C\06KZE,2)[7#"MH..>$I->AYA6#-\FWDR ('%SC9R
M_GQR12R,@9 K!VW]@L"#4:361QIJ==L4M<_>KKX.-L/F/3=.T=&.&Y-"+D#5
MI2LWZ-Y=D=P0*KYQ;#DO3[:GG<JX9;1PR<K$SF50A_'Y A!)%)-!+K766PW]
M)[NW3+:[JA9?BK3K"$#N::LE:%H"J.4XYY5M-L2?5R'!*U 6J*I&=>W9RZ?%
MNXEI+]9),)@XCAQ@@\15+[,_YULW60PP;:[AUYB\B'R^,QV6"4BR J4 Q,A&
M('P1J+G41YI@W),TC,9DC 5(HZ53;N=<.&+]JV>M%L;)+))J:;:8#.^!X'@>
M!X'@>!X-$M"=(UE7<TGZP4]),1*.DS:,<BX8M(9%('C-MONP!A0P-B3*OB)=
M]^-NEJD@I]NRGW;?33&V<!Q4K&MNRJ/F77E!1$N2C4^ZFI]+L:E+EBS"06/5
ML8['9L48Q>,%E<HL*MDHO#H[<I<''30L"LA]6S!8]EEE-1!'.H;A=<[[ GT2
MA4DBL=NR!R"^N.N\9T+K_6LXZXLF@)ZZJJJG//%>:S\="GY*"V;DFW)*99*D
M]?Y(RHNAG5QABTU0"MW2-K]-R*L35- 0G3<[KV8<M3RL)M'YES?+R&)0UGGQ
MQV=,H<78NQU0Y)."Y/H06/".WY B-(I'5%PRH9-/"3YT'0[LRD0_1/$U3TA(
MTI<(Q.I!SJ.92*-QN0.IC6,G$OP)R,66Q09#5"48+UA*1+0QAR[U:HM56/V.
M=]--M]<ASY<%NLRU[T!UU>5*VQ$[]A_Q_?() 248KFL7=F;0.>P'7GMJ"(P@
M5J@X@Q&4=#65!Y?)(:,?/&[@[&&HEJKC7?55+P>DATS\A3I:Y\@)#T.W'5A&
MKEEM:H)\Q/R"%BN 5P\W$Z7"/#DIYWC9Z<-956LXE;%PB-9B"#U@QV7QHT=,
MU5\AD;&MKJ]W=@^]!U7WP7NZG81\AU<G(<QH"1F8E7U?+];<KI5H8J@TU@0Q
MI:!Z;\EQ%[+ C-,Z3_N8PSW;I-TGV/X[0+><<,[&+=AR6Q)R8GEC-)/QW%1\
M?N"8<^R^AES@!KU#?I^(0HR&DH86OM)X/!Y,.;[*/D1I0JRRB36'-_V\[;A2
M#I^HK5D4 ^7Y"-0XRZ 6%W7RO)P\)2YWFY^1VJ%CM><+B#TNA$@9Y0_GX\&,
MU\>0=.V8DH@S6#/=]E?ZYS@).F71_;DCO_: 0<YTW!*UEUQQR'K2/?EY)=W"
MP(_K.Q*UG*PDR=HX_ X_&T:)= "HL@X>FDW0Y%D;57T4=$6.H3WRMUU;;*[C
MT/Z'6Z#4KV:B*OAU7'[.YKED5=I7H3N?I6!R@+*#4$J@/ (2@5BL'B&^B.Y)
M^#2W?-'"!+=0IMIX)\^0*L)/U3#<<<1?#X2ULV(RR:3::+/9S#Q,=80])LA6
M^ ]@1F(2)BA.AUP$@TE:"]E4MWK&+NTEL?KK9PH'+2^;^ZGZ9YVBT(M*G+^B
M),K1O,TD(12(<[3<Z/L'JJK>NF(?J"-&]U*].F8_# <2A 63PU3&HC!N.R%<
MBT<+J,OM:!U/J6>=!PN>7PPZ =6@5KJBI[+=H?.!E;HG4[V@=W%XG*J>;@H]
M7D&<R8F_YT"OWT2-;L&J6[ERCJ0>;+8_)NF'0[P/ \#P/ \#P/ \#P/ \#P/
M \#P5FZXH@7T#1\XB*K"1/Y8QBTO*UIB-6)-*S?MK&VB!T7%'.9!"Y5$G&=$
MR1#3Z:/'&S/3?.JN^N,Z:[:A48UR5)8IRIS^^@U>*XZM@^G#[2S)@PE>CJUB
M\5KBX^=Y)T: ?VD6D6Q68Z&(!71-J[06*./YUNAJSQE;57338/F^-6N>K@V\
MMFG2(JQ87'1==1*C:AA]IV&QF4_D\7KVY.B9D*N><A0$EEX&'RN7UG9T2"N6
MRY)Z<W7CBV7N^B>&NG@W7HZN);UT3B4?Q44T$UW&QW6X I-=K1FU,V7$+7A1
M*+Q"D997+^M+4C&Y".6&\9&2+-^[;OMFC=JT4WPPW5535"NZ?+G5=?1^I[*K
M^.R*375/>%KV ]BPZ57O)G%>V=U>3IVM'E8Z%P&UECX\!($+@82!E_/0W<-^
M@P(.=</$&ZC?=,+9\?T'8= V??X7=K)@U 2>,\_R6K(L>M*16<-C%G*1N9C[
M_'1':;2V8S",1U0@R *X9J.=1JKK=9PUURHJZWV"LBWQMAMK'Z_5C\'EU>5"
M_KH&-Y[KV%="6Q'X[+KF+-+$L>>W1_% K0')5V25GUAI@D1Z28]HI_'+OE=5
MM'#?+<*\SKC[LPE$J=K>L0G0E:R)MPU1M173<PGJ!NWPXO,=?G(4C<S&,.'=
MQGY$0G-.P$/:CEX94%-M3:;[(_5R13=H)Z!T8X:J6?QRG+RK>Y*_GT/KB0W?
M9Z%/5?<-CC;9EX3GJ51J*)-HV>E8RQ+3468/94ZD6[=HX//7#1DX32^J2>J:
M6@4 :<2WM3$ADQ.&U%;TGYL)V'T#6@_D6K.HS(A^&I)Q5=5UY14TC,EG5V11
MJ('2.458]*%!S8\,=QUG*4TV[-3]5_\ L!^6MR+U+ .6HDQ# NJNE^Z4H?7$
MWBUTP?HF*P^(TM=$2JFA(#*(FX<3N]:KS-J_ELAJ1X6=I$ )QL6W-$OVT]?W
M5$]@G>I*,[C;=T_YV6&=EX[E>7W%>LW%4,-F8!;>I)$UJ6.535LSD[_:<G%)
M76%MQK20%"L2'843CL_6&$FS;5!1\LD'8WP/ \#P/ \#P/ \&MS&) I[%C\+
MD[=XZCTG%NPQEL/,&8^^7'ODLHN4VIN/$!1P6OLGMG[5VCE!=//]=-]<_P!?
M!SDYFX?%0B'7<*M*O-I&69=/77/.>'EC3XY;YF*U\\,Q G4SN*2*;2N8%8:D
MT7@XIRBRU<-5&KD>BJHGJKK]^0JUQ53W?#"XZ6CEN K9C%55"#Y]L2UI[9-N
MCC2,\N:)\$D.7+3J6$QX+-):<FL-*6@^%S=P;):, SHT.>.4='+Y;5QX.ULR
MFF\0=P9II%I1)O[VF[*%[+QIFS>(Q71X#/FMI3)_VGS)1K%V?\#^NNLAJX6T
M7=(_ZK.F=]] XAH<WVL<Z:B%%0N0STT]Y-D?,9Z1]3R.V+0:SA_!LPZ\;4U&
M36$ZV./K>RDIM:41CL4>IIA'"R,;(O\ 9UA;?#95 (*8<L=^MZDT'C:JZ/'6
M<,KGFH?*")?K  <6G/=4'L=Z>LWL"+FGM\?8'IMY#T7S8BR4U8.9(D=8,5(G
MA$3G"(7C[!Y6NBO>;##KC[6ZK"Z^VLB93>*68 E%<"C9O22';C.,:\NMU95D
M5P$E=/QV%6\5B4?3V5)NHROD45:M-E1FN=0BEW\?=IU[9X(OS4$LRKX*$:\=
MK2'#N_SA,W=$NE'8%<6OUW8=I"W%C.(HG+H%6-4[9>K#6*&\S>S<[K^1WC?5
M'8)BX%H[J2 6E%SMS +-B3*#\>P.@K?+SR\L6D Z%ON!FP(L)<E=1UK/YFG'
MXVQ@T;?*J$"#"-&22\HRF\9*N6SA;4-&[\HGJ"<=%R"?TS6%YS%ZWY_H4+SQ
M85:7[':WAU.WK$KYM>4V8:G4(/W=7J1T-):^-1UN1SF/R-$N.:[,%$MM==DM
M@KE/^(>NXM2LA7AD,ON8VK;=)]TC[+%Q/JY\S?)='F;WA\MX+M-D[FMZQF-Q
M=6M@>I-RJ\ .6^6HG&P]XU=8_79X#/&N6^YA?0\)L2/Q+H<Z\D?<TFGT^/N>
MJAB=5POCY(NV5C]<L(.]N)OAQJ]M^.HV5_$,XTOOHP*+A5'F&OU%:!U9#=Z\
MU%BF1[B42B-,_P#/(KS1K*9A6]@1>"YOH/(=XBO6"LY+QQM%64A?RK3^,';.
M':+0L1W3:LEG#A9%+<+CXSC.<XQG&<ZY^FV,9QG.N?IC;Z9_^F?MVQG_ /5G
MP/KCZYQ]<?7&,9SCZ_UQC/UQC.<?Z?IG.,__ +O!A9-)0$,C<@F$J+,0$7B@
M0M)9(=)KZMAH4 "8."A@L0<[_P"!NQ'#FJBRN^?Z:)Z9SG_1X(;@/3%56"W+
MNVCV1Q-L'&5X<4<V3#Y+73(B#MHB2$5H6!$9<-%#3J$R*"56S5)HLJZ3=YT;
MKI(N%-$M@G_ZX_KCZ_Z/]/\ ^C_M_K__ &\#P8&52<#"8Q(YG*B;<+%XB!,2
M>2&7>=\-!($ /<%3!-UE/7??#=@/:**[_37.?MTS],9\&C";LK:14@.Z*C!_
M,IJ,W5[2XP$FCH\@5WD%?$8NG,AAD*);MLEGZI./JZ+-VVJ/[*FV^J>-/R9^
MWP;17TYCMGP*$65$'*[R)V'$(U.8P[=-' ]TZCTL#,CP5PY8.]$W3)PL-();
M;HJZZJ);9SKMC&<9QX-O\#P1O":>JVN )N+P: Q>-1^32D]-I$)'"6VK,[+9
M.4V,GI"835T5R2*$26<*;*K9WVUPFGIK]NB>FNH21X'@>!X'@>!X'@>!X'@>
M#0K1LB,T]74UM2:?S.L/KZ-EI=*EX_'C4K+LHZ!9JD3)%I'8XQ)GB_\ '#D%
M%]T6;==QLFGM]B>^WTUR&HPGH:I;+_RE<UU)]9T O&MR-MUA,HJP?F83):_&
M:1=1P?3E;1ON'8Z;ZS,7^)%PJDX6R[QC33;*:OXPFK[M?KC'UQ]=L9VQCZX^
MN=<?3ZYQC_MQC[L?_O\ !^^#3!TU;$1,K+XCTS9)1(O)!#AD1BI9H6.;1G;?
M"Y&*"]D=GDD$%\:?4:X:Z[Z/\9Q^+[OKCP1!7?65+6Q!:!LBOR\BD</Z:<KM
MZC)MH1+VZQ75L!/25R[D0M\&:E8,S:AHR]464-(L,(+)8;J_8Y431W"R/W:_
M3&?NU^F?KG&?KCZ9QC'USG'_ -?ICP0'*>E:NC9*N@XYX<L(I:0]211-C54?
M)6.Y<P5G*(5#C-D+(Q9(@IF QT_8H5-^01PMJW0??LYURV1<K(AEYS>L-K6G
M[2O&<#9K'X+3PRR#LR_:AAU218CM6N#6DCD02--FJY<^$>, 2S\:X:I*:D!V
MR;A'ZZ*:Y\$O-'2+YHU>M]L[-WC=%TAMG&=<[(N$]54MLZY_KKG.F^/Z?]G@
MC=]=-7#+DC?/K^9B&UR2ZNY7;$<@2NZN#)6OH3((M%I-)&^/Q?K?J#3LT'(9
MTV4PLIE7;9/3;1%;;0/F(VC7N;IC=$DDW3BR"%=R:Z8ZBXCKUP'2C,-D<6@Q
MXBUDBC780T/L"=A,$OU=5M7F6SS*F-?Q9VSX)9\#P/ \#P/ \#P/ \#P/ \#
MP/ \#P/ \#P/!167]RQ]*<S>D*NJ6YYQT3&(H=FP&M955-H53&YO%8K-0D*D
M<BCMK2^#Z01\#;O3.NS-R@Y7T(Y^S#?[\*:[>#Y /R#4T)CKU&]MWM+6M#(?
M-9+;M9.ALGEF:Z(5I2,*Z*L".?W2(C*(J3$X_4%@#"^FC/795XGNLD@GNNV<
M)IA>%@88DPK.0,-EG0T@+;F&6Z;9QEPX8NVFCUMLFSRGAU^95!3&<)9T_)]V
M?M^GU_IX*3A?D8YM+/YJ'>Z71#CT D=-P^1Q^PN>;L@1W65] R/2)T]'18R5
M086Y-EYP<4U2;)-,+9TUSA17\>G^+P?F/D9YLQ'WA);_ #C:2L?:$;II]3A"
M@;D'7HWL28PHS9$5"_Y1/X8WFB[*15_'7Y=D22:J"W+1DOA-QLLDHEJ'UJ_(
MUR/_  +"5,+".'8N\94R5?2*/UG9I@1%0=\RF<PBOS\^=,HBI_E\&Q,*X,"S
M*QK#'$=?M,MR>&BVVNF01KY&.3)62T&BY\>2P2/Q(##BA:M[&" ;.3FMN@J&
M"2>J#I:+LQ5E0?%MR8>'=&@ZKL:SV?-7*RVC)VU<K!,"_4=(-N<!O6;B8;(T
M*6@<=LMC-5 1_392&2I$<N#+* -AF)&AEVD60SE'=IJNG]_^/37Z9^@0$Q^3
MSC-^7EX;6QI(S6@I631Z1D"U3VP& H2B!6I#Z8LV*L)"5A;,*:D=4V#8(1K)
MFC-==0*B1T<N/M;IN%40F$%V%1,DLB(58*/R%61SV8W97$2(+0.;-8@8L?GD
MW*0EKU^G-' %.,MI> S!S#Q%FNY2W(C1KAVSRNCI]^0L]X'@>!X'@>!X'@>!
MX'@>#7Y7(VL0C)Z5/1\@+,X\)?&'(N*1XQ+9,008-]W*C0#&(\S('#Y9?1/.
MJ#1H@LX74SC1/3;;.,>"AS;N\O9^HXAR_P ]6;;P4!;SRH+Q<SH#,J ,4^9$
M$8!_.KN(W9T''EI7D)&Y@Z(.-&>F$],CLH94_(MC[ EFN^Y^9+54@R$'L%P6
M7LB2UQ$X<@K$I@-7+%[:Y^)]0U__ *HF":;LQ\@I8*\*:NU\)MDEFJK-7?1Y
MIE#P3G:UK0:E(2\L.QRRH2)L#4.CSD@@,)EU<&)],P%?Q1FF/#M'Q!;8I+)0
MQ:_=JEG5+\WWJ9U3UVVU"O$=[UYW.XD34D_L> R.)SBFX!(8-:--6I74\'F>
MA)>O Z7(:1.5Q(:7)12PI8S<L6)AHFX&_L,G2:JR>[9?5,,9"/D3Y1GY+0$&
MG$C'2;$\A58/XG+:RLJ%RL'/[!FUC0"*Q611R4Q026 %GQ^J36RB;M)+]9@@
MF\6SHU<(*J!OQGLGGF/TQ4W01>;N&E47>&3D%:23:+RM120"%JAFE[)/-PR0
M50V*U5JZORI+75VW0VS^OA#Z?G522W#16_R$<TZ[3S^?*V-!48#3<WZ%5?6#
M3-K0P9-*2K9F)?SNR*M*'8BT'6:!B[60CE'F@55X\1T(M=\H?8X2VV#WL.]*
M3(V:<I]&,=#(3X!'6\R=B7W,M[L&SN$NIZ-KA&:AR[N!I"#44_N,EC?9\U75
M0U'H.'N<X:-UE= HJ1X=Z4LRE;ZY?E *!P&!7YW]*^FY1:.D[WDA\)3CCI>,
M=!"04.B3&,):_P";)C2(-A?YGCQ$:#4<J/TUGRC9)JN$?NOCKZ=.Q6$,YFWB
M,@D$;&4?#KQPRLLRR#]:&*X[;J6]C=^2O.PY%T'ECJE(?*A6&SO"KUT]G+L2
MJO\ Q+1%RJ'S6=\:W2!JM+%KV%ZPL,2$QWMF%Q:5!)\6C*%W5M?\E;F.8:[F
M#5J*_?AC'E@2F,9LU<Y>8$:Q)IH$S^N2=IH!T4Y]H>PJB@78L4U@\#3$V/==
MK6!15<%SFYFOO[4FM90A@A%Y4.1&JH1L-([+%FGA=BU1=(Y3**N,?D575TP%
M$V/QV6^)J:V*LA\1'#Z"S/N);.I/CZV[@VMF&UA.*'Z- VQ? BG[$.1D\7K^
MDIS 0+(5&8V\U=M!I%!TH@R#LG>6G@QLV^/&^["L0N4L*!Q.9[C^J8[+E;(S
MT++FXZWN9"_3[:[B,#E%+)0P,"8'JTK1#$0;ID7Y=%=LENW'*LQI-Z@B&\4W
MRW?''TIQ<->4-$Y*I&8=W(!=5]'+:="GT]&W#VA"K;Y@B2;U>+'T\)5A2J)D
M<S3<(;-PCYWEBVWU9NW+U,.FO0T*G=F@X77D7^X9%9+/ +FUI.V?@-#("#1C
M925Z,0X.1A9 #D^TLE(<<)(M'*&S?8([?9S]^_XT]PY%K\'=>Q:))T2,"5[;
M?,U<V9U\$K:NYI8+2.+2.H.G80H3K.3R0>(@^8LR/<QVB?DP02%U:_JZPLRS
M<LE$R([1GD+)<W\06I3,NK>1E]8*_B;/G*@"MCUVA("K]9QVCSW5>]+A)+&3
M[P$@Q3K^4P BG^XOLU1<)%XZ/>Z-\[N'GW!U+C+P\0C<??RD(TC4G? Q+R1Q
MQ@9Q(F( \Y8-UBX1E(,#A&#K040W403>?J-?VM$\*?A3^[[-0S?@>!X'@>!X
M'@>!X'@>!X'@>"*+WCLCE])6]$(>R;D97+*SG,7CC)V2T#M%S4AC1(.-P[*J
M(N=1[71V]TV46PDKMIIC.==-\_37(<M9?P-=-=RJR"W.J5?DZ,L>!$Y0ERS-
M#)2.C*NOZ?7GS[.KPWJF2 $MPS"MK5BM?F#2D9>(;1Y.>Z[J+(JASY-FD$34
MW\?/7D=U7"S\K%]=6UNT]-Z:GPJRW9F2\Y0BH>NK*M>;0 $CI#8HU>!;THZ3
M-@6S(:W:CL_ONA9%'04R8Z^"/(]\8/1,>AT=P.@E?#I^!IKGMBU--;:+;N&5
MWU%V45MAU,VQ=8+EUN58482W$#C.VG[OX5-Q/T38[;9R'8;D2I9]4(J_F,\:
M,&6)YU7>MLPQ$?(5I#IK [$DB)R/:N=EFS;^(?ZXW5_,PT_(DVWS]-%-M<^"
MJ@CA*Z8>.[DB5=V=&XC%+"&7J\X;W1U+)/Z%EW5 M"<WIO(56#711H!VZ ;J
M$P617_>A(DB[11^FV=-<!$%=</7R/L2H;%9UQ&JB0S/F<MMRIY#>'^TA4.1A
M.0!T;(1CXD_74&(UM-786-I$HV3@W\4-?/'2[63#7J+QSND%?U_BIMLFQ^,>
M/&:3I#<+RE5(.I;UP,G"+1$^%86K4[^2:QY-G"A#J1@II"H&8<NQ[O9JFIDW
M^FM^7[W*F W6U?CWZD.5!852@8+5LPKR:P+Y0ZRC%5RBSG0T!6I_J>Y'MB\P
M76.=+Q \V=J5_!%-XR_8IIZ$(]JZSD4HN@HZQN':JG)/8)]G,A5@5PG7ZD'E
M_P#9T7?-I5_=8^PHRPBT8?:3=DJI'8RY$84-DGPU5EN@MKHL-V4T<*Z*X^P.
M?5T<L=&32Q89U?$<LD.@ZHZNC4NA%<D91#FT'(<TM6#^F)_"G4ZQ WLR'N9W
M1TK.R#07ERH.;3M=GMOKLBUU=8"MX#XV;_GY:4@[U80)$H\YUZTII_TS'YT^
M)V!8-BV%TK7%\\XW8YC&T78O1[^":P[3=X.=D541CUO_ ![/#D5^/.P=8Z"B
MMJP$##P]@Q>$.97-XX?LOH"=PZ1/40[>_3CR+*$(S$(N3"?RAN$[MGC]J/*.
M7C9RU'@F:2S955ULHB%E/ \#P/ \#P/ \#P/ \#P/ \#P/ \#P/ \$-KTC%U
M^@QG1^Y YB:"Z;.4B@*U<,L1K>+GYM'IV[(*M<L,D=CB16-H)IJ8=80PWWWQ
ME+.V<;ZA2WH'XPZ]Z(LP],9+;]JQF&SRS']I6E7L.UAHU6=D"7,X'DDM",SQ
MW&7\NC%7RVEQ;ID=&C5D"!!P0W62(--D6^$POU*8]*WBM?)0F5)0P5&YBP(R
MT<D$%DD97!F<=D(U2$HX?-5M@NBYEZ/=:NFFR#A'#'[,;Y3W424#18_SS 0-
MNW#<JFCP](;H4I]T?$R%(22CP0C2+ JRA):,,]Q>CH>405*[.=UU5UU-'2*:
MB&4<Z_U"'+6XCBMD2NUY\+L*3PF;6P9H8Z^-ZPJEK(:14GSRE*](*3AL=N*L
M+! !SJ;F6JN_Y'+=5^T>MD%6BJ&,*Z*A$G_"SI9F-!Q<'9-T"((]B5<PZ[HD
MH<AYS'2;"KK=FU\ 2EK20_"24I92,_:5E2%[('D<=@MC#4RX:;ZIHZ-L-P^.
M*_%=4L><0)(G;=V2^.4F\@;7G>*GR4$T&4A!()?=;]$(UU'78B"##$G"FI?4
M<=&.7I]P4+Z1T0W9H.DE?V'3@+K4]0L%IN@ZSYQ&HN)?7M85U$ZR%ISE 4<>
M&P$/$,0XU62):#68<@^60'IJ+9T:));*_P!=4]<?3& H!:OQ/1FQ@#B-C^D[
MFC MU'.F8]NW5CE-2;"3OL2TUK2Z FR+PK7"9E:>FGJNK4([=.W3"/Z-T%D6
M2BR>=MPL-"^$X3!97S>?$VC;) 7S=)+<L89') [@Y;%FW+>8JT1EG7%:<FS!
MV\O+2^3*W"<>*-AKX4$2=KZ918)I))I:A>/P/ \#P/ \#P/ \#P/ \#P0I4M
M%12G=;@UC9$^_P 73<$UNF3?S3EBOD?)IT/!CBH\)^F/8_KA&Z(%++=-;\ZV
MNVV_W*[XSC& IKSU\8E=T-;D&M5>V[1L)O4%;U/6-.5Z<TAP.$1-G3=42^EH
M=/Y,WB\;&&+#MUO7EBR(7DP_=ZLDV)?=-(>GNBW63"8>O.?;9OZ$S&'Q:> F
MP T3Y;+ (=(F";(8'.TWTS'[?L23J208(?2!=W*X, :#6C)3\K31VP3VQAO^
M9=78,E='%]?75+Y]/RDNGT6F<SBO. (4>BSR.:J0(_RI<TXOFGYU%F1Z-G!Z
M\@&V#.5U'R!-(@+(,FZ;95K]FZ_Y0K <^(VGRDB 66-N*Y8S?".;:Q.;\%,*
M7(6+.MKM.$3DU*,])14D@BM72L3_ #+X?&C41'!"D?#OG+-%931;?;(3'TEQ
M*)MFJ>7:"@&P^%U#24PR',C-2+U(N,I7;E&^N;4 \)=N1QY-S*1#:T1^[78A
M_J,I-E%%=]]]<)JAM-M\*U5<<0BD,DDBGK$9$.5[XY''. I$&@]7KSH2&UY"
M)@<>*/(^^1WF P76S)0<OHGHT2767RJW6UVTTT"7->>H?K=*MYX*2/\ NI:A
MF_/6P[+H?_ XA[:6.9AH4U;?QG[W]QY(NMD\J_L?K_AQC'X?N_Q9"N1?N!L$
M[YAO)SQE#MH!.(?,HN&F3>2MEYOKU#"XP"N)U53Z)IO,J,HX5Y_+.3+(ENGC
M\Y$4\9_7&R6,;!IC+Y7^=';)N6WA%_L *X$-,5#Y&LV[86S@C^Z'E '9L]__
M *DW?( X-9C9-J52_!DCEJY2=LFKQMA55(-O%]XPH9-%*]>B;8L^8RKI2ZZ.
MB 2"T_H*6 /:=8Q<S*!QMR1G#ED1#1^.'\D]#^RC/4HS34_$RT6T326#?%[U
ML;3Y!!G,:?\ :6*M<<CEK^<.-@13:;[2UA;8JN$121[$DU"IQS=@3RZV3R+V
M<_G3QC"^-,YU\&H6%\D?/5<2>31TB/M(\RAQ@N"D\UB4$6.0*/$8K8\'JR=Z
MR*4:D6[2+MH'*9ZVR16)ZLTMV;$FY9[.DA;_ &0#7KZ[\CE*+V7)-8]/9./J
M[G7HFX_\M&$,",GEA)4-;$'K(_(HY9Q&<H!18X>9D&4=1[D?E=\R=?O)[ZY;
M:-70:]U%\A@*O*]Z%2JY=@)M3F_6K"5I:60T!*QJOF$OE]+_ ,R.F8\?/!Y\
M,JZ@%J;NAIC=/^WW*H]\HV=O<#7:6 L8 Z6"3.X*0B 563! UNUY?,YB;$W!
M&KAC8L<JZ15.(93T--V,Q5UC(%TSGJ+T6T=#%7)\<53<_P#<L-<Z. GZR)_&
MZJ@$RLF7O-6$8@T;,2@VYV403VU8!F2SU9)#+E5!'=VY_%A)'3;?7\BV^NOU
M^N?!0SF/Y 6-JT5&I!:(0((Z)7Z!GO)\FJ.HR;>>#G%]P9O)9<H*@YU^5%BS
M,7*4P$2FZ)!V^:-L %\*;JZ*?1/(8OCSY!VMR5)5.;1CD@0O.54Y2=J&0T;B
MK0$!DC*[;,DM6BUH,/+3(F[WS#9)&E\29HJZ55!(?8JHHJFNWW6#IYX'@>!X
M'@>!X'@>!X'@>!X'@U6:MIH\C1!K7I>-@)<NH.3&&9:"(R<".0R49?R[EV %
M'HN^*N- O['ZR6I!KIEU^/\ )OA/&V,A03E?IRZYK1TPZ$NQS#)'% -G="U2
MA#Z=J:6"Y>D5I;JF?\^ #^'):SYF.>B).$B"1,MNYT&LP*FZRZSO ])55$/T
M-\I'/,CV';1V)7<>9.RU3 'Q8/7[,B(!G;LNBT>=*]%OR+:2*-WZA:\JB+1S
M=<;E^T27V;N\K?QBN7V@;FG\A]'YCU729Y&[:%#K3FNM9L<%H4W8JQNR\WB_
MYO4KX_LH=_5(RQI<HQ84Y; E36&B&-2*^R8M1-[L'K?=;2*W^(;%ZEYKBY*'
M%F]7$K&IG'2,&)"(U/$<0(9/(F3*@HW+6LF:023X*ICUGNJZ!!FHFY4U:J_A
M3U7")J]^1X/)7+ O8#!"J'4(!GZ\Z*H0PQ1*VO5O53"R:CKT!6S:1ZR(8!*Q
M.;J6HU(QLSLQ2'2*/NV)E%V@S57U2#&VA\GL$.4%TA).?&TA9713G-5I7AK'
M+9@:XE2&OH-$I:>%(SZNWDIC<_>QDX5B#E@U."T7$;(.L82:%%E-M--PEDQ\
MDE%181*]Y-&[B83* R69QJ7U@A7NQ*RV:5?1.JIS)Y0,B(8P2<20%K#[MBQ!
MHW%J/C+W4PDU08J/DUVJ03YSKTM$^F@THDT%AMG 8M&Y1)(>UDE@1-**C9:9
MALTF%?2[2)I*%7A-ZWCDLA#UJY4<-VF,_<ENE^313[L! ?=O<3/C;-//U&<.
M)@R]@1HC>B\EDJ(4C .<7<I 5U,K1C0_]A-S(#4/E]@!'ZS+[-]-X\Q,N<?7
M=GKKL'S= ]HOX7<%.UC4@5[,/R=51N@;V()QMN1%AWLAYRL&^6M?1XRYE\=V
M962X##8\[T5V9OQ::!9)LNJ@X7URD%CZ#Z2K_I"-1R85NSD^\<D]90&T&9(V
M-9#=63"P\',CHF9;)E'CT5/@6 "O\P+53PH-V43T5V_)M]F L#X'@>!X'@>!
MX'@>!X'@>!X'@>!X'@>!X'@>!X'@H3WU9_2='5>TMJBIQ3@0<,FE-04[%K0I
M^76"X+N[@O2NJCT-C9#&;JK/4(C&V$ZW>?J*,7V7BS;73*R.N^<ZA5WIV?WC
MP,9,S2(6^1N=]T7MTR>"Q7H$N4=P"JRU14AUIU#"(W DVDF"I1\">E"H.*.\
M*K__ //AF:2>=%M--] N1Q;U1_M:5]9=TC] .*;VM-^*HF:B4B#87.JF&UO6
MY-_+UBA)TJR,Y8V<3DPC=^RPB/4T$XPGC;.FZJ@:I>]ZW)5%B<WV+$9K3EB<
MS7W<M1TLI$6D,-XG#1M< PLC'K3AEU";-)Q"3"]3^C!Q_'*1?1%T(65RB_PK
MA+;<.=E0_*M>ET:Q.'OW'/="STF0(QVQG%BM,EGM(Z4W0EI/NE;7LVN6EUBB
M\ JX!U@RA\*CFTJ(QYT4;D7"FN%,+LW7@Z7U39G074O%/-MYU++*DJ"U[BIZ
MJ+=-YF%;2BW*YPM-*\9R0I&!085:582%F+7/%4?UR&Q1TLBQ2VURBLJIA70.
M7TG^6?H1I&JNMILRYEA=;ON3^+^CI]%)FYE*TYD\^Z6M"85^:Y_J\NK-(R+R
M1=QF!G)$"**,23Y+ O1!R*61<[.4 L3R-VST=8EUUW%K/E5 VC5=W63WC7$!
MDM0U[*H(]$;\<VBE#X],$#I*X+5CT^B]FQM%TNOJW38;#GVJ6$5W2.5/L#LO
MX'@>!X'@>!X'@>!X'@>"A73%E=+59>/+#.$SNF]:BOKHJ,4G(H?):<EY>?!Q
M?^4UN6K)#86QAEV@0F2)1.JOX]FFM&MTV/[^5U,NOPX25"D-D=$6'\9D@95?
M,[T6N>O](/5UXS^V^F9"^>2T!$<]!\H\P6>Q"G%),,%L1HJM#DCFR::FB^V3
MZBZFV-T=E$]PZ><EW#+KNYUA-SV*'&10A--YQ(6#=HP*@AF]<ISV5H5?)OTY
M$Y7)L])15K0065V7WTQML\VWQHEIG5/0*\],]/615KUK)1M@U#7'/\^$5CO3
MU\OZ^,7Z--'_ /+[IJY;IVD4:A]PUFJA!!51U, )A3;-TOAPN\<(Z(N\*Z;-
M@I +^1#NM_)*$HAI#^2WW2_1/-9"^H=$"<LVBS@#)XM1<SEYVE)K7ZUL&)@!
MFTIEY:"' :^RNP_,4<2A)9;\P%-Z[#?HUT=U03Z#A<WCMBP<F.O/L>Q>+U.9
M"\#EI(2"KCCR[NE]+0OJ$S_%M#!4(F1"F!:2AK5R")(&# H2U0U3PMHFF%V>
M[K8OWG6HI)TA54@JQU"J7 9EUE53/:^DQ4W9 !H:%X-,8C9H&QX^WKHVC'%'
M7Z*CJ/'VZA#\.5M-4?OQX*0]B]U]D\US&R!CG_9'K^*0VI>L.C19BT592]=%
MJIH5Y4(^F(UNJ.LB,"&LXZ3E=A$@*?Y%M' C8*HY;CR&ZFK;4-$:?+?;&UT*
M1:15_%(/1[BT9FG ;F/!EU<7;"8Q;M)\_D:GKP VLC!%"Z(-?5B%0AY^Z1_0
MUB[5E)D&&4UE1V@=19/Q94<OA4*AITE/G#BO[Y8=)QJ=(R9%I8K>UALR-3AL
M6<RML+2<O1FY.0.VBS%33+5R&6V&*Z;L-MF^P11O\8O-:D64A^SRU?X56M"5
M3;Z8L%YJZS$"UXZ]#/4L.L,<*:DM[)UPKJYQ_K-&7_=<?1+^G@E2,\44]$[0
M#6Z+?S_:7@[?N"[VG[<M4<"%)Q>43%PJ?;.A>66J*X5R!$(Z-&?UPDR5^Y1+
MZ;Y^O@R5C\CPFQ;HQ?\ K/;A@=FZU(\I#4Q74W2CK?2O2$E2E[L<F/<!B;5(
MDK(FZ;C5_KC5ZEE/75-333ZZY#6P'!U#QY2ZQ[=6S","OX)+!%@U =M"8&:D
M4>V$!UCMDRH'"GQ%5D%EMB,L;K%WB6_^N?N7;U/1)V^>K. \YIP=S]/ ;*,'
M6$PQ'!_+4RX]:!V,S,-D=*;G:L0<'TU'N=U2SB9*.X$)73-*.-WVBS7[L[9R
MJM^0,'8OQZT';1,X<L5U8LL/&XIK!]9 7F'[,@$1->4U;-CD<%G-QN2F8])9
M;3P8@[&NE70Y-U^WNU0;9?._S!XC> ZHB082.KR6VU#%X1!.CJ]J1098A5NC
M4<:Z8> 2DL#0#=LDD1CH:&%8J+4B39!?72+-V"+4=^!KIJC@+$2&G1\R@< @
MLPEDP-I0<Q7$C>FM2+1B2G1RM7HPP-7FR:;!5B6'&)"(0?D&>$DT'"VF,9QC
M3ZZY"OTU^/JAYI9\KN/^0LZ)6%*+#JBVD#4$GK^+I1.S*>@IZJXY-HB*9MMQ
M(PT<J>4DHL?_ "HN$#P%W^J]35U0:Y0#;ZQXFY_J;//+B,1\Z[*\NQ*PH-3Y
M^12P^=-AXS:"XMS+AIA^\>YS)M'"H5MEME_JOEEE/ZH?9G.V<A8F$11.#Q81
M%4C\KE*8A%='4_-SKF32DCA=VX=Y4+G7F-7)!9++C\>FV^/KJCIII_HUQX-J
M\#P/ \#P/ \#P/ \#P/ \'YMCZXSCZYU^N,X^[7Z?77ZX^GUQ]<9Q]<?_J\%
M0Q_$]0#.>I+S0R*V.C7\FLJ16XN1TFKK29#9[*+K5Z'+%A<B3:Z;:,U;;<K$
MOT%T7 _=%=1DHANPVRV\$=1+XV.>X7L=V#&;@5Q(9[5-CO<%[+)FLI2*E^B+
M!ZG@.K-8FU<N$!8ZZ;0-DEV_W[:/4G?ZR_WH:::8#Y"/QF\]$%ASA.0W8+<#
M3RTH26#VJ8894D/^U _[#'%E$DV^S?1R&O8N\(H82T335:N-6;G5=LV9)M@L
M*!YDKV,\RB>3@A&9LJL!5JSJ44YQ(]UYFTA \<F&9CL2APT6<JND R6K7#K?
M39QE+'W9WRI_K/!H5P\'\X7=*9984NBYD7:4TKZ!UV:M:"RHY [#RRJ>QA5N
M5+)F<AB[H;LTG%7V.'3*!"NJ?YVNRBK?;\C-3=OD-1FGQTT'9(]TQL8Q;4\<
MN*XG]8HR*6V(_-3$6%MFNLU9:;P-,G;3>3"W5@Q%574BT1=:AL/E?W6[%!XD
M@NB'WF?C]I8O/EK50E=WQJRG5D$+(?3>$VW(X7("&\@KRJJNF4'?.8SD8DYK
MB;Q.D(I@B)VT^S! &V?M=VS[7+C(;Y6?+ 6G2U;Z5U85F!X/ BE_'R$!>RMP
M5CTV-=!3;>QI XE+)='1!]B,S5^^?!5<Z_L#,/5FR*FK551+8-FG7-%:V7B]
M$9S@[)1W0E9MZAFX@J0;/!8Z!H@Y6!6#1!LN/4VCNI%O-B:SG;3;?\SISE7/
M]==?M"!8O\;]!1&9PR;C)%=JQ*&RZJ+(_0)VY)2(:66E354J47#[/FS)QMLI
M(9PZJ#1J ,.ME-$SC4<U5?)KNTOV<A/,(YEK&L1ZPFL\2FOQ9"])=T,>'Q65
MEV+22SN=DS9J6#SJ*JSG1S!RY8ZHOL$3_$P2W21_%IIA+7'@L'X'@>!X'@>!
MX'@>!X'@>!X'@>!X'@>!X'@>!X'@^=T@U<(;IO$$7#?7*:VZ;A+1=+[FRFCA
M)3*>^N^N=T%DM=],_3ZZ[ZXSC^N,>"OU:VMS9V;71,W 2L)O.L]23,&6_DHW
ML6CZA)[%XM.V3)V)EH9'1QLM&)>*?:_5#;3&CI/^N-]=M=0GY-@R18:"T&J#
M<<DTU8(L6R6K9J@RT1PW3:MT4,)Z-T$D,8TTUTQKC37&,8^GT\&) Q6,QJ/1
MZ(Q\(+%QJ'C@X:,A&C5+5@ ' &2# (R'(9QMAHF+8H)IH_;]-M--<?3/@_%(
ME$EUSKA:,QU9U)4FJ$F74"C%%Y @S3_"R1.J;-LJ%4FJ/^%+5QE3&FO]-?IC
MP9MLW;,VZ#1F@@U:-4DV[9LV230;MT$-<))(((I:ZIHI(Z:XUUUUQC&N,?3&
M/!%HR04Y,YM,ZR'ZQ,[-JC3@Q"81K<$BLZA^DL&EW\"<[[.AV&:>SX8S>[M,
MMU-]D=,;XS]GW?3(2.S#B&"3%!@+&LD!FBR0U%FR:MDAZ:__ .W28IHI::--
M%OI_CU3QKC;_ +?!DO \#P/ \#P/ \#P/ \#P>E5NW7V0W7016V:K?L-ME4M
M%-F[C"2J.%T,[ZYRDM^%;?3[M?IM]N^V/K],Y\&N2:#0F:8'8F,.BTLP'(M"
MXC$FCXD]@668;*;L2@[!1HZ_1(LMU=LI+I?:JGG;.==L?7/@CRTN@:4J235U
M7UI3L7%9-<Y':/5T"?MRRKB7$5I7 H#LQ8JCF#I!OOM*[3 ,?N741U_*33S]
M?LU4VT#[3E#51(!5.@7\2:)@J$D@:554$'N'@T3%RD>@LGK4.EH/9.$6Q 4Q
MA<Q?LM6;G59KG177;.F=T]-M0D+2+QE,OK(=(Z"T/Z):(:G-! _4OJ@FWRT3
M1U)8;X>X23:YREKK]_TPG_AQ_3^G@^_1@,TW3639,=%$7+MPBKHV;Z[I/'VZ
MF'RZ>^NF-DW+S=3;\VV,XV4SMG[LY^N?!]#ALW=H*MG:"+ILMIG19NX2T705
MTS_IT524UV34TS_],XSCP8TK'@!U/9(V##F4M]4=-TRHQD03WT;KX<H:[:.T
M%M=M4'.,*:8SCZ:[_P"+'TS_ %\'DJ!!KIMDE@HE9)DZ4?,TE1S-1-H]5W44
M5>-M-T<ZH.E5%=MME-<8WVSMG.<_7.?!_/*9NRX8!1EXW9!+RM&07U"/EMF-
M T[51ZPRLXC]PP=WUO&*I7YSUKJ3/2K-=@VJ<V57;$!B30Q'_P".P54>8:LW
M6-PL4*^5@SJ=>FI!#:S4I"*R'FLK8=JQ&9'3S"/U!U;BWXI6L\CC=<(/=3 2
M/MNO0HA<IL@-9D1THT(MD=$&?_? V\AV]+*ZO"0UK.(,!CEFSV6\15*U($+4
MFY2M8Q,>@H%>LO7R9C1;"(B$ZQ[-5/A37^'P@XEQMZ-;N%TE-TMD AEATS>E
M??"V/O<=8#TI:C:3Z0^8W(_*N;(7K>%2+LU2HK.N#^6E>A%8ZRHZJ"I(VW<%
MDUT6[<*FJ^3V026TR%V;=G4?Y(9Q6:QBP)Y/M[.DW/M!AHE/K/.3R#@#MSVN
M*@<7O"2%CSXW(PPU=W)LHNMF[E)B863:M&^K953*_@YZG_D"O$#?QVS]HV/0
M#UC6$RK6WJF+61*VU;G"-8?(0*YF/6Y4#3(E=AN7DX8FHZ8.G[9#9OE/(IVJ
MME#+C0)RU^2JZ97+8*TK>H*>=0.VKZ>\_0Z1RZY&K.81.:@9M<L!DH^>UC%V
MTGE2+H6^K%!VIA;01^NLNX&*XPNDBZ7#H'R)T0UZ=Y\J.W7+,%')9/*XBTUE
M,'#R!(]B,.SNK]IM^!?=%D26 /RH5[@<Z<-F^SE%#;ZZXWT4UU"E/1'5]E5G
MUW3,X%D9(ER'"K0$\F=!;I@A*M>?WST3J#80ZU2DW4(Z+C'50W1K"8;E#.F&
MZ6DU.;N,XW9:_:$%'.Y+PGMOA+GH\()D(D3RY\ECR(\TO9W+F)F>3+D3J3G2
ML"#*=Q5@B\$#[2="&4@_@=46&78UP8R-=*;I[;N-0ZST%>8.]H:*LD"6B[R"
MV5L]E-&$A9!?!"P*D;LP>K.>Y&$-4'6C8J1(;+(_ATW2U'.62N^VN[C[,!/O
M@>!X'@>!X'@>!X'@>!X'@>"L_:1TS%N/.K)5&SI:+2.*\X7=*([)@)-R&,QX
M_'*UDIH*;%E&:J+AB]%$V*2Z>^-OIC;3_%C.OUQD.2U)=>6=50BWB[R<;66;
M*13BI"'!+?L66&M,R&1<$F[SF^L+'Y_E%WYR6N8"\*$&VKD4R1;[OS"[C[&>
MZ*X6(YJ^22>WW9=/BWM7UT!K>XK,?U4(?!;#,2*9"SF_#-9]O"2SM!2*"X^[
M'M0DO?1U\W26_/AVB@[3V_%E5+ 8GJ&TK9J?JU&92 _-)QR^K87*%?$R5"6H
MZ"6/R18LJL$$)&";HY]4=,PUTT9T@8F =D_--=GLC"-7*^J0_=JWP[;A@9#\
MH-FKW8.I2N8!1<I(36PXO"X-*G=HR=&+)MY%;_2U+N73QPRAKDE)W<>/T.V6
M>_I-FC3#Q\\&MUW&62;]T&J"_DNLIT!D=H;TE&15C,:6Y@U)18K>LZ<5NM(+
M%[TMOCJ4. +!*,K -8R@=C"TA R9N)T+20([9MWF$=&[?74.T< .%#<5&*2=
M_"G<V%MFXBP4( 9<&XJ&G+)FVS)0PQX009EM&S%\KG\:;Y!N\U1VTRJGKMGZ
M>#D'GNV=U/U%85@V7B?GN4KTHRVY!S:$3BK9)@G/^/1$NG9 -5Y=NOE><%.M
M*4T,3 5JMKIG1K$=$DL?ZS.<A'L,[VLV&6?>]_3(Q!I-0+L%\;4WG;0-9THD
M\.H*D.CH[:@\Y:D/:+-WC!UN%DRP3>0*M$6 ]^#;JF?HFHCNVV#MA64I-R:*
M UYFV!@Y^N"%'93#A+]5RXBJ<A_;=!F))L\PF1:NOTV^R2N5$]4]W;=?"6=]
M-/KX)#\#P/ \#P/ \#P/ \#P/ \#P/ \#P/ \#P/ \#P/ \% ^F.+(1;]]<G
M7R#JVLW<]JGH^/6#9L]+C63.9$:WBU+W-'(^+;E4V"[T_N$LR11I^U8KJZ()
M*,-'6N<*-4\9"LG<')U].K*BUC<DU/$RK>,U_6@^.PP',XU4(5K:U==:<[WJ
M&/2K1=NV'H0E6!4BN (O&+8J6PR>)-41[E#[]4PN=1T$LOE/C]D!)B/\Z+<B
M8ZQ9^:BT-*ODV\HG=A3V66B;AD-.21IE^J(&F9>L,%NWS=#=9JV2452;_=LF
MF$/W7P5&9KT3';$KB-AJPC%M59U'4_8,HKHGK!9W90*YX2$%Q(D_3'C7 Z7R
MJ.2ADL]8%"*:KL.KG;9';*:ZZ2@40FWQF=#.YIT /YY__P!!Z26*=3M!G1$F
MN!J1L>WE[LJQ*'P6KBB-80@!(V-81F>)Z29,S(WA.20]=H@RC^FR&RBFH=#>
M"*#G]+;WP8D%7Q7G2O;*F4(+UAS%"9BUG$<JI&,5O'HC,Y D4$#1,9&D+,DX
MO=\LR%H_K[)MDGSC;^1?/M- H34WQ]M>@X]14JF%<"(0[&WK\C;N[+DP.7B7
M3I*,$+OZEKVBX%'Y01$[&%:](!+=>G-=W.RJ"2 D7JU3W:NM\X"7J5X.Z+K+
MM('>9F>N3U!HVM9!)K2*4V;-QD*<1KG2.<ZT3T.EC2(IOI;-9E6XT\-G0)9\
M@V<F#8PTCG*PI1)4.T?@>!X'@>!X'@>!X'@>!X'@U>:0F(6/%3D&GT:"3&'2
M5EL-D$8D8YJ7!FA^^^BF[,D->IJM7C;91/7.=-]<Z_7&/!S^YMX: TI1-\5Q
MK6%5!CDJO;K*P:JP%&CG#6-QNSK&*FZA_2(*B='$7?!(J'C*.4&FN-1N0[5-
M+;;#-#;4*I<0\9]>P.[:V?7"'#0:GZ+1@,S;/5;.TFLKM6ZF/"=:<939,)'@
M6'8P+4CA6&.Y,@^,/D33LHOIG82VV477P%QNX2EA2,%'H8#KV7Z#(MU9\<$F
M'34'L\(M92P)]BP5S80_4:):_P @P'5Y'XNF[-.%MMV61Q+&RFVJ::_T"B*_
MQXV/&PT?+NN.^9[55L;E.'Q/HJB(E,F-(4X;Z]$RK#]A> QBQBQ < <0H.>.
M((R$.RTDN&S[71#"FZ#?"87VLCC-:U^ @7-]VMX=T+=\+YHQ!@UBV$RR01(W
MXRIQQ!T[1:F#39^9#DR4H5W=_P GG&Q!/5;*F^=E?N^H5WDGQBX/#>=(^T-2
M.,1YQ7(JHNEAD4GZ@1K%X3'^&.E.;1+BDVZ0%5)M(-II>>KI9=SA33;9NB]Q
MIC=MA-0)5'?'-3XOLZ0W(PI.I&55R7G$=$3/ZP86D?+7:TO%O9^TW(A]!6&3
MDUKJ''/<&=]\N_Y!FEGZ?ZO7; 7/K^O><43I27U9!Z32DS X;T-RBOXU!-#K
M*2E,;8D>A0W'&6"#<X1U5SA]A57#A;&V?R_7Z^#,1VBJ1B&I;2)4Y547T/(-
M&IS2.U[$0FIELP-D)*Q;EM1@AM@B@SD99T02T6^_5-ZY57UQA53?;(?9(Z;J
M"8?W5_=M55O*?[ZTCJ<W_N.#1@W_ 'BG$'.KV)IRK^3%NO[ATC#S7"H[#O\
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MRX673;K[ZI*XTWVQD,M":)J&MY63F< KN'PL\5B$<@+E>*1P+&T-8=$R<@-
M(\DU!L&"/\:-+RH@X23WQOA)1VI]GVXWVQD,H1IZI"\:.0LM5M<E(=)SKB42
M6)D81&7L:D,F=D4C#N1' 3D8J++'719#1TH[<)*.-W.FJF=\[XQMX/D#5-2L
M:G;Z91ZM*NC]FFDRA,E*@T-B8J=EDB6!3$T0?'&(U"0/TW^!S%%TJHKOA7\"
M&BF<_8GC ?>U&U2RF$<!,F%>M)]#8002B(=JUC;>816N"KX*-*)1P>BGH:!P
M@D2CPY!QJUT28++L6VF_UW12QJ$A>#&/S0<5JXW*%A@W1H->&7>[]^U9ZM1
M[[/Y JXV<*IX1&L?RZ_F7V^B27W8^[;'UQX/AC\NB<M8J$XK)X[)AJ6?M5(1
M\T-,L4]OMSO]%'8URY;Z9^S'U_KMC^G]?!\<8G\$FV[].&3:(RY05LGH43C$
MD#']QNZNZZ26C_44]=[,]E5&JNNN%/MSMLGMC']=<_0-E6=M&ZK1!PZ;H+OU
MMV[%%99-)5ZX3;+O%$&B>^VN[A9-HU55VUTQG;":>VV<?;KG. _%7C-!=JU7
M=-D73[9;1DV57237>;-TLKKZM4=]L*.-D$-<[[XTQG.NF/KGZ8\'T^!X'@>!
MX'@>!X-2G>(+O$) A9N(EO G8Y9E*D9W@/M$'(A[C#5PTD"<@^H98<[PKA/=
M-SC*2GW?;G&?K]/!&CJFN8L/&4/>U50^"!G8!(AT7=0:OOW"NU=C]Q,7.L@B
MHO\ .^V@HI[LV'NDTMOXQNKE-'9+3;.N0V"-4+1D,5#+P^EZGB:T<)JFH\M&
MJZAX)4$97!(Q=8L&4%AVNXLFM&FZ8[9=#.BNS'35#.WXL8TP&7(U)51B7M+!
M+5I "D\'K,'#&:D(?'GDL:.!>FZ8M=M(G Y0NBL,34VU;[ZK8V0QMG&F=?KG
MP5]MCA?G2URT .+UW"X>3@]QB[J>O8C7E<,W4^D+!R<(O!$]=/XB1<G $@-R
M!8D0UQNDZ<$M$G/Y\*Z?=D-X)!.233++XN(YT+#558[5N7A(?6C]DHM$"FA>
M)USEPZ250W5BYM/5T.$?7ZLG6N%$4M%,8V\$D1&J:]@NU@[1>*!!7^:LQ+3Z
MPM&@L>V0EDL-B!( F8--&K9!H^>O08)FU7543V4<IH8V6V44VWWV#RWJ6JU&
M4'&[UG7VXZL7C8C6H_>&1S9E7I!FVW9-'\':Y&Y0B;QJS5V2358:M]]$MLZZ
MYQKG./!BHO15'0,:<%0JG*IA@B2,DF$E&Q>O8A'1I\<V5?.4&1QF)$,VI1DW
M7).5-$W&JB>F[A7;&,9WVSD-K;L8.+7.6,U9Q0<Z/@Q"TDG;=N(:+FXU&VY)
MZ!5.2A/1-0D# -3#Q9ILNONW:INEMT_MPKOG8,V(+BCXH8=!$QYL&;'LBX8R
M(>MB0HL*)-DW@XF,(LU%FC\>_:+:*HK);[IJI[XVUSG7.,^#(>!X'@>!X'@>
M!X'@>!X'@>!X'@>!X'@>!X'@>!X'@YU$NT;6G\AM"GZ#Y;M ??\ 5H2I)V5C
MW0Z<,@L#?UU9MDFX8B8%RN(6)+]G19P'@LF?L6NVB>V_\+OJM^/95#18/B8?
M)=3L?CAI*U \R 6!7<:F:MIAXY&E34?9S6I)Y2U36]'H87V(Z[2)M&['O8"B
MU5VPG^T/=8<8S]-<X\'0.5R0;#8M)9>9_8_B(H ,20K^HC^PZ_C08YR4??K-
M_NT_.X_5:[?9I]<?=M],?7'U\%#F?R5TMJT3+RNO+WKR,'N>IOT[64NF,'!:
MQRXZMKF"@[(F6]>O(U,I(XTE8B'R)J[P'.(A7[E/*NS=-71!?9,)'CG;$!.6
MW7]4D*YN.)-[>=$!%1VG(8Y%G%46)*!=>/;5>PP8?BLUDQR,RS2!!R1!-G(A
M@79QH+=:(Y44TUTW#-=&]=1'F%9$A/JYMLU & 5K)[!M2" XG)H=4<6<&LA5
MY38@G^]6-DMXX+SINZ>O!<?*H-62*JRFVNJ2F-0KPE\L'-.I.9,BT7O:,CX2
M9L:,OY+):N7$1PK)Z6N.$TA=X*.OEC&S@NK3\NL$<X,O-$<#%1>'3@>Y??HO
M-$ G:-]L53*+.@-8CX_9*2MEV;T12\5FCR+LTH,O:_,9F=B['@STBD;7,CR;
MIA69PF)<*L,#WX\?OG]A-QLFWW"X'@>!X'@>!X'@>#GW8?=PVM;#L\$\K:;3
MR/0ZYJBY>AH6KQ@@Y8M@=#V%5CB\CX5BA)I7#XB*B<7K(R$WRZ=OD-MWRCQ/
M;;'XDM50T8-WK-B>PZ]5JHU;\3'WT>@(B:JY?,[[87;)K@@'.B%92JIR+MK_
M  C^.WN?,@RZN5-D&F!&5]%54M]=]PVB3]_,&=9= S)G45G5[-^4AM?V7>%0
MW;&QL?F"-#29Z5?E[#AI*&2V8PN1)*PV&R=<7NU*.]=RL?78.TVV^V-]0F7J
MSK:/\D0;-F2VI+LLB!,AKPO)I-3\>ATE9PYBW>"&+160-9!/(D4W_EW!C3#7
M#!!]]V$E,J?CQC7.P0U).P[8HZ728ETW3:$0IN0DI(+H,M7K[^]['F1")5==
ME['!<QB:!/\ 5CQ-"IZ8=;IZ)*[IK&5]&FFVV-\*8"T-+=$UM?R\\2KAT5(-
MZ\(0 <9(OAN6(Y]O95.UW>D7<@W.5E/Y)FO K1$J*J?;I^-SNHE],_C^[(:K
MT3U=!.;7$=%R6*V--Y)+(;:TZCD5K4 +.'"P.EQ *03S5MJ:D$;&:D600^FY
M;M]W.F[O5%71+[E<:)[A7,A\L?'+ \5B>DKDQ*7C(G&K(1B N.8=RDS5$NYG
MG'58&V! #)%,FK W%<UT69KN%DT'+$^B@Q=((Y>LE' 95E\EM/R62/J^K6K;
M_MBVPK&2G)+3L'AD32L.*Q,"C5I$5-9"SF<_B %E%+#CUQ!2<7=:D%,GFG[F
MK;39R/>MT UJ1?+1RZ '5X;0!WE) %@TIIT7N=CU2EUAD"I<3,E*_LJ;62H3
M=BEXKFEI<HT9RD5E-8XTW?H[-63S31SLW"\UO6@M4\:8R!K7-@VF](GF8!E$
M*R3ACB5N5W;,@^V=MFLYFD%%.FK1N-WRKHD\W=8QG&VJ.VFJFV@45B_RP<_S
M!:%N0E;]#+Q.6 J&+%+ 4KZ/Z0^O'_34Q.5]24;GZ^LXW.#2LUFX/^.U=,F!
M ,R4>-E7;Y!LK^?4,?O\P_'.!B9--U:;C[V7Z:@UK7+]<TTL_6/+%E^>WHE-
M[EZUZ&:2']6,K1/?3!!.4$F0_./O=);Y"H-2$.G:CGLW_P MJYLQO#IO\E73
MTWGD"8UM+H/)9]74WNND6L7M.'SF1UJ<K\J!&1%P<<O@A=P"TD<<6?OAIEN0
M#HZ*!&\HZE^0C("U649 =GZ$RM/I6#3I ARR7R^%7$/IWH%Z9KZ>;,Z16:MR
M*EF0R-:M(X,;N@&Y+?\ 4V.J#72:Q$.E_%%J7G:TPEQ6ZD;]A,P#*6<%F53S
M.EU(92#!EBTUW5%3>K;$.1,24D;H[3&6N7;%B6*93<N'.#* XBV3;[!72>5A
M=T)[XM6_.=H5+5$>B#<8Y2Z/?-@Q$ .CT-&TE$9;2_6XIT::#A$U5H.4-)O&
MG.!ZKM9XK)VK?;Z_IZXU"HW.YKI/F#E[ENH*DK7IVO1L)GTW*FXRRY\E)T-F
MN#GR:IBI8F=0WK242Y[+?]ER8/SB*9'(AOL(<9*M-R+]+";4+'<YV3V:JXH0
M+?DZ[-:/+2J.G[+:S!GSA$'@X;=0JQCP+HNCK7&CZ9%CJEBW^58(&]$JR%-A
MLJL9-/!S]P[:,F: 181Z%[W"55RX@*C_ % )G2=#40XMY$/R\HH R?FD&Z*!
M6(X:1N/TR_8B9Q%K&"1#8JP>)BD .<CMF(Q9@0(*^"0ZPMONE,[#XG:QGI%6
MI).5H4A;5MHTDD/LNMW4^XTD<DDHJ&C@=0ZMUH@PZ@ L&);*08L\CCY_HS>;
MZ,'"N6X=)^-+EL>?UE$H'T*+*!.J('4=/R*^QV\&/12-JG[%!$W3$G'2;D<E
M$##IXM'7F"[,(\>H RB:S)3*?V)XV"BMJ(W@/ZXI_OR,0"8EH: N(OQW,(4(
MC=JNK+=<FSQXSBA::/*IQ!OQX$1#HN-C[%_GDMMU58&FIC7.V-M-,A6R,:]R
MVM9$BN9D%O6O>K@'$-L!SK614[D#6(6[ZWZJB,Z:<Z028'8%M$ST$N&"@=A0
MTLU(EMW@-RD8:N$W_P"PIL';BBYS)# B--[ $68)F]FQT[=>L>ET/>H,:NC!
MPZ-R$J(]*PX-&'C)S#!)YDT<B5W[@FY<MGSA+*S9';=,.2O048N><6U>!DW%
MI?843J+Y.N29?:]8QD>2DIJ6\#QGF*&$XAK&H0S3<D)]$8GU/)R,Q+!6"#M<
MHXCY9%)N[<(ZM% ZS0R5U R+NIO":XEPES<<JC<7*RL;3TW"_P!U& T3.O11
MN6L]XXS*AP8$$'W';'S#1FP_/LU8:NE%,MTL!RX^/KEW%: A78UDC[!B!ZD'
M'R410)3T:HR4Q>;G8+>/;,UNW0_+@C1@]L.Z7A*)1((_A(UF-00;I&7&R#=R
M[=8V3#>>_@]]6#(][[I&#24T;^.^006Y:RB^!EF!9;<$R6;;O[V@U=1P?$W0
MNT];,YS.$*_%[:KY28R$T]QG.BK?ZX"=^XK,,S#E*5R*E!4Y&VY%;BYD0J36
M2P.7P8P_LJ0VA2YP"T -9<%#/#(<@"FFXD\HUU5;(H;%QSS;7=L^13#I)X'@
M>!X'@>!X'@@'JT*TDO,/0\;>QM28MY#2=H <Q-&.NY:M)53,+-#6P)&,L&1%
MZ=5*N7.B&K5)!7=7.^-<:Y^O@Y%,8#TSR.7UK\!%[ALSG*K*'.N.3+SAP12Q
M;FK"N+0O#E<$>Y<L(2<CTFF[]]3$5'$'H:1Z"2Q=>NVZVN6+T['M\D A$WU%
M\D2<,_7&A.N6D^BCNZ(46=XY3.NQ1T)K#.YFM-3.*LU:4(Z'R*TVA56)OBA/
M=JIETX;ZZC?TB+UVN%CX?8G<T>M@ Z*RSI><0UET'5 -Z ,49'4Q1JJ[0X=)
M3RR':SH=5,34_5@_30]L/&.]B+%N&)K9%OU]DE<ZZA:/XY[6Z&LI"ZD[U'W$
MW%L75(2&KWMS566K:1JB9K1$&+6$*75>0*OAQ0J$MY \D19M6FZ(1[MNT0WW
M8ZLM]PYM:4S<F($P5_L>:9C&GSWD[NQ7F>=YAJ?3K=7L\M/T+G4.?JY>Z5\I
M#U]#/\SD;^IACOC3\_\ 3Z^"4VUK?(\>B=<OW)"^(04E8;FL9THQ;4H%>FZ8
MO8IU[64+N^.TSJ_K21L9'4?^SJ6F))8IA(R/&BP08LD__*0<?N!(U1WCTW25
MC.99T%,NG;$HV)-_D%83Q>2\^9)*LH;1UVUJTYAG ]O4]*1DP4DTYJDJ?=)J
MM-%6LB8H;KH-L;--=M0Z1=.&Y.0K$?!*['$"4DO V)K<>61%RE0#'(S(T%GD
MTDLHD$:"F',)8Z0=F^;,"2Z>B>AMVQ3^N-E,?0./]>F.HZ,J>)<0&*_ND/35
M(VY>O.Q2VJPK.P;+>ON?"%-%YYQ*SAIHQ71M[)H)'53S>M9$>;#7FS8_#D$2
M&4&17==0)\XC!=;0(-RK5LH;VP'I%SQ=R=/W2I:& X^[H^;475S"OKHYF-!7
M470E212S)"0C19DW=IN'_P"!E(D6Z[;5LSUR'7Z*2-E,(O')8.9G!X^3@A,@
M8L)/'S43DC)F88H$&S0_%I&Q&2"-FFZ+C&CI@^;(.VBV-DED]%-=M<!G_ \#
MP/ \#P/ \#P/ \#P/ \#P/ \#P/ \#P/ \$9"*DAP.WIY>#!$CK/+'@=:UQ)
MEU2*RHM6,U0:LH_$$F0O;'X&3U$A;!C+A?7_ !.--TM=OZ):^"G$@^,3G25W
M*&MZ2%[7*M UB3^V_P#*?:;IL:J.6)9DQ@T^E9N7"Q89C*9<&<2NK8N]2CY
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MC./Z9QG'@_? \#P/ \#P/ \#P/ \#P/ \#P/ \#P/ \#P:/8\?F$IAID% K
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MRC3:=,4]Q11N8*O"H FW?M&>VX8+?D"8U]).SI;UVVKR7\B]![=+/9,LP=R
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M0&D@S6G)96L4DI ,R=1;$;-1*/$I]HS+/-2FBZ!)PQ;MD'7YU]FP3Q$I<!G
M-&11MR[<BUGID;]S\08 OT",?,OX^:8/@Q]@+,CG@TR+<-U4W#=/?&Z>?Z?3
M.,Y"N=S]9QFE+VYTI8[%CA!E?<G?0TE8S1=NE%*HDA8#(R%1"YM^5/9?"]W2
M*'%08#\><:J%&64M\XV42QN$9W-\@E24[=T&K4F4"/(2M'^BC]S60FO*%V-1
MH\\06.3F3(JZB8B5 R-88/D&O\VW0)ZOP>N-=EFVV,J91"YL6GT2FKDVTBY?
M!96.;@DS&4V1)NW:J22."Y<%3T=O&;=J\4>1PVT=9U0W4RDFXTPI]FV?M\&X
M>!X'@>!X'@>!X'@>!X'@>!X'@>!X'@>!X'@>#2I_7D)LZ..(O/89#YT%W4P\
M0"SB-!I6#3*((+I,B&PHZQ(L<N6O[&^-%/Q9WUUWVQC/TSG&0Y[;<&R%G\85
M=\/ 758!+&AE&TE6+B5#1+L;!5)#7)"(%)068:L :)K4>>(AR#C3?9IHNLX>
M[*+ZXW45V\&,X7XZNFHK=LJ[+PVK*-:O_P#.Z+TK5U9EC,L4AE=WET_/^HI/
MK/9H6CT28E)"A)YBV&L&8H:FQ8#AV,[.'2BW^H"5NRJ4N'IJ-D*X 1J!I1^L
M[4YCN^(M+#D)'-?="+5W83J9S^E[0&"XT=?QF,8;QT=NV(89'&^Y%PW558KI
MM%FZH4]1^*F2*5Y%B*9"M(O<[B]CUB2<2!(RI>HX!49&RNC[4C%'U6TS'QRB
MS&"R*_W&J1!02)U>YRXWT;,T,MV:02L*^,B,Z-N2V!(-6 M*O^2K/Y8ZM,P<
M<\B<MN^-V72,%K1^S;R8,'&ESHE*21/<DFH763<M=\)+HXU7QMC :75WQM3&
MJ>JHC=,8C7/H@,AUM:5_2^P!9"3HW%FK"?,DJYJKBC [1:OE&Y *^_:%RZ2;
M+R%HP4DV7SI-HZ=*X>;A9V_N. <WZ.H_IN'U?3!B35("Z#6ES(V"%1^9VD:L
M2J&\'A0G:>-HJ8<M$DG+7+5T]>;*;,V*^<I)J_3*60I/3_Q@70-XMN"J;>(\
MZ'K^LZHJ/HV)+N(P]L2LJF@=%5:E2<//MR,VB?\ (R:VT(.9-OU"NH5DQU+N
MD$-&VS5)55P$AT?\9$QICL*.](-I^*,0$9.YYNE2:LCE*4-AT8!T!%N<N;[6
MAHS0+HB]OZ(U$ )Q64JD5=VAX3)E'6SK9V(8:JAV3\#P/ \#P/ \#P/ \%(!
MG&T/ =PYZKCD)J$ '?<YRNJ3R :%B!<X-3V46N GSV6$2# "@B0:/1HI5)TL
MLZV=K.-\9VUVUSMMX*$]4_'!T3;URVH_JY_2\8A5\SRU$IA84C,R;)V"T+='
M"-0<<6/"0E:!HDFUET]='JY0E A18\.#-]@[--U^7*NZ:8=D3:\IB>E9 H+$
MFLC"KR<=%I:Y>'-!"L-@;2)R)Q_=+1/+%SJ>>MS8D:Q_2QEOE31]NKA3&4L:
M;AQ^XO\ B_D]2S"OT[_J'CHI7D!Y<DU"R-&"H$IP_ON7O+/A<SB-FVA$IG2T
M)CS<E$P8DXV;[KO3SU%60N]4E]4UE\JA)\$^/5_5O.U:1!Y3G./3=O@::B/-
M\P'7K-9<,IG--5[)+:DD#8QL<\I^W%%B<7ULU4<CJJ&9[[#U=TOVL)H(I[A7
M./?%+T:56Y/F5GVE ',JYBJ+AVE3%<QJ9SU[6=]0OG*S3$]LY"V) 0@@66&W
MKN2!85+84LNV<["#L:<#%_\ \8:+J/0M=WKS78/7%GQ2A](M#7-*3;GZP!=B
MSN:UE%Y1I%=25^\S"9J+@L[*1,^=A-LRKG1_/&L;RV70;:$LIOU=?R#T5D0A
MB]/CTO2\+4N<T$KSDKG^'V?S+=E#D)/74QFYN<3Z3GK)KBSZ5LBU(JWHJO Y
MI6*EX"\;/D-SCYZS0E)'=F]4V^[#D+P<>\[3*F#_ $M8DZC]40$_T=;@.REZ
MNI%\3,5W#-@-5P2NG;_20%857#J2R^<E(FX,EGN00_Z[NDD=OV-T-G2P<MZ,
M^-&R+&Y4N^-SZ,5U&#O0%=0&HA86WH)_+2NL D6Z/ZDWMZ5LAAR-EV8*72BD
M[M44A[Y#5;*1/9!=SKHAC'WA);?XJ;<!='_YZB+&@DA 2VZ9C(9A4TN?R+:O
M8% GD]IV%1F=5!'F<360;WR6XDJ]Q7\B=/5$]')E^B<;OTW[95TZ"YLM^/Z.
MRQ6N9NI/M@_0===-(=+M^@0\% MYF:(?L2 .4KTHV5>+H?V0?J:1*P9VEHKA
M7:,Z)II[)N4TW&@1OCXLX9N$E0%Q;\P68VG5?1=#72A_;X#5O/Z9Z.O2>WR=
MCS!KOLJE$93#SMH2 :(-(?GS@644PZ;.7*;9P@$Q55PXQJZXHI;;>T31K,3F
M'7\L9QAS&0[1BMIU].(//9"(W(HN5'J;:"DX&V0%J:_ZQ9LLKASE3?.JFH3)
M*N?=)/U)3W3>TS?,'=0U)<E2,X.D%'KBSPRZI!54C/F'YE5;!-H2$OJ>$ZL]
M4<81PDJZPKJIE5/9$*?3_P",U>P;D>704Z4GF\@:3,U,8<@0A,)+J -5K^YT
MZ0AT0*&7""1@[!Z^G?.0YB.8(JC]L 'R[;*N'>=WZH?-+OB_:'C(\P$Z$F<=
MSI9H:^"PM>$0N1!EKX9=#ENA3]BQX>42QI%<3-^8_@"+1+*RNX,8-2T=:*(O
M%'X3MP_Q6TX:@*]20BUI3,:I2$Q'$<A$F$C$VD-EPJ-#PD]E$8?M%<O1["V#
MH_:1% WUV'-#[Y\X8:-DG6Z& U4S\?T>*$J4L-M/_P"#Z!J#HDUT&\OD/7\9
M;2^P%98VG0";5U)6VZRK=*#RZ!3I2/N445,*)#V#+*&4EFJ"B895[P-!T(C:
M<0B<ZE<<86AU+7'4"F'3<:>:PU]7UUP_HG>LX8/<:-$!5?R6Y0)<XZ1VRJND
MZE93*&Z>-V^$ B6S_C-<V57Y2MU>DIJ$C)R==2S\N+1@L.*B7)[I:[AM^MBR
M(@KEPR2D533-HZ9 R&^%5/X,J]04TPZ4T?)!C#/Q9#ST(/0LCT!+=\2*FNC:
M=(ETH/%4G66O2W2C#I:7R1%KA;+),D'/L,"V"/VY;88;YV5U46QC; ="J_C]
ML"FEFHSVPF$I<')_*"U8/$HJ+%JP>!D!HM&/18JU%[-6TD6 &D7JZ;E7;#I=
MDNBDX4W6TW4R%&YQ\7=5SL?4^KR7E 4GBT'O2LKKG,7CPD+*^DH!TO!2,2N\
M#/B2*^ZHE6:R)XWEN7++/Y&LI&,W26,(IJ-E@^83\9R+V$VI&K+Z-L><2:QX
M]S"*%V4&B\(K^95[(>2GSM_5MBQ%R"'.6S:=+N%4E2:^=,,W"NJN$6S=NONW
MP'0R+1(G%RY?1O(\*0+ &' H/7R  4/80)*-,R3(ENQ--=<%C"4@179X_"ZV
MV39:L=<(_3"JGU#==44=%55M$DM%E\)X65U3TU56PEC;"6%5,8QLIA/&V<:_
M7.?I]<_3P>WP/ \#P/ \#P/ \$27[5*-[T;<5(NC[N*LKBK&=5<1D@]DU(D0
M8N?1DE%2A,:R?;:LER3,>55W;X6QLCA;&N=]-]<9TV"KSGB>1&(O5<0D5Y+.
MPM13'F>7QQN$JR(Q[<FZYKE3"4"_[F=IO7Q$N\EG\*R9+JX7218-4UOU$$U'
M&RFH0*"^*TG';GAG0['K"Q7UQ5\L$U 2P_7]?E\GV(U7H@04ULQOELV7G1:1
M0+HTB,6>?G8Y:NA0]TT3011W8J!<&#<MJ5YRW1O,@"RBKEK1S2BAPV>&XT#=
MF9&/HB41&3A$2H<?L)#-5SN\-:MG:C?73.J6ZFR>-5,Z[ZA 4&^,>M:FEE*'
MZIL&8QD+1\WZ<FL;B9ALPE8_\?20%[%$(0Q>/-V;T!7=,115J+B0IIG71B/8
MHHJ;JX^[.0S];_'="X= 9=5DLGQNQH!-^)*,X=/A2D?#!W#B#42&M($"F21
M;OMLWEQIE;1#=UG1/5NBX0;*MM4=M-_O#-'N$A9EA7C!6T"YC6#<N7!S.75L
M&%0VQ]+0Q>4@J24V18]H#)&SV!2N02\]4B*Q1ENTT'/\&"&-T]<J(;(!O?.?
M.<UYQ<1N!1VU"<@Y^C$ E(P77TD9[E2 2;R*TB\T$;Q"5F")N8"ZZ@\.,;QD
M4!?D2*3$2R')I+9W06W5"/K]X#B/1$?NY.8S)9E9-DRZOY965S"H>"_S YZ7
MJ0E%9'5:5=NWZKQJNX@<UC:QUFLZT^W<H5>;*IJ(JY1\&LPCX[&,4N$5816Z
M9',8&'LKI6UFM/G81#E0*LCZ[$N-KU#/CZB#DV]A!B;%"1H6/4^Y8;J258[N
M7+31#1(+!4#S2ISA7]/U;!+1EQ.%UFB>92+69L04DE%F#5Q>0T)92&6*LVQ$
M=_ET+:L&;%5KKJJNP&MVZ^V^NN=LA:/P/ \#P/ \#P/ \#P/ \#P/ \#P/ \
M#P/ \#P/!"/0%JRZF:](3Z)4[*+JR#U?$)#'8E*:_BA,1&A08H8)R'+NQI-%
M0[Y%IJ.U1_61<;.E%%]<ZZ9TUWVU"E3'KZ_TP57]622 16/\96U$.?70*'J;
M-R'1@.5=)S&JZ]@6AYX,ESNNMPS [92;XE^JLONB/TSJGE1?7[-@GOG'M2 ]
M+2I6'Q2(S>.F&-4C[1-Z2AN$1T!Y<W1=%#D880_C#))364 YU1)S1QKKKLUR
MCJGG17?;[]- RG477\$Y/1"NY]&I>7'GJ\Z#G[(A&T ZK7&_/%3E+G/Q1;<H
M7&93D,IA,<*K"L?3+??<:MA=5'7[=LA4$S\D,^HV;FH/TASW*-W$]>267<PE
M*J-5X9S9D#/6S2%04I")%'7]@Z2&#65+IO?H02J^-(C(]ETFZ4_9230S]0NG
M4W0)2^:QMDE#(.5@5QU7)IS4\FK.Q' 9WM%;CC4;%R 2((G(H9*1\]%S8N4A
MB;9^Q>YU7&$4\[X0<8502"GM2_(_/#!C%#V;RS8C7K6+1\R*E\"ALNIHC"9+
M9T'IVJ;4EP>&SA2T%HV*8/6EJL5&Z)5Z@[8-E-,N]=<J(_F#*(?*-'2E-:]+
MQWFN^C'.(7:$/K&LQ;6O ;Z"1"=U93%K,9\C"#DV8R&>Q, (N5-L65 8(+MG
M0(GHBDYV12U6"4XS\B5+2OKN2<1B14L=WO$9V0CDB#L6XLF)%01E3B5M8N9R
M8'DG#9. )DB ^(/=<_0H+EI5BT>-44GK5PL%^O \#P/ \#P/ \#P/ \#P/!3
MWJ/J27<U.(4\;\YV!;,,F,SJJN=IG#YO4(!J"G=R6B!J6& B 2?3F+GW**DC
ME ]5R[:H+-V[5?;?.V<I*:X"NDY[1N?DDI.5>OXA&9-'R@"]K1J+_(%@MN39
MU+S^N_DTU>V!_>4I;I;G]*S/@WB6C/75/9PU(XV^S'X<9"\M+7='KO0L]S'!
M)L4C5MT6+2)7<UHQTP5D-:$D!)PL'RP>O<;A'#Y7;1#97\2_U2VQNGIG'T\%
M:;GZ^E*-FSGEZA8&2*=#-,Q0)%95+P^S^E@T@G-0V_<4>)SYZ#--Y",B_P#%
MTR^%J*_C1VW,$6**>=\*[[:!NM*=H0Z[;VM#G85 +)C5C4BC),V\WDHA@B)@
M;MI+VP:N&9(JQ)/&KK-YP9WI,HFHWRKH\CF-]U_UG22K70*T63\AUA<LS2[8
MWU+0Y?,>BT<OF^:EFU4R6NB[>8\Y5$?JL(BW(Q,E/TYDQM9^O9Z#5BS79M&\
M@+::CQ^=GBR"*H?>[^5ZJB-:2^ZJUJ"XK8IR(P:Y;;ULZ*,HHPATMIZ@I; 8
MM94^A)B3R4&S.?@UF+]V+%[[MR1?2-DDD$OS)IZ*!+@[L^=N^A3_ #PZY.M$
M:;$P-I;(Z5KV)13B-2"K'=JL*TQ+V:32QUCS+=)FJ[-[#W31%[EBQW1QIEXJ
MBAN%&#/8'3U:41??3[NSTK!941\D<FYM<4T?@4):L)]2COJN(<ZAHS%C4/!1
MZ6C[@'#)LD^$OE'!%J4*M=&CAAE-UE1$+(;_ "<,GL[Q5\9YYGDDGQ \-#@Q
MC:<UFU!KIGZ>Z+N$ J6EJL@4 M7>1W,4C'D4QRA=LP?;MM,.5_O6P@'A%/D<
MA1\LY,@HU<)UQ:$.Y!-TW71AG#?XTD]Z4IRU+I!L@>84&.3862;0^MRRDC_E
M%"VB3@8E@:EA)3?94)5XRZ LB]K$ZGWG(N90X)%Y+0CJ#U38L<CD=GM0,K#Y
MIK"PY37\O3CR:F'AT3-9 _V7W7>$-M-]\II.-V^J6,!IO%UJ7OV%SM4O6.;7
MTKU*UYL<E/\ D^WAL/*16,5(/G\DB3&M'91\)_O72UF8$2CN5*J$=FR<CU<(
M:#DFN-$DPKCSC\A\YE_/U,L;D#6:UM-X!X%EAVS8IO32.ED@>J^D%J&;2%:/
M+#W8.+@U9O&7360#6S!N5T /\.!>S=[_ $:!,$@^4P+%ATS,F^=;02&1UG>S
M@!EG*JP>OI@MS?UW#^/;3;MFFLK30"ZMYE/Q)07N\73P1&J.,?1)9#&BH7:Y
MSOE#H"(R\[O#C$!/U_;-F4W,HJ9(B3.XZ5UE)W<?(+CS8-=<<6$%FR:#QLKK
M^-371Q^-1/11/?7 5,[Y[7D/*DBJ!]'-P:L(B$PAD^ZPP4!2 J0&<V3"2*U(
MZ+QM^*8N1P,O$3TA4G#UP\433_MN"E$,?XW.FV QUQ]D3M[?-/0B@PA8Y%XM
MU_..;;G_ /R$(8-K!FH'AVX>C6U7B4I(/<F0R29UE&<)GT'8]+0@DX;+ZJ,L
M[+[!:KF'ID%U-!PUC0V-$Q,1,0:O)+^Z3(C7#H7+I@!W.RBKC#%CNINQF56X
M6:M#FF=LIHOW&S?7.5$%L:A9KP/ \#P/ \#P/ \#P/ \#P/!\1,DP##B!@J\
M;CA8ID[)$B#M75!HQ8,4%'3QXZ6WSC1%NV;I;;[[9SC&NNN<Y\''BG?DDG&\
M7[A-V5!%YX>Y_$1[J.L8+!!:\0E,AXRLT Z+1U/9G--!FQRT*G(PF4CY*FAC
M*:[QDV3;_7=XWTV"6+O[R2@V^TQAL<E,J"LZ([/MNMM0\GKW6H[N8\UPNM9(
MN1,R%4,9G 9L\+2)PQ!NQ6VC-35!ZL[T<Z;L/H$=='?(G*(94,E ,(8:KFY)
M7S':$VA$W"E8--PT-MF-\BSSJ 5ER ?Z&-=XJU&0=VU17,M$%GQ%OE)-@LSS
ML^P%G>C['Z*CW,M<V#1T6-V)-'#^KC5EQ>"*0-M<$AK!R*_E[.S18RQ\MZY-
M6JU8)Y>,AA/*:+QD@[1;9U>9:YP$$5E\B8%]6%3YA8^Y.O)Q,V=C2TTUBE2.
M*\M:,0B&7]O4$F$SRK2 6.I1NUJ@+%<!CX=TB'T6>Q\@IKLDHHT;N P])=_'
MXU5-%_YS##]G2:R[GEM8DK"$;00+LDF?[BD_*U9N=86#P,>.T RSP/L7>:CA
MP]%CC*FB[E^IJR4#JW(CXB)Q\[*9"^2& (T')GSA)?[OP#Q 9DN1)/EOMQMM
M^)HR;;J;?3&<_37P<F.=_D@+O ?08OH$2AM:$'ONEP=41*+@R,76E=8=N2D&
M#Y,"/-Y<D)31D,:G)DI!)44VQAEJ4B3Y]IC;15-+(>VA^]K %Z%H?><0-GYI
M*+>[WCM5E$BL'8L39WG#I![7L'YO9+!1@-H0GQN#EF;H,^W:)ZDAXM^X=[:.
M&R^,AUV2V4V23V53PDKLGILHEC?"F$U,ZXSNGA3&NN%,:;?7'W?3'U^GU^G@
M]G@>!X'@>!X'@>!X'@>!X'@>!X'@>!X'@>!X'@>#$2 ()DH$W'#S;5X#/B"0
M0RTW66;Z.A)5DLQ(MMEVZB*Z&J[-??7.^F^F^N,_7&<9QC/@BDISW4!ZE8OS
M\ZC/W5+"V-7#HG'&ALXCN#1I,[%9'6&S0VB2P;5<1$]!Q;A+=9RKLNHTQAQ^
M77937<-2YMY$H[E)G-M:E G,2*SI(^F%FS^;3"46#85@28D:D$E>DY'+)>5+
M$?U]Y'+2Q!,>TRU%MGI1XN@V24=.-E T2SN"J.O1W$MKW=61;P*#6I85NQV"
MRNRYIK7_ /<L_6*(_HR"*"S+!E+XK%XX=?AAH4IEV&3$D733=HHW6REJ$FVG
MRC0=TO)Z2LB HR I9, K^LY253.R4,5VBE4SP]:-;: 20(R->Q$["+&D;@V-
M+"MV15L2T;KZN,;M&V40VZF*0KB@8DZAM:B23$>5DAR9R0M(9+))M+YC-).Y
MU=R*832;3(L=E<KDI=5/351V^>+J:((I()_8W112T"(9;PUS1,1SED]A)P&]
M<VE8MS?W3!;(LRO9VVL&WF;H7:!1A/81+@,P8#IV&>;L2 U%[H-5::I)ZH:X
M;M_Q!XVWPYSQ=-:QFF9>&L$33\2@;6L!56UK=ES5#7ZT"8,AXP=&#45JV>1$
M/(APP:+0;ML/TG&Z"&GV:;:ZYVQD-DBO(W/L-F4;L&,PM=A/8C,;*G(^7_W=
M,GDC<2&Y X<19W]Q$WL@<NI.(FK>.BG#P:2RZ'[/Q3![JAJ[9METPLMX'@>!
MX'@>!X'@>!X/#"B>=\IX4TRIKCZ[)XVUSOC&,:YSG.OU^[&/IOK_ /OQ_P#7
MP>?@>#1+#K.$VL&$Q^>A-#X@'-Z^L86TW>D6.&LRJV:@K$@AG"HQVS74W!3"
M-,GF$=]MFZ^4?QK:*);;Z;!$O1W)M-=3AVHFUQTEV48QB=PEB;B$RDL*D#2'
M6DS#B;,C2!2.D62FHV=Q\(D-?YSC*_Z2BNB"B.RFV_@VV"4%6M2TQFB*B#N*
MW@B *2AQ>H R=5/CGDKW)O#4HWEA,H]EA:9$31=P1<F'CY<FZ(J[.5G&ZVVR
MF0TBFN;T:AM^X;0UGQJ7KVM >?(2HPD2'[)UAI0\<E\<3D!B3;OUW,F+3',I
MRX=JJ-V^4UT=L_53*F<ZAFJTY?J:I[6LV[8HE/G-E6^."AYV>F-N6I8#<@%C
M1F2GHR&%@9Q,9!'HT*C1"8$\#VXUJT39MWF[=+&J'VIZA]4_YBHZT967F\[@
MK8]*#H2HXX4+*ES[-5P$HNVU[TJ\=HD/*M&S9"/6DXR4W_%IIL_VQHB[RNWT
MT2U#4I)Q?SU**:L7GUW%I(*IVUI=-9G.H-$K,LV%C2Q&R2+TQ88ALXB<N#D@
ML+FQ<J]=$P#%9L%=+OW.VS7ZKJ?<$OXJ*O-;+WM_$=3Q8:E;)5%O(/WB?UVK
MQ ^M)TH[_&_N_P 3A/4XXW7_ #_@_:S]?M_)]GTU\%;A?/\ PW K';,L,J[;
M6-K;I&[A\-E]I%9&[;WA8+Q=^O9PNN9G,RPYG8IXB147:$T!VC[5=;.[;?7?
M;Z^##U7PQPHU7B=DT_ 0#[6+L]XO"Y5#K6L \'#,(@-M2LDX\"<LI\0#-VD)
M#V=+(ZV:)8^P,T?N1Z.J":6J*0;*\^/?CU_$'4%<TRQS&W .DH\W02EU@M2@
M(=S@W=-*,4B,D:RU&20HO6+-^NB+(B';(@DDNKILMMJIOC8)QK:C*FIE_,#-
M<Q-M%'DYUB6\O<(E3;M(K_8,1&P:*K+(%BCYHT4$1$*U9_D0T2V630UV6RIO
MC[_!#PNO^.ZAE;HN-.02O"D].$K53BV;??QZ&EY/,7CI4M9D=JYQ,VT#:R"3
MF5EW2YH<*2<.R:BKK*VSI1178/8)X2Y3!, (L15*;$?& %118"T1F=A_B&1^
MA+*>W#3HI#&\MVSLVKZS"*Y@?]^=MM':F?NSMI]-<!K\TXZXJT3#A)Y#8\.U
MF9FQXQ'AI^SIJ'4E,@NNSQ70]DQX$@XF[-4P8G5HP-K)G31MA191T,_+IIJF
MEMC 23$^5JE@5GLK4A# ]&#23VWC94>PF,S<!)/)KP+Q,Y/Y!)0Q.1/PY1\0
M)PUFX1SLVQEHOC?9#9/"BFNX;%+:.I:1,;@#S./M2([I@+K K7%FY/(<LK !
MJQ-_$,Q5)DX.ZH#6KN).'391L*U:?G2W5WWQMOMOOD(=VX\XSJ8^%N=]"P,&
M(0 W")4RF$@LB:"P V70JN5Z,ALV.)'9IK%RDX:U<4Q%_P";))."KT5^%FNX
M6320TT#?87$.74U85'JV<URT56G%D=*PL!7TT;,,2.62<])FUI6>B'BYY#29
MC'TJM)_@JHX2>BTRA)+9331QJVSH$ZR*51B'L6Y26R,#%QKLL& -2$B+CPC%
MT=D1-J%CX5N[).&R"Y8Z9>HM&;;7;*SIRMHDEKMOOKKD,]X'@CO%O5-L_3%:
MVA7>2BLM6@"0W$UC67ZD[;M\.EX4FSP3_8WEJ#7;"FXW&N7FJ>?NRGC']?!D
M6UCUX\(L [.>0QV6*R Y$Q8MM* :Y$E*HP.7,26-,&23[9R\D$>$M573YDGK
MLY:-T]E%=---<[8#<_ \#P8]L6%O1B1IF2'NPR[3!! LV>-UQBS#*7YL/4GZ
M2F[51IE'_'^3&^=/M_K]?IX/ECDDCLP B)3$CP64QB0#VQ8#(XX48FP)L4]2
MU69DQ!<8NY'DA[M';&Z2R*FZ:FN<9USG&?![7YT(+>AAQ,P*'$)&^7%QY@_(
M-&;T\3:B21YR.#-7"R:Y1\W!AGCU1%#7=31HT66SC":6^VH97P/ \$=VT!KN
M45I-H];;ABUK(Q'W["<K%9*\AXK$:73^THF4DK J$="AB[?ZZ.-\.D==T=MM
M-\YTVVQD(]*PCG%_8$!Z5,.(@O-%H9O1L LIW.E]1LCAUGGP[U.O6&=I#K%I
MII-9,+8*-D%47KAV]11RCG9377P?+OR'S9N"K>+8J.,H16HJIF5'5S%6FQ1E
M&(O4EA1P/$9I VL=9D4 SL%((Y'V35?1R@OO]C9/.NVNV/N\$"V+Q-\>P!)@
MO:D/A<9;G&K>,,=YG<$UC3:0*#Z3+4$HGK@K80] [)'E$$EXX0>;?F)D VB2
M;M5;5LAE(+..ZUI:X*^@0MMEK*X+"R8<U7)R'SL\DH$,PQH1C LM'IU$9&V-
M9)!FZSIGNMJ_W4SME717.VWW8\&BDN)N72[BL7K^J!ZA.GS4S/P<VE(9DTD"
M)&R)(VF-D8E,@9R)N;L0;8TO9(%9"QD2Y5D<)H).GR2ZZ>BFH:P]^/;C]\F'
MT5IUKIL!_!L,W0F=CM=ORL;G<]$"5B6[*9-53:P*[7SF2#MWFR^XX@[<Y:[(
MZ.5]% D@3S_5$>HF+<RGG)D_7N@EK#QPV2SR5[2*0M1*B\E2#8DV\B3F)9)F
MU&*;?K[/EU,C6NR2VRJ.BGU#3[KYBY%MF?-"5W1.*&K&L^!I4R&T.S<\!D,P
MB4(DR=UCP,6&,90)7?'(!+ &LI8$!R7\R#>,_P"0;.&^Z>5<!N$5Y/YXAHN,
MAP=8!<LX;<DAZ$C&YMZ<E1 -=LL;R=K);.:F)25,E_[N-(S0M^PZW7VVWW(+
M[Y_QJ9V\$O12&1V$MS36.-7;1"02F1S,KJ\,&C.R\BEA-8P==(*FR!%5@T<D
M'&^Z3-OLDR:ZYPF@DDGC&F VGP/ \#P/ \#P/ \#P/ \#P/ \#P/ \#P/ \#
MP/!S+Z J*X95U94L"4N+H*0\O]"P'IX#?M8MP]8[5='AJ5:1F,P^/MID*J%M
M8<-1/KRHHX0V6DNSMT^;X_$K^-'9'(5'MBQK+^/NW1M74Z&N(CSJ%FO.QJ*5
M5#:GD-PRFU'E]R?NDGTR'@Y(9$3DA,%HE+3D#DKQ+]Y! (/&H:;*(-G:VJX=
M6JGF<QK7F2@S751O9O;:\$H:(6\52%IO]7-YSU*&P@JURT@XUR*;HE+3D.&V
M5VJ*8MMJK^7;9%KIMOH%-[+<]$4G<-JPU2U^MK8I.Q^;)7.H\;B5:U7++2J>
M^<7-!8)#H12TD"5,!B*N)4$L;.^@^9(E&HUN"V(N'B#'0BOJ%(9!;'R-RV'1
M2T8O/^H8K9U:?%]%;XLNHVO/D/2K>4=HB'L4V4JHL*D%)O#1TA9#)M(D2H&,
M2#5T/PFFLSW8[?KY5"VM:6_W>8[W>P^8ACL=XJ+WA?B->2<E WS^8OU:LJ@%
M#TZAFCIE QHJ)U1/;!(F)_!I:J]W6>I1Y4(X>+_N,$M@M!U<&O:)R.I[HI>U
M;:W_ %+MYKKF;T&*C$"EU52NKK#O.*0&V94:9*5\\LX"9BT!FKPUDPQD35F.
MP#2570V:X>:K!S)0O_Y1E9Y#\-P\U:U$C847A-_2N05/O_=<+CDO^0R_ </L
M2H(<+K)1:8B@_-56#(S-,*+N-6(B<@94EJV3%E')$+/UC0G3=0=;4L1=719T
MS.W8O:5Q]KDVX&%H\UR,)55:!*2JN.QILK624OA]L''4EA+IN@T/,V;L=#3;
ME1NINKM]X=>O \#P/ \#P/ \#P4_[FCUND.:K>EE%6G;M;6M6U4VK.8 RJ(/
M7LB)SN< 8"<(PV*%H]/:ULG)YD]DC-MJFR'(M'CI3?\ %JKG[L:^"G]GTP4H
M,;4O7<(>V>]Z"GTUYAA73%B$AZ4C*+4Y(G_.\8Z!DDCA8V,)Q6*9;P.CQ[@D
M^8B66@O*#I9'5O\ EW^@;K\8=W].="PPO8EZ,)PQB32J.?(''GL\K?%7NIW=
M$-#SE#HNV8I'R,?C<D=5_891^ 6&.U6J Q;9NO@:EJAKMNH%BNADY%<%=VTV
MH:^[:J2T*&7D[-PI6$7A9-9_9+6LA$]B\4DD?MBKYH-G$=782L0[R@(_!J\_
M9RVP\U5U4T2#FJ8Z)[E)E8<G(G%YUS-)PO\ 'Y9\#@L(Y^W-5X7@DZC\'8=U
MQ2>2XA5LQ6A7^4H[:6&-A[\N*D3$AH*PW_<_,@Q<!ME16'WB2CO/5@XL.S)I
M6<GZGQ2#T;-:*0B5L&::B/3?58UK=UG"7%8PMW%A%A<_,*_27>_Q(7&'#3+W
M5%ME]M^0)8^2>S[L@$SIUG7MH]#5'"W]+]5R5Y)* HO-W+%KXAVM(;<^Q*<C
M]*1NS=E&C7\Y)M\L]D1*13#??79YKE'7& J1#P?:UK&(9T>X/=!5'U'8O0]5
M<W_Q["!1073,:YA"QN,=+6"]LZ)32L)"<Q&1F=YS&@IAH08$%Y(8&L%WN^4\
M;)A)7#?0/R!6S:E00N\ADYC9*-DBS_IF-F*B,@(U"0%;\W!:G1"$;3/51 H5
M+9K?G51)_8 QI"'QUDRC#%+&'^&FWX% PM\=,][L;_Z-%T PF5FQ.AK9F3W>
MN8G"HZ\5.Q*O*S^+.X7%2MI-O#S;IG+)_$+/M9,+IOE8F_7(*Z--%U63-- ,
MI5A[NOH6H[EGBM^WU71"GJ(C;BM9)"*/CD-"7%TVWQ>M@V,U&5_T+SV.L6Q*
MDB3"00.(-%OX6.8./ ;_ "WSHXW74P$B"NFNLMK2,'V4"O1T.<?''*+,D<%E
M%/9;4P([3BT,I&>Q.N*M,M@#*SG10R&L@NU.,7SUV/=/VFC(>M@D-*-T BZL
M0/0]0\RMJ..U*5F77>/D("2>SYC(Z2)6-!;F@T\[8&S![TT!G::*40:*5_SI
M(&Y86J^*-2,.)Q9 7EG]C-JW<!KU;+=<0IC5%2@6/0E%5\>LSJ.9 )E ^;"5
MDN=IX_\ D'M>;K12UP9C84TKZ#61S])F+P&9--4PBS4@_7T<)$FH_3</@KR8
M_(>J!ID5*9;UO@A/(]\<\@M4N1I82@4B$CE5H7A#^PXV@LG3#89%QH>M1$4(
MED]D,*BEU4GJ"J?[*^NX6&F\DZ.,?%0)(6;FQ$[.;SFM(Q=;^51MS#[#>\^!
M>OXO%+<D4D#M \?RW<&N6&1%\3=(LVJ3EHNNYTTTQOC& B>6@[\IVKOE4C*U
M*DK6Z(N&YIM9?.)(G3)6Z*OO^HI!"8,&H^IW[@8C@('&U8.!.8J0!%R 30=A
MKN81VPW(9=[A\LNEW?LGG9$9I.>K:[)#^HH[4MCQ>$<S#5:^VHLMTT.'1:[*
MMN@Z$G<<*LU>8U5W!C^&8;?QKQ950SHR?,4-'0860QOKBQY)7<)LY"^I6!@/
M:])2.*7P(@Q80='5^B/ZKC1\R8@!>JT=*XL.#!M@#4^>%+'(.;:DA)43NP<N
MWK-(-EIZROD?DT?JO$Y:7/'K%$CN&UHXF9J[05$;*AQ6P%8IW*[OC52&)-8?
M9,;@[ B3;(J9#[IJ)AG(1NYR]>-E0BS:5]I..2>FM+H+]#FI0:^.:+V+7[NQ
MZV1AI:+=RC9]=$?A4<@;D# X6F,GKHV-K]TF'^JRN[U1LZ0UU_86SN'4CMNO
M2-DTC5PXI(+@KVQ@%I5]-8M;-"P;2TB%-6E& $B(#Y[**U<AI*.GM5)OL+B3
M YTP<I*M2FN^NS9;1)XV#EG+8]V)BNZKLD+6DOJOH"JN/_E!VCACF6E) %BD
M^M1ST50LNH4G_EW-(E-BL!0ZOW@CN6N(*1WP40PX=LU5],:YSL&S7M+^K;3L
MV50M[7?3L@IM]:U<F\!I%1DA<CPA^CODLY<D,8D<;* H S$CXLMSNF=-C=FK
MTEN1"L,.B;C!A%VT:AL=IV+\E6\/GQJ'I76!L9F/ZL$V5%@%7-9&$C12+](P
M<?QZ>YT4?0,TQF2,SI%X]R3U:;%DG(Q1VY*X8E6:>,!--$'.Q@_5$6$2^2]&
MRVGUN@.O:V?XL.MF+:(Z4P&AD0G='38A(AE;1I5-TXGKPD'#FU'>J1 ?C9EM
MJONCHKJ$ ]J\E='L^A+RFO.5<N#\744IWY.X"L/1$(IE>Y.1FS6L#U!L-5F^
MRXU_UY2C2/C5B*64M]4Q1/57?Z/-LY"XMB"[\K-MR4P@;&>#W<P>].S7HK,$
M@(V6M1LUG5!VI8 X@:+)PZ1*!WXV]B@YB%4T51P05RDU52=);?BU"EE=N.ZI
M'(N84[6*]=&8^&L;@*S+*?.($\BCQK);!Y;OH'T-%CR$4@$=3?UK%;R80U4X
M,4;N6\;?$%'*RB*&,[-PS]5R+O2TIMSTC/;([&JYA-)[O%^I88/YK!0L+4LT
MB5&WF2E#B!6M*8U9C25U/,;<'1!J,+"M<1M1OA#]1U^<@^1;!TXGUW%;/YI!
M3*A \^2D%ZJ!X-!G9NN; "G*Y=2\JK'34PL2.?P.)- 6]=,D'SMPJ0;H))/6
MJ*6VW^NTSL',JEM.E^3@@;C5*L[D%\\TSV&_CJ5DTI7MB3=45QA<E2V%:=21
M^LCQ*-'Y)*15'=&$Q]?R-PP:O28B+-&3A3[6RSITU#=>#X)UU7<&XMJLHPMZ
M.5%+.2Z23FJ$D#A(R5YOM'FLOHG84/.A7P)@7;;]1@9*)9:H;8<Z,_[?*KM?
MU-7"7T"X5N\?5'VG,.>.CI,ZM:&$ZU58'@L8*Q_$)*O!S5Z\.L \SB,PCFA\
M8_;RI-DZ40(I*Z:MFRB&K9/9VJOX.@'@>!X*J=V1\S+>).P(C'(\7ELDEW,-
M\Q.-Q4 '>'S<ED4GJZ4 @0 2%'MW3LD_+EGZ+=)+1/;[MU,?7Z:_7. J:ZM"
MS/\ (7D*$5# []CTC@E@<.!;:3?\^34&/;0!U)X[&[7C;I*?U]HKNQCD6&$7
M9<@)33P%2004R]1V71T6"JQR??)8_@P<PDXOZ*S8F*8">BX\!JH4<TKBUQW<
M%&Q8;GG?9S 9"TE=:R#ELI/GKYTTP9:Z QHHBLLV**K?M!;7O"N9ID=\<XF.
M+6I8+FI>R81+)E9J=9.+=E@.(QWFKHB&%++G8>'0_43^8B>E@YHZ62'-4LNR
M>-D4-<:YQH%7+2D/1]8'K/M*!R"^&3,9Q1I'X ?*TB?A=?36_F_5$I8S@BQI
M%C''",6MNX&4G&ZQ_10?L4-J/$'C,>2T2RAN&NE.@^P?[?%*U\>ZWG9H?<<H
MDY!@ESC,F_\ EW7NW3//3@52%@Q\_1,;L4Q/(_RG+RKQ%P7;M1Q9DN^=LW1<
MFT:;HA?7@RR+%;PFN(3T;)NAY%T!;D2G]JO6]PUA_:@:)":_F8V!KQ5D^ US
M"@,:*.!I443T%D-UB#_1RN]0SEO]== @[Y!8ET!9<@?W52<&.%I-\>AJ$W53
M4>6"V.+DEQ6.UTW,W)#:R9"@NX6QVEJ4"_(5LS6PHJ@R*R(C]V4]D==_!&,F
MWZ,Z&ZNJA:6Q_IBM-(9U3<Z5;R@!49D?7]=<Y69\?=H1VH[DT.R*#O ;*QFM
MGS55@7:&7'\B+D"RPY^PPPT9YV"^O(DPOY.NX&0ZD V,.M>9$&E/$8ZB _GX
MP(D-+Q>2A9=<1,E%Q.[*'0Z^)/#"1P0])+HM51Y0$TUT1>N<HJ!>OP/ \#P/
M \#P/ \#P/ \#P/ \#P/ \#P/ \#P/ \&H3RP8)5D4*SNRYG%J^A(+5IL:ET
MT/"XS&A.KY\V&,MB1LRZ9C66'9%XB@E^137[UE=-,?7;;&,A4\I\A/-2,AKP
M?%).O:D)L/$AVTN^IG,8G=#PK2).?P2M2Q+1$R;(")IQE/&5R&RN=\,V^N=U
M?LQC/@LR/LZI):0&@15@5Y)2I$J<;" S"4QPP_>FX#N*(21 >.;OG#AP4AFY
M-BN]U3TRJ/RX0W4_'^1/.0VJ22>-PT(^DLND 2+1T7JCN2/2(JQ"AA^CAPBS
M;[OBA)=LR:ZKNW":6F5-]<;*;ZZX^N<XQD(U9=&\^DI$[B ^\:C>RICD-J[C
M;6QHBN<0VD,[4JT%JH+3+[/,;%[-1VCK;'V?58[C]#7ZNO\ 5>#(YNVK7<8E
M4JC4VC4[8P^#;V,69P(^$EA7>([8E.@TLS9"B*WYVIY["2S0>KG;1!V['.4D
M]\[(*XT",*.[4Y;Z(A<)FM7WC6)IO.A3-^/CV)_"U):))+09"R"<0D8$>?(+
MB9K&(:KN_*C-MMW#%LW66WQ^%+=3 9YUUSRJR/1"+O.DZ(:R*P'@H=!@J]LP
M1(E+R)T5'3H(?&VFYW"IE^<"R\2[9(M\**NVY1HHEKOHY1SN$EM;1K-\8S'F
M5A0AV?Q-"%<; VTJ!K&-;"$Q3>>$X+L,3?;/M9@/@R>32PW.G[B8C'[FR>&_
M^L\&]^!X'@>!X'@>!X'@>!X'@J7..TN5*X>6> 1MVMI5:U?1V?323T77,PA4
MCODXK6T5=2.5C U7M3S:3FY8Q !?MRWW3TWUQHGJIMIK],X#9JQZLI6SH\P-
M)RMC BSY_+&"D!LXG'X;8PS>'NIG@@N6B#HTX?L6KX! B9UGOMG/YP"&S_Z:
MHZJ9T"? Y@1(A J0 "@XX!.C6)@(:$/6Q(28$$VJ3T:4%D6:BS1^.(,U]%4%
MDM]TU4]]=M<YUSC/@K<5[@XS!O)>.,=7<Z#"5?;N4YT->W-7K<C#MV4@91-[
MK)F"D@U=A/TI23;#EOV-$_Q/G":&WT4WUUR&W[]/\VIFJRCFU_TQ@[=8YD7I
MP5_F;#,O+6%D]]DAA"N$L&<YFS0FIKG5MN-_9U7SC/X_N^G@^+H#IVGN8&E9
M%[KD[6$1>T;,2JH;-3;P0'AD8D+F!SRP&KZ<R,X4%#HW'W8VO7;-)UOLIG<F
MY:-\:?Z[[M0_(Y;?+0I&536*6=1+!O-9&&-S.5 YK!&Z$HE9"H0TNCY20&69
M/5(L;?T/&6!5FLNINLM%&*+I/.6*6BFH>^.=4\R2]Q8+2*]#4E(G53!WDBM%
ML&M&$D%Z[CH[191_(9LBU-J*1@ RT;*95>O,(M=/Q[_7?'V[?0-E5O:DD7+-
MDM;]8I/2$T?UNP9J3N,:.WMA"G8]B4@S5KL4PNO+ASPLT37':ZY=H[ND<;IX
M_+I]P1A&.O*NF$#F-B 15@NP<$O8ISC(6V\.>-S2-H [+9U 88,QBZ^BC\,.
ML!]HRW(I9V:;:XV7TWV;ZY5\$_N)-HC*0T72"G7VI85(2:\D8-6J\8 K %X\
MCH&/O\OM'3$T?3/Y6'(ZMU=5T6+K;;=/\>N% T;6\(.I=H>@T=RSB:GJE/70
M*?-Q_P">)O(;&IA'(.8U2D*2^S?8TU-RME_W7&N<Y05_)]WTQG'@@:>=Y\[P
M"7W#!;!5F@-A1Y^K8C<DP)P$T[KF%.+R:L-ZY<2"0M$'B']MR/!ANDX(:I*,
M!N5L?R"C9/&^^H7$8:AQC?0.-_CV+8*T9M]!K79N@D+9?CRD/1PU3SKAFVRD
MCG5'7[==?MT^FO\ 3'@C&U;S@=/-(2]E*Q1XA/+7K*FA68XPP;V82ZW#K6.0
MM8]HW7TV% GA5\CJH[W^NJ>JNNWTSC/@EU%=!PGA5NLDNEG;?7"B*FBJ>=M-
MLZ;ZXWTSMKG;3?7.,X^O],X^G@B65WS54(M^I*'D\L:"[4O,989>KXLJ@[W7
MD[.K!@DS-OP.DD-V35P,$F$W&B2RB:CE%)?9'&^&ZV= QLTMZL0UR511TJ;+
MNYO8@>>6!"-U1*#X".Q5&8IH:=$BBJN= 9I/$Z:;#L;)_>X_UN4]L92V\$P/
MBP\>P)$W+C&68AFX?D-FJ2S]=!LV;;/%=M6;%-R\75_6TSMHFFGNHI_3&FNV
M<XQD(*YTZFI3JN.2&54E*5I4%B\F)Q4RZ5#%A>B!%@\=HMMTE"#1!NY0,#6Z
M1%OJGOLNFQ>-\N4VZJF4=0L-X'@>!X'@>#\VUUVUSKMC&VNV,Z[:[8QG7;7.
M/IG&<9_IG&<>#U-FS=FW0:-$$6K5JBFW;-FR6B#=NW1TPFB@@BEKJFDBDGKC
M7777&-=<8^F,?3P>[P/ \#P/ \#P0]4E]U1>>;/Q5\M:2?--VQ*Z1L?"*#MK
MF-V7"FXEW(HZXP]0;Y7V9M3K175=+[VZR:VNR>^VO]?!NPN6M2+R5(.!A<&R
MBY@<)2.G463(%*-"0(&:2+Q1^F_<?R09)P<_CMU5=&^^"35PCKIMKIJIN&F5
MO=L)M%S<+6/_ ,RQ4HVTC=13S:0"]Q":$H 1.(S9XZ%J**J:D0"L=F[!=%YK
M]NJGW[8^F/LSX*FV'V+RI8M"3.4V97$SGM!$*S@ELXQ*:@4DT)M2J)O+1 N%
M3>)($-7@60,\E'3$IALOEL8&-=F[Y5JAC=OOL%UX+#Z[K2-"HG7@&+PZ+)N%
MT1(:.-F P:L^W_*HZ_ DUQIJ\(J_K;[*[YSNMO\ CVSMG/VY^@;/LH'T7=$M
MMQNKIBS_ !/7^VS7"[,?],O/QNG6<X4;L_IC*OTWVQI_3[O_ -/@^K+QIC"&
MV73;&KK*>&NV5TL8<Y6UVW2PAG[OHME733.=?M^OW8QG./\ 1X/H\$15U>]4
MVO,[GKZ R]A(9?S[-Q5=VR%;:.$W$5E1J%1N?#62N5TDDWK=S'Y0W^CAOE5#
M#M%RUSOAPU<)IAX5M>,$M216]%XNN1U*4G8R583'^5:)L6KB1+U[!;/1=1QS
MARMH;!JQ2Q1JF'2?VZX6V52SC&R6W@EU-1-7315+?11-37&Z:B>V-]-]-L?7
M7;3?7.==M=L?Z,X_IGP>?@>!X'@>!X'@>!X'@>!X'@>!X'@>!X'@>!X'@\%$
MTU=-DU4]%4]OI]VBFNN^FWTSC./NUVQG7/TSCZ^"C$:XY>Q_ARX>/_[W&JOK
M2C_7 1&;HQM1N/#;=-SFWI>R<K1W!795]B((V<FW6UPZ2_=V9[;ZY1PIC70(
M3Y7X$LBJ.E9=?]K6!7Y *P(SI>G:OK:.GD$ )"QJVYUJR>3V;3.2$-7)@[+P
MW-@TAH(8C&;(20.%?N=$OO;*H!*?R"U]?EO41=57UM#0$NCLDK.*J 6#=^DP
MG!.R1]MQ<FZ%HJE2K./:QM.%CEG&VZV$5=7*>-=5%,;_ &:!4:7?%#9<U:M@
M"]_QB'#8)%>BW5-3>$P(^QLZ*V[=?<U6=O1:8&R3B;9%/H[6\GJ$<,T8L4V+
MU[H[<KZNVROX<IA;_A?C0KRJRFA25'X62DDLB]1UF$C5:A)8(@%=5'18:2#Z
M^AXI]8$OG4^F9YT<G,@-F3I<CLZ($#.^OXM=4<**A5_H7XE772Q2R"4YZ D$
M=?V%;%Q7&E)*\'F89*8G,E:F#4=R:]!DHY*0^^S7G6N<&T'S-7;+65.)"_W<
MZI?L;_0+/6/PG$)OQW;W.$<%UQ64NN^&1)O,Y/$HF57@S&RXC75:UN#F$7AQ
MB0O2 87%X_5 -J&:)D-5F+<6UV_-LXTW7W"-H5\<CF)]QN^Y7UH?W5.)+8UK
MF)C%#C*4*Q3>$2"N M:4LZB(/68_VY&+@I6'A'4?3D6HY7^6C<H--%T=5%6J
M[<.I'@>!X'@>!X'@>!X'@>!X*\2FB]I#T_2W0Z)I@R0JBH[_ *S=1S(?\K\Z
MYNN24,=;&436KI/5BE'TZ:5241V15V<Y(:YQNGA+;"@<_NK/CJO"Z;SE5FU1
M<M;5RTL:900Z>D,G@QR62V!!(KS9=O,TE'0\ U,B0,K*SB%W\9437(O6+40Z
M9M%-FQ'7.Z6H='VT.DM3UK4-;4D.!NPL!<557SA"9.G>^[.H(SH+CD@>,W;!
M=CLM+1\28?>RSLFH@L\UUU42^S;.V@5,Y/YUM]*R7_0_2TC*GIN&"= U'5L1
MD.&#XA"(3->PK>L$A)7!P:0>LSB-DU''JJ9CFZFFJP09%4T/\*CESI@(5L?X
M_NB'?,K+E2I[)YR#0-*XI;=.IV<U-.B)Z.2!]V=)>L82)A3&+6+'A ,9%&SP
M:$U4UUPMINV5<-_PZ[)(IATHO*#SFRZ/LZO('.&M;6'-J]DD5C5BZA-3Z,)D
M9X*Y%M96S!NG2.KY<(Y<_LMTE%?I^333[L[8QG&0YC"?A]KL-?82WTY*V+1$
M5G_*;>ESF)JZKY3DP+R8TY?K6MFPU&;(M6]IU.V(RMT'EVR*CC(R?R)@LCLH
M\;/&86$ZFX'&7TT9#H5) 59#QO$_7O&[!',77.+HA.E(M5,=C!!1[J8'NW8*
MNE:T_8W'+;[Y?;N-=M5D=T\[[A71K\5DSCO1"W4,2Z!PC:<UL^42JU]Y$"DY
MR-/HH\NVIY+%4JXC"DV3 P&>M.9*D9U ;+)MEL'(QNCOMHBHSQJX"<:SYIO2
MNEK7JC8;79NK+#[7D?63"R]I85;2!A%Y9=X/H0M7A*NMXFLBYE367#W(1!VF
M7P/4$K)/M\ZN--Q^X4ZB_P 7=T1*LXR"KUM250VJMS5W55,XLV*&#NSLS/;]
MM:K9Q29 P_$PP!))1%H_%*Z6!%5MW#4@(9$/Q#-5=$L9P%JN6.0K$J3H"+7$
M0KFM:GC+^FKS"S:OX9=-A7!J&M6WK6I^<.G\>-S>#0])S'RK:LW3MYHR9!&;
M5\_UU18JJ;.WJX5YZ>^.:^[SM7LZ2QG>O(TIT),>29/35G$[2GFV:D,<VC0F
M-YG-*/8P]>!6R[:'167HN/EEW0HCOHDF]6;:8QLF&"O;XZNDK<O,Y-7$/YW>
MP(Q9Y,B;&[3^4#-YA 6_7W'_ $1&B!V/N:D-.7\V5KVBY)'221 Z^8:/C/VC
ML,1"RC34-+L3XP>J)+.GNM;K4E0$(WE@YB!.TU,7X$M!(C ^RF5_U=-X97Q"
MF7H/>;@JT668;,2I=\U:F]5T&#AD&5:MV@=8>9-+TA0R!T]9-'4[7H*)TC''
M!B44=*SB]>Z6HTD10(=B\4AI^!QMT-BID&V;'&2VQ%^^:JN'#-[IG9-N^(!6
M?I_C^^[K+2:[8@?!Q[H&K+VI2Q.6 I*;:)5?F*TH_P!]-AUBEV=5OIU'E+2C
M5A6 ).MA:KI+^-D227W+[-\;>"%T?CAM>RK:*I= @*?D=6GM/D0C$RLH?,SK
MRZ)Q6/:\AB4KKR./!3NMTAXXW0C $C&6RFIK9IHT!C7[#5OMC+-$+_<\55<M
M<0&$1>X6U76?-YT')N.I;+$.7X%I(9:)B4;A455C,&=Q-ZC) QJ, 463]-Z_
M'89:M_O33<X7V33";ZMI.HZ1&E@]1UU$J\''C! \9;18,T%ZDB9$@_)**.U$
M-,+*M6*Q)5)BVSM^L-9_8T:)HM4DD= E'P/ \#P/ \#P/ \#P/ \#P/!HEH;
M6%K7<TQ4[4"\LM6.E&\&3E)-</'4I*Y;;MQ3TT0:B#SE(<.<JZN%==&BVRVJ
M7X\8Q]WW8#C)<OQG72V;7Y!*-.QJ853TIS=2\)GS*Z)HF&D(Z]N?YL(_L*>,
M-H)5.HYZVD%39="9 25Q_+.G@D+OKA35);?0-AL;X\[22(6BSJFN*+_R4E/4
M JR?]F?-B2FG8).Z<,\6Q/F:41\B:@%9'TX#*8M8 1Q)1[=L+*CB#5??7?=J
M^W37;A=KCWGN=\\@^A01K6-)MIW<B,UK; V3RB8?K1090E*5*(:2<E+F^)(X
M*)%*N754W=/2CI=HLDHN\5<[+?0.=[_XUKW2K+IN 5@,KBDX!?U-Q\.=YA!6
MY-)/S:GT@YLD'+)O<%/BBT#3>\_PLK&T2+1T"#,DV9MVZ0758,EVFSIZ'SSK
MXZ^GEUSXFOHKSL+AB?1-AW77H_\ ON2QDG!Q97I7FJ]Q,3"885+( \9"RUA5
M<@3)MA"#-PB9>(*;/'+)=XWR&)KCXQ>C:X95^I'FU) -8U$.?\VC#@\L/_VY
M?I6FNJ+-MHQ!9JO_ )>,]G8$M6-@)-Q)-Z@YRV*C$&3AI_&?=MX/H-?%C<N"
MA0N$:5*\=(M(H5J]8K+#:+VE'HOY&Y/UXQ@<$>ZP1XN+C=9TY),1,"^:[(*8
M42W:)-V8S?770.RL4EUS2*L)B<*5C&HI:# O9PN$1%]-R;Z*21H D)X96D@*
MR?>&"CH(=-0S1B]?)9#JK#=G"J:7[FB:2ZX<K+)^.KIIHI+7="W&W#2+H;BV
MP*"Z(E$[EGZ:S2WFL@>V72T_C#:!UH,(GQ[6;V+8(F1.G3UN7P#E::K-3=9@
MDAL&>'_'[<14E-[.% :)YWM!_P!>Q*^*['04F_G(&+5?.>6ZAY0Z?K\B\1K>
MN4\&))#(T;+A%&K3+120- KIUA/\*^,AUC@0DG&FQ.'Z1*,1.!P[<#&JJ1CA
MQV25?PD9$H^EJH9"KQT,UB+P6>_='MV3=T4258-$'.5TU%]VJ ;]X'@>!X'@
M>!X'@>!X'@>!X'@>!X'@>!X'@>",K;D-I1B(*EZBK^(V5*D'J/Y8Y-;)?U4'
MP&P@Z5?D-)0/KRS%]GS;=)/5-KD=KHMA3;.5T_L^FP<QE.N.G%*&JKY&B2,+
MB_,DFHRJ+)D7*K%VUE-@;/[-4DXX<JVN5>'@D-/M2GD-(N$M6.FB"@I^TT_)
MJIJNJ%GJ [:87M<A.F$:Y>Q@['(S>1N6O%)4P-IQPI2_4TWYB2!O&C48T7^D
MZ=P)Z>&N=\I:[,-?QXT4VUV4P$V=%7EB@HE#)+B+*R]S-KKI&E!XQ,RF"3:E
M+LLV-5D,-NR"@\I]& -])='2Z>J.RBB26VNN<;9QGP<_*,^26_\ HT0"VK;B
MP2)EL[H^,]*5G$;+Z6&QC:6TT5D$FAA=Z^/1JH9R*CDR3E0@<H(8;9<C2H(V
MW?K$F*R:[!,-L,?)6[?1?G6P*QJ2'S:+7W&>/I(I#CMVKP[H"+)]C3<A$H8W
M'U.SJ>7QV9:1X='3Q9XJWE+;79A%S"N<)MV>'"H6BHOH*QIU;EOT3<M.":FL
M>K(G5]DLEX?9FULP2:UO;A:SH[%S0R2.X+6QL3(6$BJ$VU)"W@C3".NC=5!R
MY36V_$%<>@?D?(4::Z<;,.;IO8\<Y49R$K8DICTI%#V7\8 Y]K'H)N@G_)"/
MXX;(IB,G[H* 8O'B&I0R+PEA=/#G&40U@O\ (Q=X6/7QJ^XM()V!S7$K7E]N
M@T[I0>5['DJ\JWG>]([%\6J/JUVSVFMD51>;U0>S6&-V^AV)D&6'*K/;0K@+
M%UYUA-)%?<!J.<4RPB$1O.I)O=% 67'K+_O523Q>OWE8Z'@MEPUU!H@[K.7[
MB[;%.VR+1[(QRV-'267NBB26' 7;\#P/ \#P/ \#P/ \#P/!2R^.C[FIJYZ"
M@C"BH3+:SORY(W2PNR%;R?QV51TV3@-@V3("S^M-J;-,'HP'&JT(X;:IR+54
M@\W02VU;:*;K)!61GUI?G)LC!TUUH]C5]3F1,*HG;FS:\:LJYC<0@<XNGF+E
M,_A[&]P6ZQ/>.65:IB7K+_<EC^$TPUQG3?3&V@7UYHO-ITC3<>N(?'5XN.DA
MZQ10X6N4;FLK#X+94OK]B>;DVC9HV=,)4TBVA1MG33.NK=YIKC=3Z?DV"L-]
M="]0![".\U0ZLZ_KVQ+RK"^U>-+R6LQ6>15S:%7188:$L[LKU[5H4A 6;]N8
MP]3W'JRQKE-BLBMG539#58*P%OEHM<(WEB>_&;>2.Z_CW74YF!J&]&!BL!_R
M]XA?UX)O*21:4&*KC9:4/%9%8B<? -]!#=H0DXHFP<O&"+/9YL$R2[Y"[7C\
M0ZBGP7F$#*HSQ\<?G;>T;7U_%2 M1"U,0?H",6160PE4>@^1SA_6<M<;D8J4
M? DV!0=EJ@5?:+IN=0MSU-T0ISISV=O83#M9YH+)U@P2#/SCV'B&8^R;&AL"
M7E\MD;6,3!_&(9 V$NV.''FHI[NS%#W"GXL_;G. H@7^5<ZP9S@:QYIV(V!0
MT$Z=M+I>+J7**' X1 >6)^Q@LN>57+W$$VUMV03))YL3 LGC&+-_U$=DRCL8
MX4124#Z@OR[UW(KSD]'"JS+:.X1.B#.5STN;-!J^TJ+635=! -FQ:1.Z_P#U
MIE(S=I62I!E(HSS^^/G05V,7<8;_ (R&X7!(=< A?949Y)?Q(HU0F%:RJ0QR
MV%7J&L6*6S"TXU)Y#0S=E^']O^^F=12QI+\;9WPDH(_+G3[MD5?L#8D>QN<W
M0@8=96 L1%GEG.D8<#(;/2>TQ:,8\1EC\W!VX^+N7,WC ^,B'3YP5$Z/!R#=
M#?*BVN=<X\$3WG\@E)U9&YG_ &P4>3JP8M*:]A^8>.BD]7VRYL+H5AS'_=""
MP^+.O[EB<*M-9XR+*BMG/T>CMF&N^CMPUU4#7+LZ^L^@3W(,%L..T0&DO1SR
MV0<OF!VT)1$:Q@!BKZMD5IMWS4C(8(@8=BI0,CNS?9%ZDR<C%U_IG+O"6<J!
M]M4?))S]+N=Z1O\ M<PUHM"[1218)&Y"\>R1) 8]L9.K8]+T) %")IK5C/9,
M^'*1R0OFHML38&&*NZ;=17=%(-S"?(EQS(Q+8X&N#]P:_7J-N)6_R_M)NL=S
M?!N11>HG$=9.H2@^D3"<RJ)DA+5RQ3<-]2S)5DKNFZU_#X,U#>\^2Y\T?/HS
M;[%9J/B#6=*JEXM.XO\ M1US.<U>KN(TE$7#*'3(JS/MCA(4RPX*"CRJ0]XW
M0=K)([A'<%^0.I)S9]DL!LCBCJD(=5%3S,)9P]U(E396?SN\[ZY_DE5%82ZC
M[4N,ET8L*E<C=!^FJI)4@Z4;J-TMTL8W#6+N^3?GV(\W3J\:2G$2M\F(KR93
M&$#?I,1D.DAV$PH_8Q> 'YLRB9(="YVC#(H2>[@R/ZYE%-IME5KIC^O@NQ5=
MRUQ=0R2%JWD*AUM#ID9KZ5MW@.11DO'9D 0'NR0$R E8D(='NM1Q9F\0V5;Z
MI.V+QNZ0W5;KI*[A"/7?7 'D@)6TC/Q(I*@<KLN(1R>DACU!DWJ.IS,HC\.F
M%\RK9PBME:"UN?F@-,KJE]%4TB>JW]$DE=M0P7179L9I>PJ<K..MF,VE<XO^
ML:?L 6V0ECG>O1-E1B8RD>1<$(]&38368N!45_:8@WSID[?,E<*I8WRHWT7"
M>JIONI[O$QL]5DK_ +N"RZO(S:L>*M04E8#R$#F+TP/C1K]LP&'(M%BKL ]U
MT9+Y2(:8;;[;H:ZX^O@F#P/ \#P/ \#P/ \#P/ \$*](VH1HOGJ\[M$@6<I(
M4[45BVFWC+\FN%:2+_+Z)%I:J#5+MAY9<7DJB(V0U<:M7'X=U,;Y3WQC.N0I
MS0/R-Q&SI;/(Q-V\ #A8!0-"WU(+/K>PMK#@,<4OLG(0T?IZ9*9CX8F MU-Z
M"378C4='VYAB_043U15VU0W"78M\A_&\UD ^+1:Z6!@X0E46@V[5K$;!_7"S
M*;3N;U=%8Q+"BD2T$0LV:LRN#4=1;EEV2G\XQRQSC#I1%)0/.$]P480A\"-3
M"S8ADE/S+T4&=0L'91&+[J/;B.TO#VSU\7AH]_'",@G8O0 BF5298>R'55JR
MROC&FVP>N*?(?QY-W$70C-N[D,3/-.*1IVK7EJ#19(?T&1= Z3/_ ,P5@[(4
MSBEER9BL'%%W"R0MP<2V&?L8?XRW\&,S\@'.</C?\U:UJ1H3NX)]%O6:\3B-
MMG1K:#\YW(K4]B'#V<P+#\&K6!$@.;RY=RDD.%NE%W&B^XU/#S(9_K[I\KS1
M_LX[#0\%(L;ZZ$"T,]/SV9NH9'X1D_7%E6 QEKI^U!FDR+77:N-V.6V^S3[U
M'Z>^%L?9G3<(UJCY)**DO/FO0%O&P-0QC6;WI$D#:)E].H)+HY0-BE:]EEV5
M]+ T?:NSM%O<L4"6DB=CV#1FS>)_M93Q]JB@:1GY%5]N9CENM8?&']FQ>V7$
M(D4'8EY8YA3"(:=N&.2V,HVLA.(_PB!<R&#J2!D+<[-W#C'],8PU_P"]>"TD
MN[5YB@0X&7F=J#XR+DA=$0'?&0,L8H.LO)N/K46:VRN TV;1 ]/"S46,.*XT
M#DW+A/\ 5<K:;8W\$4COE!X9*,T"+2[E<"W06(2= N[JZY!P=2)SN0"(G%9G
M@N1KQJ-UA)*4'F@[8SE7 ML^6P@NNDKC;7 25KW'RYD"$DJEGX:"3DHDL,TW
M(PVP!3\')(?9,8I^3#IJ%)Q5F;@.0]FS8.'65-MQZ.'11KG&V4EM%,AL5+];
M\\]"G",;J"Q$I8:&1I"8+,E(S,HWEW&%I5)(*H;#+RR.@FL@8#IE$2(M]LPW
M<_Q[]ME%SA)3=/7<-LZ!M5[2E.SRR L-)63+ (-?2!5B%?-!ANSK$)[:"X%7
M(<B_QLR&D)K+'C0=HZ6QE!GAQE=7_5)[YP%6+-^0RK8YQ/IUO UFDG(2WEJ=
M=-U973Q"3NB<A#P2OFTVD#&2I0V.2@W%145?$F8H\2798:A7[I-%SLFKOIIL
M%C*]Z3JJPUM0HF0+*2YC._\ *>21W2.2U-<!:#6LA-O$XN[5> FZ.K5O7YMJ
M32)YV_BW+5TAE%SOLNEKN$_>!X'@>!X'@>!X'@>!X'@>!X'@>!X/!1--9-1)
M7351)739-33;'UUW3WUSKOIMC_MUVUS],^"+%J,I]Q40V@UZZBJM,!XY'8@+
MK7<8EF),(Q$<C<QD&V%?_L4QX/(AK^NGC^B?X-/I_H\&M4;R]0?-FLVWI2LP
M<))V7)%YA9$FT7*GYM84G<*N5MC4YGDI(G)G+GR2KU?*.Q!^X_!^=3\>-/R;
M_4-4N/DN 7*56-ES$G$$B%D\TV*9_CWR3@>24Y@L=2R(@#T%OD%V8]E(7KI=
MF5<(8U=KM5-,:J:[(I9T#9:OY5YWI:6/YS5=2Q.#RLC XG5ZYD(V<)+HUS!1
MP\5$80.16<K-!$9!,13?1%FT311^J6-]M=M_KMD-+BG%=%0ZU1-FAHF+;MH;
M6-,5C5<&3%#D8M4C&D6?0 .-&H'HDAH^%%G<0Z-/!ELY5V3T'YQHGKIG=7.P
M9RF^..:.?9F>L6GJG"PN<RB-M8?(94U(R(H:+Q=@44-CP3UZ=,E5%AHXLNJX
M;I?_ &MU%ULI_;^97[P_&O*=8KRCI<Y,6G^8(3J*7UO,)Q")8Q'/8NR=5C7L
M#@ -@Q:Z-TU7C!;6OF9!75WLMG+O;;&/]5]-,!\JW%/++BO+6JE>F8PM7]YR
MS><7!'%5C2B%C2E1L&8*%96\W*Y)E<[C8\Q:91W7_7_2:IM_Q_@Q^/P>F*\0
M\J0BV0UZ1:F8X)MF.XD&D>FB;V0N"(!"5L-!<C9 VSPRX&"!QE@DFFNV;H)M
M]]4$?\'U12SH%JO \#P/ \#P/ \#P/ \#P:G)H+#YF]AI*51P4>?UY+$YU!W
M9)KHY6B\P2C\ABB<C#[[?U:%=(W+"3+"NO\ 7]=ZKK_HVSX(;OCD3G#IM/\
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MH@$?8[,EB(0-(\+&=F_\?NY=A;(7T!>]?=!V%3%X2".(0RN(XQZ<?7>WKYR
M@KGE9A63\!-(\7(9-DV(>U(WT"%>/%OHIG_^C=VZFK?*OYEO!:2Y;T$Q"B-[
M2@)6.2<A.QD7%4:KL8'I1Z>3BU51X>I4&Q=PY18J CIDZS<+.L*?C2&X5<9S
M^-/;. X\U!U397(@*1<;6G(3#$[6?8<(A;F\+>*)V40A7(G5(2?VK6EK6))F
MCA,"2)!K:&/*KW=.U4AXA=V%>/M?PN44UPR/Q^6]T'%:KX[IL0X9FJ_N^L)@
MU@4Y:5V9=)P:S*=Z*DY"\D9Z[=EU&PF/SJDBNCB&MG&R7ZY48Z;97=85:Z:A
MW2ADVB5B1QC+X/(!LHC!-8D@/."'&'0]VL'*O091-!?7&,;[,2XU=NI__BJE
MMC_L\&T^!X'@>!X'@>!X'@>!X'@>!X'@>!X'@>!X'@>!X-2G9R21J(G#L0A)
M"QY(-::KB80*-1^.D)$YRNBGEDU-2H@*CP]35%393[W3A)/Z:9Q]?NSC&0YR
M"^L^HK=AK2\*RJ.,5/5%261?4)Z.AUP%@4LLL@WYVMB)PZ<N:L(5E,RD2TW<
M#(G8#)CD@M]5R#0:XVTT:K9^\)$ISY$JPN>7UA"0D'GP<U:4N0BHK0SK&?QB
MTGW(%=]EC9"5_CS[U7 5_ K+8BM-D=55-3:2Z6VN$=,+;!.73TUOFO(?$9?0
M\"C-CJAK%"N[;C<BE,>A;G-+(A9&M,"D7DLM.QR*BY(*))CEM%"#G#;#/5Q]
M<?=]N<!1R$_,90TUE-;5NTK:V6]MVO6%/7-#:O29Q<S)GM<VK4DDM\N8<9"R
M)\P9D:E 1O7^Y1ZBNKQL@;!/4-'#,TQ64#37'RHV!3 PO(.EN6[*0CDH@LFZ
M3J5S5[B &)BIS=O-Z-B<:%S>KR%@(34%;X=>]Q[5\S60;MB)!@\099V53U3W
M"S$ ^0)E*YA5L)E%#6571B==!6+RI,4S,AK0YBI[[A%5E+P"Q61?VM,"^LE
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M37[AD421<J:ZEW39+3?*6^R^@?)77R[\Y6E:M0TM$HS93FR+UCE&3FM8LJ-
M;EB,#N&,R2424^:0'R!^C'G]"L(JNK-1KA7]Q@R?"WS7#MD4:+[A/O1?9K?G
M"8Z,SM4'YE68%I5SRV+'A4\JMV8J!A<%A/:TALAE=0E9>*L][#E#[/=1<DP8
M.-=FR#O9JFZ48NDDPK =^7"*Q1R99R?FVXA3JMF=_&;V0TD%4NU*TCG-<G!B
M+3-1[.DW32MY2.Q22,Y4X'1[9P51CN^RF6V7>N&>P6"&=F6"^Z$DO/+KE"PQ
MAL% !EM#Y8M9](.(O(*O*6NWK-*6,_U)TJ98[),4GYS9DY:I.?T6&R.,9=K(
MH;A,,;Z[Y>EDL2B@.Y(,O*W$\/U"S9O':@=9_9L77<Z2*L!K\RU'M"4[#+LE
MOV J"JA!/**F<H_X-LX"7Y_8D*JV.[2B=&D@8?#UD+:YU9$"I$F6(J?B'! (
M$*S(G9 ;?J:YP@R8MG#I;[<_8GG[<_0,U&9&"F<9C\MC+]$O&96"$R./DT4U
MDVY,$='MR8I^DDY21731>CW2:FNJFFF^-=OIMKC/UQX,[],8^OTQ_IS]<_\
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MMRFD(39*%VB9R0D$T@=]URQJJ<5X^E!G$.2B> LN!R!"/LQQ%LM&R4S"S55
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M3]5XX S:$TQ,C<6>,70=?==<*Q6#+*_E0T;!%8&G.[9/?4,Q-8-U#%:.-6!
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MS9"4KEK#&DUM,5LV>2G5CH1/9?NVJ6R2R2&^Z 7\\#P/ \#P/ \#P/ \#P/
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M+^T;,3VL>6=7N[L:15@YU>Q! 6.C!K-5-=@1S"O\00W)81RYU<?C2V"]D.F
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M;5OOC90HUQD(QL_Y#ZNK.ZP<7(/D5Z2&U!U/8UKVTTBUD%VT-)\P3FF(/+6
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M-?L) 66+ZF&,0_NZ-6 F':$69)JZ;:MIY# YI!?3;5R@6%,W::FKALBIH&K
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M*'Y+#W>[!9/+H=EXAOG9'*^O@WVI:@JVAJ]C53TQ (K6-;0]GLPC4*A89F"
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M1$Z*52QNU,B I >U)Z.-M76A+=73;3&-/Z!8+P/ \#P/ \#P/ \#P/ \#P/
M\#P/ \#P/!S[^1ZG[4L?GB82&AYKT%&;MAX;36NQ=%6I)Z_7./R\GC"93)@,
M()L0DH78A&SC9OE_HK^MILKE/[=M\_4(:ZOYOTIC>/V;R_'+(@4KLV?3MGT[
M9U.CY?-K((P/?E_J]S')06 ATY')Y0^%]!RV/E$$A3!P_<G=VV_X]]<9QJ$P
M?'29ZCG%72RU.I8W8->R"R"E7OX=5=F*!T97!148YUIF%6 H\!!'Y1O%D)I>
ML>EAQLQ77R]_3?HKN4VRR^[5 (8ZI%= W<!J&\.<[:Z4B5=VP1YW"GJ]K4&G
M&9C!*P#R>SYO?U@/VAK]]\C([$I\MB*L6Z#'^1'2%$.^9+?L)I_8$$T!4_8%
MXQ.ZQ]QS;MRK@,2J=MMS":6L8Y6%IO#8+H'NL1#GLZ2&O=LS.>KT<G6#@PWD
MS=ZW([_I*OT5W&SCZA8 34W2LEFWQL71*I;TB'F,K1BQ7M> A[1D8.HP!,3R
M#,B;AA(:H8F/[/ L7?0HL.@[0'(_C<O5=DE?O165^H8'O:M>D+%O!^^H&4=<
MP_:ON%NFI>.>U38)N'5*:Z6%F:[>\K@T8ZN1_M&PYN\=HRU,F+>L'8]P.W::
M$L9TRTQX,]T)0_4RU%VS?D'NKH1YTRS_ +=MZC:D@,M(QV&Q4TRKFG1QFD))
M6:QE] ;4C)R<PDZ^<8+M?R(HR1TW;;H*)Z.LAJL(SUZW[@AV) ATIM!7'5W5
M*!Q=XJZ<\^:\ENJ$<O*HP21V<J1]K($;[%#M02J26IK1LLY2VW_364UR'9#P
M/ \#P/ \#P/ \#P/ \&@6;7C&TH@^AI&33^(-'[A@XW.5E.9%7,O;;#WB3S1
M)C*XJ]'FF3=SNCA-?1-775=';;3?&==LX\'' 7R5::WQXKV_(HK:TM^2RO*"
MO-O4ECS>6D9)?8"PE4[Q'5LR$FR)?89L^:C;*=I#=%L;)(ID,?7.,ZZYT":>
M/I-UA/NH;.VFXN\@_.-3R;K43%Y7;H1W!F%R[7!:]-3JD4XA#Y,B.GQ(+0$9
M"3.-HE7XYBQV8O&>&"C])7=9()$ZUM5])ISSC4</EUEU\V,]PL>?;:(1A\7@
M1&2 ))Q-?%OX'Q66L=D7SE@W<KA'NCX>JFJU+C,ZXVU4;[>"$ZWH2^HI%KP=
MV-<G9BU>5]U==I(5%&TVGMC7!<'.;^C=('7<<K>5C9,A.@#8+8$K4DC-TS4W
M(KD V-=OM^NJF@5)5/?*4;KC>.\Q!.AV4CJ&\NJ997$A[!%F1K^U>>&--A5J
MMI.P5GI@&4D\LEUAV$_2B<G+K_R(=W$&N"*JB2SE=4.LEB5A>%D\0PJNJHL^
M=1JXE(=STNXGEEFY!55E2=G$)%74ALT'8,E@[&0R:M9O:L-!E@Q4@*0>.@[\
MJJJAJIE+7ZAQW/RGMPXA:,0@4QZ\LB*4U*.ZZ3YXD=/']34S2ZGA]J1-;FYA
MT_*'*K5Q*ZQCD1*+L$"$IRYC:[-L]S)-UWF6"R@3"EI\J(KH-N?E ^P#M'2>
M^YR_KR!PXF91=0D\RO*EJ<41NB5[F\O7?+16$"I-;\7:(-=M\,GCN./-TFN@
MY-R'=;_,&#?W_P#Y5?W8 _S*_L__ #!_L7^3:_W3_8V#6(Y_=G\-^3]W^ _G
M\_I_M?9^+]C_  ?7[OZ>#</!%;"[*Q*V>0IL;)\/K#%,BCPD':ASZX]CL$9Q
M D7%N92F*VB2,D&BI^$>+"LOOY--D4;N,H814UW\&R!+!@\DE<V@H"6 #,RK
M96/(3^,#B;5V<ARTL$8/QE.1CD5-G(K<\$VPZ:86UU_.A_CU^N/Z^#[CTJ"Q
MIS&F9=9ZDO+Y$G%06K0.9*Z+FE1)<YHB^6$L'R 5ED:"<[9>/MF[/5371+*N
M%54=-PPK*S8(0LJ0T^SD+96RHK#HO8)^*?K/TWK"&30O)P$7D&SA5HF/<LBY
MB%%&VGX5E-]%&2F-]=?\/U#=G+=)VW7:KXVV1<HJMUM=%%$=\I+:;)J8T61W
M362VSIMGZ;:;:[:Y_KC.,_U\'H'#AX<>Q$BF34:+&-&[ </8H)-63%BT2T0:
MM&C9'71%NV;H)ZZ:::XQKKKC&,8^G@UV#3^$V;&T9A7DJ!36*N2DD"MY#&B3
M8N(7+0^2%H?*1R+YDHJW5=@)2!>CW6FNV<HNVJB>WTVUSCP?#6=GP.XX:/L&
MM)&UE<.*OY&+8&V;=\U17(Q&2F(=)&>6Y)JR>HKB), >,U==TM?HJWV^GUU^
MF<AOO@>!X'@>!X'@>!X'@>!X'@>!X-+L6PX94T&E5EV(=;Q>"0<(_DLNDKU%
MXN/C\?%(;NRIHE^BV=KH#!;-/=9RM]GXT$--E%,ZZ:[;8#'#;;K<V6@88'+Q
M)UW:$->V'7K@%NL:#S"##T03AU*P<A&(NP#T'JA*!N^B^KG[%='[?.F=L+:?
M<&ZEBC(&*)FB6ZR8X./>E'ZC=H\(.$V0]LH[=;H,!Z#I^]6U01VSJB@DHLIM
M]-=-=MLXQD/F!2 3)!HPL(=;+M"P83(&:;EL[&D<"3C?9R+=/0Y-!F6%[.DT
M]\?B<H(K:;I[Z;ZZ[Z;ZZA  CL?F(W*W,)97)%$I(ULYY2BS0IDD"9_YPL,(
MY<58D:.#QP1Q86V'"?X@Z;G=^O\ ET_$EO\ ?K]0LO\ 3']/Z8_I_H__ $?T
M^G]/_I_3/@_? \#P:E#)Y"K%%OS<#E(*7B!<HE\*)$H\2:E6;&70"3E87-8X
MZ7:**IHF(O*P;P>]0VSA1!TVWTVQC.N?!KU83.L;,'G;"K(D//M'TIE,(D$@
M:LW[5TK)ZFE1ZN9/''N"K5H_TWATM DF&R/V803<Z+[I_7\NV^X2=X'@>!X'
M@>!X'@>!X'@>!X'@>!X'@>!X'@>!X-1GL[B]91 [/)H07%1:---7QD@V$F#B
M[5KLNBVPHF)CX\H9?;?F7UQ]C=NKO],_7Z?3&<X"E2OR(U;)-(-(J2A\_OFJ
M#LME\.L2X(0"?C(92)2OYK6<2FW^9.):Q!%F&L6:6 [)/L)(;[-V\;*)[?1=
MMNGJ%AX=U)SW8)&,"87;,1D1.:2%:*15B.>JJ.#DB0J8%>RHEBGNAIE1UBGI
M..D6/K]-=ACQ)7&<_?C'@D2?V3!:L"L9#84F'14,3DL8AHY\2V5PF^E4T-LH
MW$P#1-!)99P4D!\B@T:I::YV575UUQ_7./!56"_)%Q19D<F,I@%XCI4-@0=&
M021F(AMCKR9./J3#%?*'@L+S#M)C*P8^<9_B7CL2P>MV+_&47&Z6^,XP&;*_
M(+QB$CE;R\ET'!D8I;(:12.%R5+8P\ JQV'R85"YC(9*69"G#& @H;,C;408
M>'U!C8445PU=[HKXV3P$O#NBZ/+33_+D?9<9<3O_ #'*5'F)?M*I'M;'#5JI
M<;^*;CUD$U]'^M5I9/I;YQA!P+^BZ.^^FVN<AA+?ZJH&@Y)%(M<=AM*^?S14
M<B")2 )*$8AA4L:1CHO0[/D :\&B>2!QPFU1_E2++\BJFN-?K]V/J&L1SM[E
M64MY^N,N, U5JTO"PM@#)(-DL-/1=W8\LU@D <OXY+P@,_L%FLRSD:+))-E!
M[YVFHFBOOE-3[0V*-=:\VS$E$0\7N.&&RD]4@:4.8L7RJCB0JV?$)]/H F.T
MRWU_+O*895LA)-<9^F=FHAQOM]OVX^H6)\#P/ \#P/ \#P/ \'PDR3,.-(%R
M*NR \4Q=DGRVB*[G=%FQ;J.G*NK=JDLY<;)HI;9QHGINIOG'TUUSG.,>#GY(
MODBJ,M&),8YLA]E=8R6"25E&[#KRJ8A(1$Q@BAFL)[9D<>R,;/0\8W;)2%O"
MD&#5/&-EMG)L?OG7"3C3?8+"B>N.:CJFR(BY84_5TD$%BN=&[]7;.9#9MHS>
ME("*T^K?'Y',IM>MCP%I]OUUW(BG"><X_'G/@L2HIHDGNJIMC1-/3913?;_1
MKIIKG;;;/_Z-=<?7P4W??(-QX.>0QH[NH7II8L; RV!%$XQ.W$<F0&40Y>?Q
MUU&I4VBRT:,.340;*/6S5!WN[5TTVTPE^7&=/!^G^W^+=56BA"XX'*'H(>)G
MXA&.C"UA%6@TW%*Y-B)C'F,3!R$BJV>0J_(TYT?,D]\8'25#;.^$E]O!\K?Y
M$>-'L%CMDB[M&'(A+09N3QM]'8I8$B(&(S&I:A!)!)&<<!Q,A)=X^%ESE-BY
M>Y9X;(K;X^[?&O\ B\&YZ=I<MJR.G(PC<T67=]!A8Z?I0R@F76@]EL9?H^4B
MC>*6.D,WKXB<DVHU;^/&8)X)/,ZXPDAOG?3&P?3?_8G-_+9*%B+XLI" D+$Q
M(-H:W7C,T/Y-ZQ4;L:DNZ2L5CAU%KH#"I*/76SC9+"+)!9QM]$45=] @QI\B
M7(D,L&QH+*Y**J@6P39V#$K&)AGK6KKZB)RA671D@M2O+ #!UX;*1PV%(E-W
MJO[ZCU;8$\5UTW2TUVR%A-^L>=-)"SB7^;$9WE3^RSE.MXTA_(N#_P#F7&O[
M5W/1-P(08J$&3X6RG 9ZJHLFFWP-*-7N%,M%DUM@Y^SJB.FENCZ8[MB,'?O+
M%"WQ(JSG5,+I5^(F"7$TZ8)UV9%/;"VM)S&C0V,$HB"MAD%2VRYP>R[8)Z_E
M<;Y\%;YS2'R/J4K94'C\5M>4R>09M%Y6EF(W<(@ML )41H&>(5ZK:48;7>C5
ML@,16V5QK)M,8^0&L'3C#<PO%<.D-G& Z(\75=.ZF==GS>957,(J8MWHU_;L
M< D)=&Y&6EP-6C:@![;L4V4_D$:"%WD\C1MMA)=RPU^GX=LYU:?@SH%:85RQ
MT-%.DX;=I4";*@NRZ<LBKNYA,.)QNN9949=\_?V+1\S4F(FS5R\W.TJ[EA^O
M1Q&/;;OD 3YH[3^B8]/'@V.%49VS'89R9M+3<J,VK ^@@T0MHY';8(NHI(.?
M:AIF\:@@UH3X$5EX=K*W5N2TE'IQ(0Z23\BB^))I*:JJB=%= JM7_/\ VX@8
M#3";<_7!O.Y50'&]-]"RW7H:$/74IM2KK$Z2(WE9D6;,KL#/I)74@(6"&+M1
M.[N*HN6#S795IC<5D0X#:.::C[VK]S3EKW1&>B2DUA-EU^_L\9(^D(O*!1RI
M0GQC#ZWM0>H#<7:\KEWK,.W(PW*IY503<Z.U-2_W-F^SG;P=:)Q-;-G?-+.4
MU;!)K&;'M6&1-(1'C&L5:3.H7%D-QC4M(Y,S>2IG'GA>GQYEP1=L69)?+YR-
MRV:[K953VR'+,=S+V)S.4M:FJ2@Y*:\O$^C^?^D-&U<&8151$] I3JZCO7G/
ME>BS%H(%0#W^Z(\$L3.[IT,8RC)V2#-7B2RJ>BX;#S5QYT]7@WGD8JTF<&@A
MUWT?7W2%?F[M>/W<,@BW4DUZ.HFRH=F*S0^-(3F6@7*L/D+EH^P858R5!9TO
MOD3G3<.S,1-EY"$U*'(@:@Q#8I(&.8[('L=?D]&8>0%! LSLYBIJ0!LL90+8
MHE&FF'.7*31XFFZ30<ZK()ALW@>!X'@>!X'@>!X'@>!X'@>"'^A QZ24+=,;
MBP1U))-)*IL".QX R6%-W)<V>BI42+8).#K\6&;_ +#UYIKMNZ<(H::YSG?;
M&N,^#CO-^'>JJ<&V?#^4_P R?/FU'3*=\W5T'G.L"M+FZ[)+<7/M@3CG.O2F
M#S(%BF9J,@)9_%FZA-)A&2#E^$46T!+#$VH?8MSUV1/9M,2TRCO2L<BWX_D1
ME5>"A/4BD<PPD<]E- R[CEH_;5Y>K3\:P/6/2]NU9JJ*BP>[G9JXSAFNEG(6
M?X@HJZ:UNFT+%N6)R= O9G,7% 4A-35@#Y9^Y8]75N>B=M1LT/0F)E?63M9'
M^!VH00:*#W^B^5DWJJRB^O@J;->2>E[4HON+E[%/$X?OU9\@)BWHY<LEEE=;
MQ6NJ;4FU-2YO;0YG'IF;FSBR@F*S<+QH3H-;KIG?T572[)#51?0,0GRWW$WB
M<FUU_P _MS%C5OW '![N>F"Y.551TB8OLQ(.(KB?/B-N$P;.OXQ2SY%AL@(V
M=?QBK?\ "2$OLK[[(AZYCREV](I!.WA7?H4NO()7W,U<$X]TR5B@(K&I-3,,
M7YO<QN/L;L'XAX1Q?09T^"-&Z;5U'_NSHZ_58J;)[A.U2"K?4Z1;#"%G$YZ(
M!T73%W=4UPVNC8K-Z>ZOJJO$8TQJ==@*DV\)A\8Z$9RIK)W(S=^R%J/H<Y>*
MI+M3NR^@=!CEEV5,.9$+*K*KIH(M&=UX%)1BN))F&M)?!)',F3)!/,KT>2I&
M'NU*[6)[/2"34JND]28J)LU%]E4?O#E1KRUV)R^5O2K^?8T7L2AK&G7)W11%
MY"R,#JHN8*@)Q&()VO2\50+6<@<&S"ZJ;@0B5ZEEEAPTQ(R$@06?,G)'1SX-
MOI;D;I>):5LJ#$S.MXA+;L[G@EY5_(KJ>K$ G.MZ=.SWI.HKHCBD4GLK%+W
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M<Z)I;(JA!T.^/RO1,(Y)J^?R-S;57<H\ZRFBV%<3"/#=X98AN3U_$JDS:4M
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MFI#T#E=DRJOS<>L :[C ^81F8 %(IE5NLQ4(L2/[Z?\ _+Y04T4"K\K^4:_
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M2 @V3'5PXV46U9LT$<;?C23UU")9-S#S9-(_F)S#GRD93%\LV([^W)!54%,
M_P".%FRDF&C_ .*?@G#'#%A(SCU^BC]GXTWCQ=;7&%%E-M@D-_7T"*09:L"<
M(B!&M7,<UA[BO'\:#.X,O$M6.HO6++1)PR4 *QS4;IAOACLWRVPAC"?V?9CZ
M>#"1VF:AB$'"UG%:LKJ.5S&R@TY'X$$A4<&0X(;#R)"7BC8J-,QJ(=B9&RUL
MF50=)HZN$B6FKK7?"^,*>#7VL/YXEKX@U:1&GI&1JRVU#A%!*-PXH[KZ\S:0
M.>K'5],,5E8S:99*8CC&[S_4E5_Y-!UG?.5]-]@Y:*_(I<Z<?(,_MA/]\M?E
M;$\.([_Y-6GM#MJ>?]%!J65D*LFUDO\ :V++T $]B.JO\KJR_>TU0RP_K]G@
MM.Z^1JGC)675G#P]CZWDP%;N(O6A:&#4Y66P^@MA3E@?4CS^8 TQ@\.*K8DH
M3&&GP(RS6T;M%VZ#E^RT7"-Z[^46J@='<_2[HI.1Q*96-S#"+ME)]A$,B8 ]
M,JT%!+OL'6,(DI X.-(N'#RU13^6<Z;1UENR>-'!;#I@[T3"_H:R4Y]3J]FP
MQ-42F5BQ\U&E3B0@RAG+!,DF++?=&)$1 R( 2V9Z.VCD>55:$6"J2R#C*:NN
M_@Y:<=?)';-BPN!V!T!"!+FN[3YVXKG<'L6N*\FE>CC/4/53LP,,<G1,59$H
M,,["*11; <BE(6)-N-9#BN,$\H?BRXV"R+?Y,*2)GT8M&ZZZ$F$B:")^5F@>
M*5;_ #+VLUJKL\[3=BAIYHB>UT8%(C8@/#-SEGL^:[M'C<DBLJ+VW>IAL 'Y
M#:;E!&H1L>AULFE;LMF74E"UA "*%459_6\MGT2M1%;0;-W;I_%:M4K8F_.R
M(:F0CS8=ELJF]5W=MTU NA,)8 @42E$YE1!(3&(;'C4JD91?/T1' H^.<EBS
MY7.<X_U;1@T4WS_^C7P<[>:OD2#6-54F+7*' 1BZXEU ]YA?596!\=.=3LRF
M:C2>42RB);<JB.**R^AY6%-$G:[IJ/8.FY;"BB2+!7.@8KECY#TK"@$887#$
MI<WN8Z%M&9,14<A#,"(ED?BG7TIY@&QZ+,R,Y,ZJ3Z-$\Q_20L/WU46:A5!?
M5QNDY1^H=2O \#P/ \#P/ \#P/ \#P/ \#P0%U994HICF#HJXH3H%6E]2T=:
MMGQEO)&+LE'WAN 0<Y+!S VR8$PKYP*?N1&J*^$7;=7"2F<Z*:[8QGP<RI3\
MD<W$%H_J\+L8_"$_C8F_7MB2='G>RG4I 6%%IC2L7_/#XM,)A"F<M@;=E:3Q
MZNP275<X_CTL?R&N%,XV"RYCN'6GC?:92ZAI(Q7W/-UCHC&'==1'_P#("(&G
MQW672\B?SH@:E* +]MBZ.F&S-QLX8;%%]F(YFU6?K))KAF^N^I);4H[C4_5I
M()B+=*=" *K/EBE8SBRS+.$RBA[CMT5(HE#H88#21R?U?UHS;[(;MG>N&CY?
M?=+79+&V P5F]NI4_5<3:R]T[=6K:, R5K.>:5.=B59/99.H[9DCJ 6>ADGF
M^9F@548P1-.2#&+I]L"=.$/Y%<<B_9[[!H54?*G5!6J8L\M**6G'KQ_RQJ":
M%ZNTKW05(+%;V53\BM%K.:>&/9*N//P(PC7TE09X6(I$47PG=@NAH\5;). M
M=S;U[ .IW<V_RUA5OC0$%)_P)&86! 7$%!$)&F@Q?.XX,9G'Z,KT-CA19FZ<
MH/!C/*&CK5/?.'":Z"(1[\@78;SC2FTK%CP&,3&3-"6LM*Q"121M''#NE*T7
M83'H<]&/V'#;8W-0-4MGND?&I[9V(21X.;[:[)J[X\&L=&]PCHMK"@M!.6L_
MD+NW>&1LY.,@S.20F.53UW?46KD$\?ELRZ,KLC,RA[LD\#N6:171EMHU7>M]
M&SE'?<+"49U!!.@DF*D*C\[&J*-;!R?:2L(.#OH.;K6U)#3<BB$T9H&R#@-*
ME)K$"R;5OKJLFNW&.%?R:XUUQL%D? \#P/ \#P/ \#P/ \#P/ \#P/ \#P/
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M#PT434^[\>^F_P!F^R>_V;8V^Q37_P"[3;Z9S]N^O_;C/]<>#S\#P/ \#P/
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MKHGIH$/]$\81[H S9DFUL^PJSDUH\V%>6#1F'-8,2RPK.1R_>42E04/FT1E
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M[*%H\1TR@[T2PIA%7'V;9QM_3P2CX'@JK&.V>99E.D:TCEC."$V6TB*W\+M
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M1P2RCY,S)9"1#ZM$UF#XW,9$2ELH).V[C"R;AT;DIAT]7SOC/W+K;9_I_3&
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MN%=\Z)(-VR+=NFBV011T#V'.>P$ZA5#1BT9+)YX<H:6U?8XR:K.T0AB6V36
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M2C]DS>(Q=UH\ 1TZ6$9=I-UV[?10=L6)JM,HK%'ZC@&?C=Y=UKR154V!3)E
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M"9.(E@J0L5W."V[@B#>-5T6+C5N^<Y4"VE=]:VG,.BJVHT01HF<@6U<Q.>=
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M<R%!W<*DR^.2UNA8/*CPJ,G6@>14?*"TN";C45&K_=YL)_DF;C535-# 77Y
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M6^ZVG^';. RT*!<Q35X8<5V$HF5D83(AHT^M#1< -OHE*PD<3'!F1?<*@Y<
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MPE%JQ9\)E4J*I1./3!"2-'C:+1@--6!0-)F_VD0[+#15UHLCKKA5+?7 <HW
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M*XUPJY7_ !ZZ_E<*8TQ]V^WUVS],?7/]/![_  / \#P/ \#P/ \#P/ \#P/
M\#P/ \#P/ \#P/ \#P/ \#P/ \#P/ \#P/ \#P/ \#P/ \#P/ \#P/ \#P/
M\#P/ \#P/ \#P/ \#P/ \#P/ \#P/ \#P/ \#P/ \#P/ \#P/ \#P/ \#P/
M\#P/ \#P/ \#P/ \#P/ \#P/ \#P/ \#P/ \#P/ \#P/ \#P/ \#P/ \#P/
M\#P/ \#P/ \#P/ \#P/ \#P/ \#P/ \#P/ \#P/ \#P/ \#P/ \#P/ \#P/
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0P/ \#P/ \#P/ \#P/!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g552144g80l77.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g552144g80l77.gif
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MG/_>O?_>G/_>M?_GO?_GS@
M
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#"  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g552144img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g552144img01.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 'P#R P$1  (1 0,1 ?_$ 'H   (" P$! 0
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MXIG^CYW3+B%PSZ8L*Q;E#.E+Y;)1M'*0*+-1XXD'K!TBHBFB"GR%6)V'N(@
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M/#:^-O'R]6"9MEQQ'*K-:+)".*U9+',T.LOYRQUQTF5)S7[#*KQIWLY"+I$
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M[.!GXY]7IQ&,E8N=9/(N0AW_ -.Y:RL>\14;/F+AHJ)B.VSAN<Y%"" E,41
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MZ?@.#Z+:W2;..D+1>,ZI%JG%46*0(1[!Q+3D6^>?"T1_0BB)_:0OH4 #H/O
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#!__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
